Document:

<PAGE>

                                                                   Exhibit 10.10

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                                                                  EXECUTION COPY

                       COMMERCIAL MANUFACTURING AGREEMENT

THIS MANUFACTURING AGREEMENT (the "Agreement") is made and entered into this
25th day of July, 2005 (the "Closing Date"), by and between AAI DEVELOPMENT
SERVICES, A DIVISION OF AAIPHARMA INC. ("AAI DS") having a place of business at
2320 Scientific Park Dr., Wilmington, NC 28405 and XANODYNE PHARMACEUTICALS,
INC., a Delaware corporation ("Purchaser") having a place of business at 7300
Turfway Road, Suite 300, Florence, KY 41042.

                                   BACKGROUND

     A.   On May 10, 2005, aaiPharma, Inc., aaiPharma, LLC, AAI DS, and each of
          the other Debtors (as defined in the Sale Order) filed voluntary
          petitions for relief under chapter 11 of title 11 of the United States
          Code (the "Bankruptcy Code") in the United States Bankruptcy Court for
          the District of Delaware (the "Bankruptcy Cases").

     B.   The Debtors are authorized to continue to operate their businesses and
          manage their properties as debtors in possession pursuant to sections
          1107(a) and 1108 of the Bankruptcy Code.

     C.   aaiPharma Inc., aaiPharma LLC and Purchaser have entered into that
          certain Asset Purchase Agreement dated as of the 6th day of May, 2005,
          as amended as of June 7, 2005 and July 18, 2005 (the "APA").

     D.   It is a condition precedent to the closing of the transactions
          contemplated by the APA that the parties enter into this Agreement.

     E.   Subject to the terms and conditions contained in this Agreement,
          Purchaser desires to engage the services of AAI DS to Manufacture the
          Products (each as defined below) for subsequent commercial
          distribution by Purchaser.

     F.   AAI DS is willing to undertake such Manufacture for Purchaser
          according to the terms and conditions provided for in this Agreement.

     NOW, THEREFORE, for and in consideration of the foregoing premises and of
the mutual covenants of the parties hereinafter set forth, the parties hereto
agree as follows:

                                    ARTICLE 1
                                   DEFINITIONS

     Capitalized terms used but not otherwise defined herein shall have the
meanings given to them in the APA. The following words, terms and phrases, when
used herein, shall have the following respective meanings:

     1.1 "AAI DS" shall have the meaning set forth in the preamble.

<PAGE>

     1.2 "AAI DS INDEMNIFIED PARTIES" shall have the meaning set forth in
Section 8.1.

     1.3 "APA" shall have the meaning set forth in Paragraph C of the Background
Statement.

     1.4 "API" shall mean the active pharmaceutical ingredient with respect to
each Product.

     1.5 "ACT" shall mean the United States Food, Drug and Cosmetic Act, (21
U.S.C. 301 et seq.) as amended from time to time, and the regulations
promulgated thereunder.

     1.6 "ADDITIONAL PRODUCTS" shall mean the Lifecycle Products and the New
Products with respect to which AAI DS has Manufacturing rights under Section 3.1
herein.

     1.7 "AGREEMENT" shall have the meaning set forth in the preamble.

     1.8 "APPLICABLE DEA QUOTA FORECAST" shall have the meaning set forth in
Section 4.7.

     1.9 "BATCH" shall mean a specific quantity of material produced in a
contiguous process or series of processes that is expected to be homogeneous
within specified limits. The Batch size for each Initial Product is set forth in
Exhibit A attached hereto and incorporated herein by reference.

     1.10 "CGMP" shall mean the FDA's current Good Manufacturing Practice
requirements as promulgated under the Act at 21 CFR (parts 210 and 211), and as
further defined by FDA guidance documents, as such may be amended from time to
time.

     1.11 "CLOSING DATE" shall have the meaning set forth in the preamble.

     1.12 "COGS" shall have the meaning set forth in Section 5.2.

     1.13 "COMMERCIALIZE" or "COMMERCIALIZATION" shall mean, with respect to a
Product, the marketing, promotion, sale and distribution of such Product.

     1.14 "DEA QUOTA" shall have the meaning set forth in Section 4.7.

     1.15 "FIRM COMMITMENT" shall have the meaning set forth in Section 4.1.

     1.16 "FIRM FORECAST" shall have the meaning set forth in Section 4.1.

     1.17 "FIRM ORDER" shall have the meaning set forth in Section 4.2(b).

     1.18 "INDEMNIFICATION CLAIM" shall have the meaning set forth in Section
8.3(h).

     1.19 "INITIAL PRODUCTS" shall mean those pharmaceutical products listed on
Exhibit B attached hereto and incorporated herein by reference and only in those
dosage forms and presentations listed on Exhibit B.

                                       -2-

<PAGE>

     1.20 "INITIAL TERM" shall have the meaning set forth in Section 9.1.

     1.21 "LONG-TERM FORECAST" shall have the meaning set forth in Section 4.1.

     1.22 "LOSSES" shall have the meaning set forth in Section 8.1.

     1.23 "MANUFACTURE/MANUFACTURING" shall mean the manufacture, processing,
packaging, labeling (subject to Section 3.7), quality control and testing of the
Products performed prior to their delivery by AAI DS in accordance with the
terms of this Agreement.

     1.24 "MARKETING AUTHORIZATIONS" shall mean the United States new drug
application or abbreviated new drug application, as applicable, for the
Product(s).

     1.25 "MATERIAL CHANGE" shall have the meaning set forth in Section 3.3.

     1.26 "MAXIMUM PURCHASE QUANTITY" shall mean, with respect to each Initial
Product other than the methadone hydrochloride Product, [**] Batches of such
Initial Product in a calendar month, with respect to the methadone hydrochloride
Product, [**] Batches in a calendar month, and, with respect to each Additional
Product, the quantity of such Additional Product agreed to in writing by the
Parties.

     1.27 "MINIMUM ORDER REQUIREMENT" shall have the meaning set forth in
Section 4.2(a).

     1.28 "PARTIES" shall mean Purchaser and AAI DS.

     1.29 "PARTY" shall mean each of Purchaser, on the one hand, and AAI DS, on
the other hand.

     1.30 "PRODUCT(S)" shall mean the Initial Products and the Additional
Products.

     1.31 "PURCHASE PRICES" shall have the meaning set forth in Section 5.1.

     1.32 "PURCHASER" shall have the meaning set forth in the preamble.

     1.33 "PURCHASER INDEMNIFIED PARTIES" shall have the meaning set forth in
Section 8.2.

     1.34 "QUALITY AGREEMENT" shall have the meaning set forth in Section 6.5.

     1.35 "RAW MATERIALS" shall mean any excipient and component materials used
to Manufacture the Products, but excluding the API.

     1.36 "RECALLS" shall have the meaning set forth in Section 6.4(b).

     1.37 "RENEWAL PERIOD" shall have the meaning set forth in Section 9.1.

     1.38 "SPECIFICATIONS" shall mean the specifications for the Initial
Products set forth in Exhibit C attached hereto and incorporated herein by
reference.

                                       -3-

<PAGE>

     1.39 "TERM" shall have the meaning set forth in Section 9.1.

     1.40 "TERRITORY" shall mean the United States, its territories and
possessions.

                                    ARTICLE 2
                 LICENSE GRANT TO AAI DS TO MANUFACTURE PRODUCT

     2.1 GRANT. Purchaser hereby grants to AAI DS during the Term of this
Agreement a nonexclusive, royalty-free right to Manufacture the Products in the
Territory and to use any and all of Purchaser's licenses, trademarks, regulatory
data and/or technical information, Know How and Confidential Information of
Purchaser related to the Products (including, without limitation, the Purchased
Intellectual Property and the Licensed Intellectual Property) for the purpose of
AAI DS carrying out its obligations hereunder, subject to the conditions of this
Agreement. The Manufacturing rights shall also include a non-exclusive,
royalty-free sublicense of the Azathioprine Product Assets to the extent
exclusively licensed to Purchaser under the APA.

     2.2 MARKETING AUTHORIZATIONS. Purchaser shall maintain the Marketing
Authorizations in full force and effect at all times. Upon request by Purchaser,
AAI DS shall use commercially reasonable efforts to assist Purchaser in
connection therewith; provided that, in exchange, Purchaser will pay AAI DS its
standard fees and expenses therefor.

                                   ARTICLE 3
                                  MANUFACTURING

     3.1 ENGAGEMENT.

     (a) During the Term of this Agreement and subject to the terms and
conditions set forth herein, Purchaser agrees to purchase from AAI DS, and AAI
DS agrees to supply, one hundred percent (100%) of Purchaser's requirements for
the Initial Product(s) for Commercialization in the Territory. Notwithstanding
the foregoing, Purchaser shall be entitled, at its sole cost and expense, to
qualify other manufacturer(s) to manufacture Initial Products solely for the
purpose of such manufacturer(s) supplying Purchaser with quantities of Initial
Product that AAI DS is unable to supply (i) in breach of this Agreement, (ii)
pursuant to Section 4.2(e), or (iii) during events of force majeure.

     (b) No later than [**] months prior to the commercial launch of an
Additional Product, the Purchaser shall offer in writing to AAI DS the option to
Manufacture such Additional Product. AAI DS shall accept or reject any such
offer to Manufacture such Additional Product in writing (an "Option Election
Notice") within [**] days of receipt of Purchaser's offer. If AAI DS elects to
Manufacture such Additional Product, the parties shall enter into a contract on
terms that are substantially similar to those set forth in this Agreement,
pursuant to which the Purchaser will agree to purchase from AAI DS, and AAI DS
will agree to supply, one hundred percent (100%) of Purchaser's requirements for
such Additional Product for Commercialization in the Territory and containing
specific terms relating to such Additional Product, including Purchase Prices,
Batch Size and applicable Maximum Purchase Quantities. Notwithstanding the
foregoing, Purchaser shall be entitled, at its sole cost and expense, to qualify
other manufacturer(s) to manufacture Additional Products solely for the purpose
of such manufacturer(s) supplying Purchaser with quantities of Additional
Product that AAI DS is unable

                                       -4-

<PAGE>

to supply (i) in breach of this Agreement, (ii) pursuant to Section 4.2(e), or
(iii) during events of force majeure. If the parties are unable to agree on the
specific terms upon which AAI DS will Manufacture any such Additional Product
for Purchaser within [**] days after Purchaser's receipt of the applicable
Option Election Notice, Purchaser may contract with a third party to Manufacture
such Additional Product, but only on terms that are more favorable to Purchaser
than AAI DS' offer. If, pursuant to this paragraph (b), AAI DS elects not to
Manufacture an Additional Product for the Purchaser, then the Purchaser shall
have the right to contract with any third party for the Manufacture of such
Additional Product.

     (c) Notwithstanding the foregoing, to the extent the Purchaser intends to
Commercialize a Product in a jurisdiction outside the Territory, for purposes of
such Product only, the term "Territory" shall be expanded to include such
jurisdiction provided that AAI DS agrees in writing and AAI DS is or becomes
compliant with all laws, regulations and other legal and industry requirements
applicable to the Manufacture of such Product for subsequent Commercialization
of such Product in such jurisdiction.

     3.2 MANUFACTURE OF COMMERCIAL DRUG PRODUCT. Subject to the terms and
conditions contained herein, AAI DS shall Manufacture, hold, handle and ship all
Product Manufactured pursuant to this Agreement (a) in accordance with the
Specifications, this Agreement and the Quality Agreement, and (b) in material
compliance with CGMP applicable to the Manufacturing of the Product to be
Commercialized in the Territory.

     3.3 AAI DS CHANGES TO MANUFACTURING PROCESS. Except as required by
Applicable Law or CGMP, AAI DS shall not Materially Change the Manufacturing
process of a Product or change the facility where a Product is Manufactured that
requires a change to a Marketing Authorization without the prior written consent
of Purchaser, which consent shall not be unreasonably withheld or delayed. AAI
DS shall notify Purchaser of all material changes, including Material Changes
required by Applicable Law, as soon as practicable after AAI DS learns of such
change. A "Material Change" is one that requires a submission to the FDA prior
to being implemented.

     3.4 PURCHASER REQUESTED CHANGES. Purchaser shall inform AAI DS in writing
of any proposed modifications to the Specifications or the Manufacturing
process. Any proposed change shall require AAI DS' prior written consent, which
consent shall not be unreasonably withheld or delayed. AAI DS shall make changes
it agrees to as promptly as practicable; provided, however, that such changes
comply with Applicable Law, CGMP and the Marketing Authorizations.

     3.5 COSTS OF CHANGES. Unless otherwise agreed by the parties, any and all
direct costs associated with changes requested by AAI DS and changes required by
Applicable Law that apply generally to AAI DS' facility where the applicable
Manufacturing occurs shall be borne by AAI DS. Unless otherwise agreed by the
parties, any and all direct costs associated with all other changes, including,
without limitation, changes requested by Purchaser, changes required by
Applicable Laws that apply specifically to a Product, and changes required by a
change to a Marketing Authorization, shall be borne by Purchaser (collectively,
the "Other Changes"). If the change is an Other Change, (i) the Purchase Prices
shall be adjusted by the change in AAI DS' cost of Manufacture of the Product
caused by such Other Change, plus an

                                       -5-

<PAGE>

amount necessary to maintain AAI DS' profit margin on such Product (with such
profit margin calculated as the percentage markup of the Purchase Price over
COGS for such Product), and (ii) Purchaser shall reimburse AAI DS for costs,
expenses or losses associated with write-offs, obsolescence and/or destruction
of any work in process or finished inventory resulting from any such Other
Change.

     3.6 NOTIFICATION AND APPROVAL OF CHANGES. Purchaser shall have sole
responsibility for obtaining any and all necessary regulatory approvals from the
FDA for changes to the Specifications and the Marketing Authorizations for the
Products other than the Azathioprine Product and for reporting any changes to
such Specifications and the Marketing Authorizations to the FDA as appropriate;
and AAI DS shall have such responsibility with respect to the Azathioprine
Product. Upon request by Purchaser, AAI DS shall use commercially reasonable
efforts to assist Purchaser in obtaining any such approvals; provided that
Purchaser will pay AAI DS its standard fees and expenses therefor.

     3.7 LABELING. Purchaser shall be responsible for the labeling to be used on
each Product and the packaging thereof, including any changes to such labels;
provided that Purchaser shall ensure that all such labeling complies with
Applicable Laws. AAI DS shall use the specified labeling (and only such
labeling) on the Products, and shall not use such labeling on any other product.
Any Purchaser-directed change to a Product label shall be implemented by AAI DS
as soon as reasonably practicable following AAI DS' receipt of written
notification of such label changes. Purchaser shall reimburse AAI DS for costs
incurred in connection with any such label changes, including without
limitation, the costs of obsolescence of goods-in-process, packaging materials
and supplies and finished goods not suitable for Commercializing in the
Territory due to such label changes.

     3.8 FINISHED PRODUCT RELEASE. AAI DS will provide the Purchaser with a
Certificate of Analysis and such manufacturing documents as are necessary for
Purchaser to release each lot of Product for human use. The Purchaser shall be
responsible for the final release of Product for human use.

     3.9 RAW MATERIALS AND API. AAI DS shall purchase at its own expense and for
its own account all Raw Materials, API, packaging components and other items of
any nature whatsoever that AAI DS may use to Manufacture the Products. Except as
otherwise agreed to between the Parties, all right, title and interest in and to
these items, and in and to all work-in-process incorporating these items, shall
remain the sole property of AAI DS until Products incorporating such items are
delivered to Purchaser.

                                    ARTICLE 4
                   FORECASTS, ORDERS, DELIVERY AND ACCEPTANCE

     4.1 FORECASTING. On or before the Closing Date, Purchaser shall have
provided AAI DS with a written good faith forecast estimating Purchaser's
quarterly requirements (broken out on a month-to-month basis) of each Initial
Product for each of the first [**] calendar quarters during the Term. In
addition, on or before the Closing Date, Purchaser shall have provided, and
thereafter not later than [**] days prior to the commencement of each calendar
quarter during the Term, Purchaser shall provide, AAI DS with rolling [**]
quarter forecasts estimating Purchaser's

                                       -6-

<PAGE>

quarterly requirements (broken out on a month-to-month basis) of each Product
that shall cover the succeeding [**] quarter period (or the period until the
expiration of the Term, if shorter) (each such forecast, the "Long-Term
Forecast"). Except as set forth in Sections 4.2(a) and 4.2(b), the Long-Term
Forecast shall not be binding on either Party, but the [**] calendar quarter of
a Long-Term Forecast shall be a "Firm Commitment" with respect to each Product
and the [**] calendar quarter of a Long-Term Forecast shall be a "Firm Forecast"
with respect to each Product.

     4.2 FIRM COMMITMENTS.

     (a) Each Firm Commitment shall be a binding commitment for the quantities
of each Product forecasted for the [**] calendar quarter of the Long-Term
Forecast. The quantity of each Product specified in any Firm Commitment for
delivery to, and purchase by, Purchaser in any calendar quarter shall not be
less than 80% of the quantities forecasted for such quantities when it was the
applicable Firm Forecast (the "Minimum Order Requirement"). Notwithstanding
anything in this Agreement to the contrary, in no event shall Purchaser purchase
less than [**] kilograms of azathioprine API during a calendar year, which shall
be (i) used in the Manufacture of Azathioprine Product under this Agreement or
(ii) delivered to Purchaser or as otherwise directed by Purchaser in accordance
with this Agreement; provided, however, that in no event shall Purchaser be
required to purchase any azathioprine API if [**] kilograms of azathioprine API
were used in the Manufacture of Azathioprine Product for Purchaser, and AAI DS
shall only invoice Purchaser for unused azathioprine API, if any, following the
end of such calendar year.

     (b) With respect to each Firm Commitment, Purchaser shall submit to AAI DS
binding written purchase orders (a "Firm Order") no later than [**] days prior
to the requested delivery dates confirming the quantity of each Product ordered
(which shall be in full Batch quantities), the requested delivery dates (which
delivery dates shall not exceed [**] times per calendar quarter and shall be on
a Business Day), the destinations and such other information as AAI DS may find
reasonably necessary to Manufacture the ordered Products.

     (c) If Purchaser fails to order and purchase the Minimum Order Requirement,
then within [**] days following the end of the quarter in which the Minimum
Order Requirement was not met, Purchaser shall pay to AAI DS the difference
between: (i) the Purchase Price for the applicable Minimum Order Requirement,
and (ii) the Purchase Price that was paid by Purchaser for the quantity ordered.

     (d) AAI DS shall Manufacture and deliver the quantity of a Product
specified in the Firm Commitment and related purchase orders. Notwithstanding
the foregoing, with respect to a Product, in no event shall AAI DS be required
in any month to deliver more than the lesser of (i) the Maximum Purchase
Quantities for such Product, or (ii) as applicable, (x) [**]% of the quantities
of such Product in the applicable Firm Forecast if such Product is the methadone
hydrochloride Product or (y) or [**]% of the quantities in the applicable Firm
Forecast if such Product is a Product other than the methadone hydrochloride
Product, but AAI DS shall use its commercially reasonable and good faith efforts
to deliver quantities in excess of [**]% or [**]%, as applicable, of the
applicable Firm Forecast when such quantity is less than the Maximum

                                       -7-

<PAGE>

Purchase Quantity. The Firm Commitments shall be delivered in accordance with
Section 4.4 to such location as Purchaser designates in writing to AAI DS from
time to time.

     (e) Notwithstanding anything in this Agreement to the contrary, AAI DS will
not be required to Manufacture and deliver to Purchaser more Product than AAI DS
is permitted to manufacture and sell by the DEA through its quota system or
otherwise under Applicable Law.

     4.3 CHANGES IN ORDERS. AAI DS shall exercise its commercially reasonable
efforts to comply with any proposed amendments to accepted Firm Orders that
Purchaser may request, but AAI DS shall not be liable in any way for its
inability to do so. Firm Orders may be amended only by mutual agreement of the
parties and such amendments shall not affect the Minimum Order Requirement.

     4.4 DELIVERY. AAI DS shall use commercially reasonable efforts to deliver
Product within ten (10) Business Days of the delivery date requested in the
applicable Firm Order. All Product(s) shall be shipped F.O.B. AAI DS'
manufacturing facility. Title and risk of loss of Product shall pass to
Purchaser upon such shipment. AAI DS shall be responsible for arranging the
shipment of the Product(s) from AAI DS' manufacturing facility to its final
destination, using Purchaser's preferred carrier as Purchaser designates in
writing to AAI DS from time to time; provided, however, that Purchaser must
provide AAI DS with reasonable evidence (e.g. a copy of the current DEA
registration for the destination) that such destination is authorized to handle
the Product. Notwithstanding anything to the contrary in this Agreement,
Purchaser acknowledges and agrees that AAI DS shall have no obligation to
release Product for shipment to any destination for which Purchaser has not
provided adequate evidence of authorization as required in this Section 4.4. All
shipping costs and Taxes associated with the sale to Purchaser of Products
hereunder will be for the account and expense of Purchaser.

     4.5 ACCEPTANCE OF DELIVERED PRODUCTS. Purchaser will have sixty (60) days
from delivery to inspect and test Products for noncompliance with the applicable
Specifications and will only be able to reject or revoke acceptance of Products
for noncompliance with Specifications if Purchaser notifies AAI DS in writing
within such 60 day period. Products not rejected in the 60 day period for
noncompliance with Specifications shall be deemed accepted. Notwithstanding
anything to the contrary herein, AAI DS shall not be responsible for damages to
Product during shipment, and in no event shall AAI DS be responsible for
noncompliance with Specifications for Product that met Specifications at time of
delivery F.O.B. AAI DS' manufacturing facility. In the event that Purchaser
legitimately rejects Product(s), AAI DS shall use commercially reasonable
efforts (but within 60 days after AAI DS' receipt of Purchaser's notice of
noncompliance) to replace the defective Product(s) and shall credit Purchaser
for return of such Product(s). If Purchaser and AAI DS do not agree whether the
Product(s) failed to meet applicable Specifications at the time of delivery
F.O.B. AAI DS' manufacturing facility, such Products shall be submitted for
testing to an independent laboratory of national reputation acceptable to both
Parties for the purpose of determining the results. Any determination by such
laboratory shall be final and binding upon the parties hereto. The expenses
associated with such analyses shall be borne by the party whose position was not
substantiated by such testing.

     4.6 NON-CONFORMING PRODUCT(S). Notwithstanding any other provisions of this
Agreement, Purchaser agrees, if so requested by AAI DS, to return to AAI DS any
Product(s)

                                       -8-

<PAGE>

that fail to meet Specifications or otherwise to dispose of such Product(s) as
AAI DS may direct, each at AAI DS' expense.

     4.7 DEA QUOTA. As soon as commercially reasonable after Purchaser's
submission of its first forecast to AAI DS, AAI DS will submit a request to the
DEA for a DEA quota related to applicable Products ("DEA Quota") for calendar
years 2005 and 2006 based on such forecast. Thereafter, except as provided for
herein, AAI DS will submit timely requests for a DEA Quota from the DEA for each
subsequent calendar year during the Term based upon each Long-Term Forecast
submitted by Purchaser on or before January 1 of the calendar year preceding the
calendar year for which the DEA Quota request is submitted (the "Applicable DEA
Quota Forecast"). For purposes of submitting a request for DEA Quota, AAI DS
will submit the request for [**] percent ([**]%) of the quantity forecasted in
the Applicable DEA Quota Forecast. In the event the DEA requires additional
information (including, but not limited to, firm purchase orders) in order to
grant DEA Quota, Purchaser agrees to cooperate in good faith with AAI DS to
obtain such DEA Quota to enable the Manufacture of the Products.

                                    ARTICLE 5
                             PRICE, TERMS OF PAYMENT

     5.1 PURCHASE OF PRODUCT(S). The initial prices to be paid for the Initial
Products by Purchaser to AAI DS shall be set forth in Exhibit D attached hereto
and incorporated herein by reference (the "Purchase Prices"). The Purchase
Prices are in United States dollars, and are exclusive of applicable Taxes.
Purchaser shall be responsible for the payment of any and all Taxes applicable
to the Products and services described herein.

     5.2 PRICE CHANGE; NOTICE. AAI DS may increase the Purchase Prices effective
as of each January 1 during the Term by the amount equal to the sum of (i) AAI
DS' increase in API and Raw Materials ("COGS") and (ii) the percentage change in
the Producers Price Index, Drugs and Pharmaceuticals, Preparations, ethical
(prescription) (Code 0635) (or any comparable successor index as mutually agreed
to by the Parties in writing) during the twelve month period ending on the
September 30 immediately preceding the January 1 Purchase Price adjustment. Upon
request by Purchaser, AAI DS shall provide reasonable documentation that
reflects the increase in cost of COGS. AAI DS shall provide written notification
of any increase in the Purchase Prices by the November 1 prior to the January 1
effective date of the increase in Purchase Prices. In the event that the price
of Raw materials or API increase by more than [**]%, the Parties agree to
discuss in good faith additional price increases. Such a price increase, if any,
would be in addition to the annual price increase.

     5.3 INVOICES. AAI DS shall invoice Purchaser for the Products at the time
of delivery, and Purchaser shall pay each such invoice, in United States
dollars, within thirty (30) days after its receipt of invoice. Purchaser shall
make no setoff or deduction of any kind from any payments due to AAI DS unless
Purchaser receives written authorization from AAI DS authorizing such setoff or
deduction.

     5.4 Any amounts payable to Purchaser hereunder, including, without
limitation, claims for indemnification, shall be administrative expense priority
claims in the Bankruptcy Cases pursuant to Sections 503 and 507(a)(1) of the
Bankruptcy Code.

                                       -9-

<PAGE>

     5.5 The obligations of AAI DS under this Agreement shall not be discharged
by entry of an order confirming a plan of reorganization in the Bankruptcy Cases
and, pursuant to section 1141(d)(4) of the Bankruptcy Code, AAI DS has waived
such discharge.

                                    ARTICLE 6
                           REGULATORY MATTERS; RECORDS

     6.1 ANNUAL REVIEW AND STABILITY TESTING. AAI DS will conduct an annual
product review for the Products and upon completion of such review will forward
a copy to Purchaser. The Parties agree that AAI DS' Manufacturing process and
the Purchase Prices do not include stability testing. Stability testing services
and the fees thereof shall be governed by that certain Master Services Agreement
between the Parties of even date herewith.

     6.2 ACCESS TO AAI DS' FACILITIES BY PURCHASER REPRESENTATIVES. Upon
reasonable prior written notice, and during normal business hours, and at
mutually agreed upon times, AAI DS will permit Purchaser to inspect AAI DS'
Manufacturing facilities once per calendar year to ensure CGMP compliance,
unless product quality issues require further action as reasonably determined by
Purchaser. Such audits shall be performed in a manner that does not unreasonably
interfere with AAI DS' conduct of business. Purchaser representatives conducting
such audits shall follow all security and facility access procedures as are
reasonably required by AAI DS. The Parties agree to use commercially reasonable
efforts to resolve any quality issues discovered during such inspections and
agree that the results of such inspections shall be subject to the
confidentiality provisions in Section 8.9(d) of the APA (as incorporated herein
pursuant to Section 10.1).

     6.3 INSPECTIONS BY GOVERNMENTAL OR REGULATORY AUTHORITY. AAI DS shall be
responsible for handling and responding to any FDA or other Governmental Body
inspections or inquiries received by Purchaser or AAI DS regarding the
Manufacturing of the Product(s) during the Term. Each Party shall promptly
notify the other regarding any such inquiries. AAI DS shall provide to Purchaser
and any Governmental Body any information reasonably requested by Purchaser
and/or such Governmental Body concerning any governmental inspection related to
the Product(s) (with all information provided to Purchaser being subject to the
confidentiality provisions in Section 8.9(d) of the APA (as incorporated herein
pursuant to Section 10.1) and with AAI DS being able to redact any information
provided to Purchaser to remove third party confidential information that does
not relate to the Product(s)). Purchaser agrees to fully cooperate with and
assist AAI DS in fulfilling its obligations pursuant to this Section 6.3.

     6.4 COMPLAINTS, RECALLS, AND INSURANCE

     (a) COMPLAINTS. Product complaints received by Purchaser with respect to
Product Manufactured by AAI DS hereunder shall be faxed to AAI DS within five
Business Days after receipt to:

     AAI Development Services
     Attention: Corporate Quality
     2320 Scientific Park Dr.

                                      -10-

<PAGE>

     Wilmington, NC 28405
     Facsimile No.: 910-815-2381

As more fully described in the Quality Agreement, AAI DS shall investigate all
complaints directly associated with the Manufacture of Product(s) and shall
provide an update every 30 days and a report to Purchaser regarding its
investigation and any conclusions. Purchaser shall investigate all other
complaints associated with the Product(s).

     (b) RECALL PROCEDURES. Except as otherwise set forth in the APA, Purchaser
shall be solely responsible and liable for conducting all voluntary and
involuntary recalls, stop sales, field alerts, market withdrawals or other
related actions (collectively "Recalls") of units of any Products other than the
Azathioprine Product, and AAI DS shall be solely responsible and liable for
conducting all Recalls of units of Azathioprine Product; provided, however,
that, subject to Purchaser's compliance with this Section 6.4(b), AAI DS shall
reimburse Purchaser for all of its reasonable out-of-pocket costs and expenses,
including, but not limited to, notification, shipping and handling charges and
amounts refunded or credited to customers incurred in respect of any Recalls
relating to Product(s) that do not meet the Specifications due to AAI DS'
failure to perform its obligations under this Agreement, and Purchaser shall
reimburse AAI DS for all of its reasonable out-of-pocket costs and expenses,
including, but not limited to, notification, shipping and handling charges and
amounts refunded or credited to customers incurred in respect of any Recalls
relating to Azathioprine Product that met the Specifications as of the time of
delivery F.O.B. AAI DS's manufacturing facility. In addition to the foregoing,
in the event a Product is Recalled as a result of a noncompliance of the Product
with the applicable Specifications as of the time of delivery F.O.B. AAI DS's
manufacturing facility, as conclusively determined by an independent third party
mutually acceptable to the parties, AAI DS shall pay for the replacement cost of
such Product that is Recalled. Purchaser shall reasonably consult with AAI DS
and take into consideration AAI DS' reasonable recommendations regarding such
Recalls of Product other than the Azathioprine Product; provided, that Purchaser
shall not be required to consult with AAI DS in advance to the extent exigent
circumstances preclude prior consultation. In addition, Purchaser shall use
commercially reasonable efforts to mitigate the costs and expenses associated
with any such Recall.

     (c) INSURANCE. At all times from the Closing Date and thereafter for so
long as it customarily maintains insurance for itself for similar products and
activities (but in any event no less than six years following the termination of
this Agreement), both Purchaser and AAI DS shall each maintain, or self-insure
for, products liability insurance in an amount of not less than $15,000,000
annual aggregate. Each Party shall name the other Party as a vendor under the
Broad Form Vendor Endorsement under its policy, and shall also provide the other
Party with such evidence thereof as is reasonably requested by the other Party
from time to time.

     6.5 QUALITY AGREEMENT. The Parties shall enter into a quality agreement
acceptable by both Parties (the "Quality Agreement") as soon as practicable
after the Closing Date, but in any event not later than sixty (60) days after
the Closing Date. The Quality Agreement shall cover certain quality and
regulatory matters not fully covered in this Agreement; provided, however, that
in the event of conflict between the terms of this Agreement and the Quality
Agreement, the terms of this Agreement shall govern.

                                      -11-

<PAGE>

                                    ARTICLE 7
                         REPRESENTATIONS AND WARRANTIES

     7.1 REPRESENTATIONS AND WARRANTIES OF AAI DS. AAI DS hereby represents and
warrants as follows:

     (a) As of delivery to Purchaser F.O.B. AAI DS' manufacturing facility, all
Product(s) delivered to Purchaser during the Term of the Agreement: (i) shall
have been Manufactured by AAI DS in accordance with the Specifications and
material compliance with this Agreement, the Quality Agreement, the Marketing
Authorizations and CGMP, in each case, as in effect at the time of Manufacture,
(ii) assuming compliance by Purchaser with Section 3.7, shall not be adulterated
or misbranded within the meaning of the Act, and (iii) shall not have been
Manufactured by AAI DS in violation of any Applicable Law in any material
respect.

     (b) Upon delivery to Purchaser F.O.B. AAI DS' manufacturing facility, AAI
DS shall convey good title to all Product(s) so delivered to Purchaser.

     (c) The execution, delivery and performance of this Agreement and the
consummation of the transactions contemplated hereby are within AAI DS' powers
and have been duly authorized by the Bankruptcy Court and by all necessary
action on the part of AAI DS. This Agreement has been duly executed and
delivered by AAI DS and, assuming the due execution and delivery hereof by
Purchaser and approval by the Bankruptcy Court, constitutes legal, valid and
binding obligations of AAI DS, enforceable against AAI DS in accordance with its
terms, except as such enforceability may be limited by applicable bankruptcy,
insolvency, moratorium, reorganization or similar laws from time to time in
effect which affect the enforcement of creditors' rights generally.

     (d) The execution, delivery and performance by AAI DS of this Agreement
does not and will not (i) contravene or conflict with the organizational
documents of aaiPharma Inc., (ii) contravene or conflict with or constitute a
violation of any Applicable Laws, or (iii) breach or constitute a default under
the provisions of any material contract, agreement or instrument to which it is
a party or by which it is bound.

     (e) AAI DS is not debarred and has not and shall not knowingly and
intentionally use in any capacity the services of any Third Person debarred
under subsections 306(a) or (b) of the Generic Drug Enforcement Act of 1992.

     (f) AAI DS shall not seek to reject or modify this Agreement in the
Bankruptcy Cases, including, without limitation, pursuant to any plan of
reorganization or liquidation filed in the Bankruptcy Cases or any confirmation
order entered in the Bankruptcy Cases and AAI DS shall not seek to modify this
Agreement in any subsequent chapter 11 cases commenced under the Bankruptcy
Code.

EXCEPT AS SET FORTH IN THIS SECTION 7.1, AAI DS MAKES NO REPRESENTATIONS OR
WARRANTIES, EXPRESS OR IMPLIED, AND SPECIFICALLY DISCLAIMS ALL SUCH
REPRESENTATIONS AND WARRANTIES, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTIES OF

                                      -12-

<PAGE>

MERCHANTABILITY, INFRINGEMENT, TITLE OR FITNESS FOR A PARTICULAR PURPOSE.

     7.2 REPRESENTATIONS AND WARRANTIES OF PURCHASER. Purchaser hereby
represents and warrants as follows:

     (a) The execution, delivery and performance of this Agreement and the
consummation of the transactions contemplated hereby are within Purchaser's
powers and have been duly authorized by all necessary action on the part of
Purchaser. This Agreement has been duly executed and delivered by Purchaser and,
assuming the due execution and delivery hereof by AAI DS and approval by the
Bankruptcy Court, constitutes legal, valid and binding obligations of Purchaser,
enforceable against Purchaser in accordance with its terms, except as such
enforceability may be limited by applicable bankruptcy, insolvency, moratorium,
reorganization or similar laws from time to time in effect which affect the
enforcement of creditors' rights generally.

     (b) The execution, delivery and performance by Purchaser of this Agreement
does not and will not (i) contravene or conflict with the organizational
documents of Purchaser, (ii) contravene or conflict with or constitute a
violation of any Applicable Laws, or (iii) breach or constitute a default under
the provisions of any material contract, agreement or instrument to which it is
a party or by which it is bound.

     (c) Purchaser shall comply in all material respects with all Applicable
Laws relating to its Commercialization of the Product(s).

                                    ARTICLE 8
                                 INDEMNIFICATION

     8.1 BY PURCHASER. Purchaser hereby indemnifies AAI DS and its directors,
officers, employees, Affiliates, stockholders, agents, attorneys,
representatives, successors and assigns (collectively, the "AAI DS Indemnified
Parties") against and agrees to hold each of them harmless from any and all
losses, liabilities, obligations, damages, costs and expenses ("Losses")
incurred by any AAI DS Indemnified Party to the extent based upon, attributable
to or resulting from: (a) any misrepresentation or breach of warranty made by
Purchaser in this Agreement, (b) any breach of any covenant or agreement made or
to be performed by Purchaser pursuant to this Agreement, (c) any negligence or
willful misconduct by a Purchaser Indemnified Party in connection with this
Agreement, and (d) the handling, storage, shipment, labeling, and
Commercialization of the Products, it being understood that Purchaser, by so
indemnifying the AAI DS Indemnified Parties pursuant to this clause (d), agrees
that it is responsible for all product liability claims associated with the
Products other than to the extent arising out of AAI DS' breach of this
Agreement, including but not limited to negligence on the part of AAI DS.

     8.2 BY AAI DS. AAI DS hereby indemnifies Purchaser and its directors,
officers, employees, Affiliates, stockholders, agents, attorneys,
representatives, successors and Permitted Assigns (collectively, the "Purchaser
Indemnified Parties") against and agrees to hold each of them harmless from any
and all Losses incurred by any Purchaser Indemnified Party to the extent based
upon, attributable to or resulting from: (a) any misrepresentation or breach of

                                      -13-

<PAGE>

warranty made by AAI DS in this Agreement, (b) any breach of any covenant or
agreement made or to be performed by AAI DS pursuant to this Agreement, and (c)
the negligence or willful misconduct by an AAI DS Indemnified Party in
connection with this Agreement. NEITHER AAI DS NOR ITS AFFILIATES SHALL BE
LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING FOR
LOST PROFITS), WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY
OR OTHERWISE, ARISING OUT OF OR RELATING TO THIS AGREEMENT, WHETHER OR NOT
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

     8.3 INDEMNIFICATION PROCEDURES.

     (a) In the event that any Legal Proceedings shall be instituted or that any
claim or demand shall be asserted by any Person in respect of which payment may
be sought under Section 8.1 or Section 8.2 hereof (regardless of the limitations
set forth in Section 8.2) "Indemnification Claim"), the indemnified party shall
reasonably and promptly cause written notice of the assertion of any
Indemnification Claim of which it has knowledge which is covered by this
indemnity to be forwarded to the indemnifying party. The indemnifying party
shall have the right, at its sole expense, to be represented by counsel of its
choice, which must be reasonably satisfactory to the indemnified party, and to
defend against, negotiate, settle or otherwise deal with any Indemnification
Claim which relates to any Losses indemnified against hereunder; provided that
the indemnifying party shall have acknowledged in writing to the indemnified
party its unqualified obligation to indemnify the indemnified party as provided
hereunder. If the indemnifying party elects to defend against, negotiate, settle
or otherwise deal with any Indemnification Claim which relates to any Losses
indemnified against hereunder, it shall within twenty (20) Business Days (or
sooner, if the nature of the Indemnification Claim so requires) notify the
indemnified party of its intent to do so. If the indemnifying party elects not
to defend against, negotiate, settle or otherwise deal with any Indemnification
Claim which relates to any Losses indemnified against hereunder, fails to notify
the indemnified party of its election as herein provided or contests its
obligation to indemnify the indemnified party for such Losses under this
Agreement, the indemnified party may defend against, negotiate, settle or
otherwise deal with such Indemnification Claim. If the indemnified party defends
any Indemnification Claim, then the indemnifying party shall reimburse the
indemnified party for the Expenses of defending such Indemnification Claim upon
submission of periodic bills. If the indemnifying party shall assume the defense
of any Indemnification Claim, the indemnified party may participate, at his or
its own expense, in the defense of such Indemnification Claim; provided,
however, that such indemnified party shall be entitled to participate in any
such defense with separate counsel at the expense of the indemnifying party if
(i) so requested by the indemnifying party to participate or (ii) in the
reasonable opinion of counsel to the indemnified party a conflict or potential
conflict exists between the indemnified party and the indemnifying party that
would make such separate representation advisable; and provided, further, that
the indemnifying party shall not be required to pay for more than one such
counsel for all indemnified parties in connection with any Indemnification
Claim. The parties hereto agree to cooperate fully with each other in connection
with the defense, negotiation or settlement of any such Indemnification Claim.
Notwithstanding anything in this Section 8.3 to the contrary, neither the
indemnifying party nor the indemnified party shall, without the written consent
of the other party, settle or compromise any Indemnification Claim or permit a
default or consent to

                                      -14-

<PAGE>

entry of any judgment unless the claimant and such party provide to such other
party an unqualified release from all liability in respect of the
Indemnification Claim. Notwithstanding the foregoing, if a settlement offer
solely for money damages is made by the applicable third party claimant, and the
indemnifying party notifies the indemnified party in writing of the indemnifying
party's willingness to accept the settlement offer and, subject to the
applicable limitations of Section 8.2, pay the amount called for by such offer,
and the indemnified party declines to accept such offer, the indemnified party
may continue to contest such Indemnification Claim, free of any participation by
the indemnifying party, and the amount of any ultimate liability with respect to
such Indemnification Claim that the indemnifying party has an obligation to pay
hereunder shall be limited to the lesser of (A) the amount of the settlement
offer that the indemnified party declined to accept plus the Losses of the
indemnified party relating to such Indemnification Claim through the date of its
rejection of the settlement offer or (B) the aggregate Losses of the indemnified
party with respect to such Indemnification Claim. If the indemnifying party
makes any payment on any Indemnification Claim, the indemnifying party shall be
subrogated, to the extent of such payment, to all rights and remedies of the
indemnified party to any insurance benefits or other claims of the indemnified
party with respect to such Indemnification Claim.

     (b) After any final judgment or award shall have been rendered by a
Governmental Body of competent jurisdiction and the expiration of the time in
which to appeal therefrom, or a settlement shall have been consummated, or the
indemnified party and the indemnifying party shall have arrived at a mutually
binding agreement with respect to an Indemnification Claim hereunder, the
indemnified party shall forward to the indemnifying party notice of any sums due
and owing by the indemnifying party pursuant to this Agreement with respect to
such matter and the indemnifying party shall be required to pay all of the sums
so due and owing to the indemnified party by wire transfer of immediately
available funds within ten (10) Business Days after the date of such notice.

     (c) The failure of the indemnified party to give reasonably prompt notice
of any Indemnification Claim shall not release, waive or otherwise affect the
indemnifying party's obligations with respect thereto except to the extent that
the indemnifying party can demonstrate actual loss and prejudice as a result of
such failure.

     8.4 EXCLUSIVE REMEDY. From and after the Closing, the right to
indemnification and other rights under this Article 8 shall constitute
Purchaser's (and its Affiliates) and AAI DS' (and its Affiliates) sole and
exclusive remedies with respect to any and all claims arising under or relating
to this Agreement. In furtherance of the foregoing, each of Purchaser and AAI DS
hereby waives, and shall cause any Affiliates to waive, from and after the
Closing, to the fullest extent permitted by Applicable Law, any and all rights,
claims and causes of action that they may have against any other Party or its
Affiliates in connection with such transactions, except those arising under
Article 8.

                                    ARTICLE 9
                              TERM AND TERMINATION

     9.1 TERM OF THE AGREEMENT. Unless earlier terminated in accordance with
this Article 9, this Agreement shall take effect and commence on the Closing
Date and continue in

                                      -15-

<PAGE>

effect for seven (7) years (the "Initial Term"). In addition, after the
expiration of the Initial Term, the Agreement will automatically renew for
consecutive two (2) year terms (each, a "Renewal Period") unless either of the
Parties terminates this Agreement at the end of the Initial Term or any Renewal
Period by providing the other Party with written notice at least twenty-four
(24) months prior to the end of the Initial Term or applicable Renewal Period.
The Initial Term and all Renewal Periods shall be collectively referred to
herein as the "Term."

     9.2 TERMINATION. Notwithstanding Section 9.1 herein, this Agreement may be
terminated as follows:

     (a) immediately upon the delivery of written notice by one Party, if the
other Party materially breaches any of the provisions of this Agreement and such
breach is not cured within sixty (60) calendar days after receipt of written
notice identifying such breach (or if cure has been commenced during such
period, if it is not diligently prosecuted to completion);

     (b) immediately upon the delivery of written notice by one Party, if the
other Party has been unable to perform its obligations hereunder for one hundred
twenty (120) calendar days by reason of force majeure (as defined in Section
11.11); or

     (c) immediately if (i) the Bankruptcy Court enters an order in the
Bankruptcy Cases appointing a trustee, examiner with expanded powers or
responsible officer in the Bankruptcy Cases, (ii) any of the Bankruptcy Cases
are converted to a case(s) under chapter 7 of the Bankruptcy Code or (iii) the
Bankruptcy Cases are dismissed.

     9.3 EFFECT OF TERMINATION. Upon termination or expiration of this
Agreement:

     (a) Cessation of Activities. Except as provided in Section 9.3(d), AAI DS
shall stop the Manufacturing of Products; each Party shall return to the other
any Confidential Information of such other Party.

     (b) Reimbursement of Cost. Purchaser shall reimburse AAI DS for its full
variable and fixed costs that AAI DS may have incurred in connection with the
Manufacturing of the Products, including any Raw Materials and API purchased by
AAI DS before the effective date of termination, that were reasonably required
by AAI DS in order to meet Purchaser's requirements of Products as set out in
any Firm Order or Firm Forecast applicable at the time of such termination.

     (c) Purchaser to Take Product. Purchaser shall, at its option, be permitted
to take delivery upon prior payment to AAI DS (pursuant to Section 9.3(b) above)
for any Raw Materials, API, work-in-process (at AAI DS' material costs) or
finished Product (at prices then in effect under this Agreement).

     (d) Firm Orders. If this Agreement is terminated by Purchaser pursuant to
Section 9.2(a), at Purchaser's option, Firm Orders not yet started shall be
cancelled, or, if requested by Purchaser in writing, AAI DS will complete or
cause the completion of the Manufacturing of any work-in-process that is subject
to a valid and effective Firm Order on the date on which the termination is
effective. Once such work-in-process is completed, the resulting Product shall
be

                                      -16-

<PAGE>

shipped in accordance with Purchaser's Firm Orders and paid for by Purchaser in
accordance with Section 5.3.

     9.4 SURVIVAL. The Parties agree that the following provisions shall survive
the termination of this Agreement; the definitions of Article 1 to the extent
such Definitions pertain to terms in surviving provisions, Section 6.4, Article
7, Article 8, Sections 9.2, 9.3, and 9.4, Article 10 and Article 11.

                                   ARTICLE 10
                      CONFIDENTIALITY AND PUBLIC DISCLOSURE

     10.1 CONFIDENTIALITY. Section 8.9(d) of the APA is incorporated herein by
reference and shall be binding on the Parties, and as incorporated herein shall
continue until the fifth (5th) anniversary of the expiration or earlier
termination of this Agreement.

     10.2 PUBLIC DISCLOSURE. Neither Party (nor any of their respective
Affiliates) shall issue any press release or make any public announcement with
respect to this Agreement and the transactions contemplated hereby without
obtaining the prior written consent of the other Party (such consent not to be
unreasonably withheld or delayed), except as may be required by Applicable Law
upon the advice of counsel and only if the disclosing Party provides the
non-disclosing Party with a reasonable opportunity to first review the release
or other public announcement, to the extent practicable.

                                   ARTICLE 11
                                  MISCELLANEOUS

     11.1 SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and shall
inure to the benefit of the Parties hereto and their respective successors and
permitted assigns; provided, however, that the Parties may not assign any of
their rights, duties or obligations hereunder without the prior written consent
of the other Party, which consent may not be unreasonably withheld, conditioned
or delayed.

     11.2 NOTICES. Any notice required or permitted under this Agreement shall
be in writing, shall specifically refer to this Agreement, and shall be sent by
hand, recognized overnight courier, confirmed facsimile transmission, or
registered or certified mail service, postage prepaid, return receipt requested,
to the following addresses or facsimile numbers of the Parties:

     Purchaser:

     Xanodyne Pharmaceuticals, Inc.
     7300 Turfway Road Suite 300
     Florence, KY 41042
     Facsimile: (859) 371-7692
     Attention: Thomas P. Jennings, Esq.

     AAI DS:

                                      -17-

<PAGE>

     President
     aaiPharma Inc.
     2320 Scientific Park Drive
     Wilmington, NC 28405
     Fax: 910-815-2387

     With a copy sent to:

     aaiPharma Inc.
     2320 Scientific Park Dr.
     Wilmington, NC 28409
     Attn: General Counsel
     Fax: (910) 815-2387

All notices under this Agreement shall be deemed received (i) upon receipt when
sent by hand, (ii) two (2) business days after deposit with a recognized
overnight courier, (iii) upon confirmation of delivery when sent by facsimile
and (iv) five (5) business days after deposit in registered or certified mail
service. A party may change its contact information immediately upon written
notice to the other party in the manner provided in this Section.

     11.3 WAIVER. No delay on the part of AAI DS or Purchaser in exercising any
right, power or privilege hereunder shall operate as a waiver thereof, nor shall
any waiver on the part of either Party of any right, power or privilege
hereunder operate as a waiver of any other right, power or privilege hereunder,
nor shall any single or partial exercise of any right, power or privilege
hereunder preclude any other or further exercise thereof or the exercise of any
other right, power or privilege hereunder. Any provision of this Agreement may
be waived if, and only if, such waiver is in writing and signed by the Party
against whom the waiver is to be effective.

     11.4 ENTIRE AGREEMENT. This Agreement, the APA and the Quality Agreement
constitute the entire agreement between the Parties with respect to the subject
matter hereof and supersede all prior agreements, understanding and
negotiations, both written and oral, between the Parties with respect to the
subject matter of this Agreement.

     11.5 AMENDMENT. This Agreement may be modified or amended only by written
agreement of the Parties hereto.

     11.6 COUNTERPARTS. This Agreement may be executed by facsimile and in any
number of counterparts, each of which shall be deemed an original but all of
which together shall constitute a single instrument. This Agreement may be
executed on signature pages exchanged by facsimile, in which event each Party
shall promptly deliver to the others such number of original executed copies as
the others may reasonably request.

     11.7 GOVERNING LAW; JURISDICTION.

     (a) This Agreement shall be governed and construed in accordance with the
laws of the State of New York excluding any choice of law rules which may direct
the application of the law of another state.

                                      -18-

<PAGE>

     (b) Any action or proceeding arising out of or relating to this Agreement
or any of the transactions contemplated hereby may be brought in the United
States District Court for the Southern District of New York, and each of the
Parties irrevocably submits to the exclusive jurisdiction of such court in any
such action or proceeding, waives any objection it may now or hereafter have to
venue or to convenience of forum, agrees that all claims in respect of such
action or proceeding shall be heard and determined only in such court and agrees
not to bring any action or proceeding arising out of or relating to this
Agreement or the transactions contemplated hereby in any other court.

     11.8 SEVERABILITY. If any provision of this Agreement is held to be
illegal, invalid or unenforceable under any present or future law, and if the
rights or obligations of any Party hereto under this Agreement will not be
materially and adversely affected thereby, (a) such provision will be fully
severable, (b) this Agreement will be construed and enforced as if such illegal,
invalid or unenforceable provision had never comprised a part hereof, (c) the
remaining provisions of this Agreement will remain in full force and effect and
will not be affected by the illegal, invalid or unenforceable provision or by
its severance herefrom, and (d) in lieu of such illegal, invalid or
unenforceable provision, there will be added automatically as a part of this
Agreement a legal, valid and enforceable provision as similar to the terms to
such illegal, invalid or unenforceable provision as may be possible and
reasonably acceptable to the Parties herein.

     11.9 NO THIRD PARTY RIGHTS. Except as otherwise expressly set forth herein,
no provision of this Agreement shall be deemed or construed in any way to result
in the creation of any rights or obligations in any Person not a Party to this
Agreement.

     11.10 EXHIBITS. The Exhibits referenced in this Agreement are an integral
part of this Agreement and are incorporated herein by reference.

     11.11 FORCE MAJEURE. If either Party is prevented from complying, either
totally or in part, with any of the terms or provisions set forth herein by
reason of force majeure, including, by way of example and not of limitation,
fire, flood, explosion, storm, hurricane, strike, lockout or other labor
dispute, riot, war, rebellion, accidents, acts of God, or acts of governmental
agencies or instrumentalities, in each case to the extent beyond its control
despite its commercially reasonable efforts to avoid, minimize, and resolve such
cause as promptly as possible, said Party shall (a) provide written notice of
same to the other Party, and (b) subject to the obligations set forth above with
respect to said Party's efforts to remove the disability, its obligations that
are prevented from compliance by such force majeure are suspended, without
liability, during such period of force majeure. Said notice shall be provided
within five (5) business days of the occurrence of such event and shall identify
the requirements of this Agreement or such of its obligations as may be
affected. The Party so affected shall give to the other Party a good faith
estimate of the continuing effect of the force majeure condition and the
duration of the affected Party's nonperformance.

     11.12 NO OTHER RELATIONSHIP. It is expressly agreed that the AAI DS, on the
one hand, and the Purchaser, on the other hand, shall be independent contractors
and that nothing contained herein shall be deemed to create any joint venture or
partnership between the Parties hereto, and, except as is expressly set forth
herein, neither Party shall have any right by virtue of this Agreement to bind
the other Party in any manner whatsoever.

                                      -19-

<PAGE>

                            SIGNATURE PAGE TO FOLLOW

                                      -20-
<PAGE>

                            EXECUTION PAGE TO COMMERCIAL MANUFACTURING AGREEMENT

     IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of
the date first above written.

                                         XANODYNE PHARMACEUTICALS, INC.

                                         By: /s/ S.A. STAMP
                                             -----------------------------------
                                         Printed name: S.A. STAMP
                                         Title: CHIEF FINANCIAL OFFICER

                                         AAI DEVELOPMENT SERVICES, a division of
                                         aaiPharma Inc.

                                         By:
                                             -----------------------------------
                                         Printed name:
                                                       -------------------------
                                         Title:
                                                --------------------------------

<PAGE>

                            EXECUTION PAGE TO COMMERCIAL MANUFACTURING AGREEMENT

     IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of
the date first above written.

                                         XANODYNE PHARMACEUTTCALS, INC.

                                         By:
                                             -----------------------------------
                                         Printed name:
                                                       -------------------------
                                         Title:
                                                --------------------------------

                                         AAI DEVELOPMENT SERVICES, a division of
                                         aaiPharma Inc.

                                         By: /s/ Ludo J. Reynders
                                             -----------------------------------
                                         Printed name: Ludo J. Reynders
                                         Title: President/CEO

<PAGE>

                                    EXHIBIT A

                                   BATCH SIZES

<TABLE>
<CAPTION>
 Product Name                  Generic Description                   Strength    Package    Batch Size
 ------------                  -------------------                   --------   ---------   ----------
<S>               <C>                                                <C>        <C>         <C>
Darvon 65         Propoxyphene Hydrchloride Pulvules                    65mg       100         [**]
Darvon Compound   Propoxyphene Hydrchloride+ASA+ Caffeine Pulvules      65mg       100         [**]
Darvon-N          Propoxyphene Napsylate tabs                          100mg       100         [**]
Darvocet-N 50     Propoxyphene Napsylate+Acetaminophen Tabs             50mg       100         [**]
Azathioprine      Azathioprine Tabs                                     50mg       100         [**]
Methadone         Methadone Injection                                 10mg/ml   20ml vial      [**]
</TABLE>

<PAGE>

                                    EXHIBIT B

                                INITIAL PRODUCTS

Darvocet-N 50 marketed [**]
Darvon (65mg) marketed [**]
Darvon-N marketed [**]
Darvon Compound-65 marketed [**]
Methadone Hydrochloride Injection ([**]mg/ml) marketed [**]
Azathioprine Tablets (50mg) marketed [**]

<PAGE>

                                    EXHIBIT C

                                 SPECIFICATIONS

<PAGE>

                                      [**]

<PAGE>

                                    EXHIBIT D

                                 PURCHASE PRICES

                                      [**]

<TABLE>
<S>                                    <C>
WILMINGTON PLANT
Darvon 65 mg Pulvule 100 ct            $[**]
Darvon Compound 65 mg Pulvule 100 ct   $[**]
Darvocet-N 50 mg Tablet 100 ct         $[**]
Darvon-N 100 mg Tablet 100 ct          $[**]
Azathioprine 50 mg Tablet 100 ct       $[**]
CHARLESTON PLANT
Methadone 10 mg/mL 20mL vial           $[**]
</TABLE>

<PAGE>

                                    EXHIBIT B

                        MANUFACTURING AGREEMENT AMENDMENT

                 AMENDMENT TO COMMERCIAL MANUFACTURING AGREEMENT

     This Amendment to the Commercial Manufacturing Agreement ("Amendment") is
made by and between AAIPharma Inc. ("AAI") and Xanodyne Pharmaceuticals, Inc.,
("Xanodyne", and together with AAI, the "Parties"), and is effective as of the
25th day of May, 2006 (the "Effective Date").

     WHEREAS, AAI Development Services, a then division of AAI, and Xanodyne
entered into a Commercial Manufacturing Agreement dated July 25, 2005
("Agreement");

     WHEREAS, the AAI Development Services division of AAI has been dissolved,
leaving AAI as the successor in interest of AAI Development Services under the
Agreement; and

     WHEREAS, Xanodyne and AAI desire to amend the Agreement upon the terms and
conditions set forth in this Amendment.

     NOW, THEREFORE, the Parties hereby agree as follows:

     G. All references in the Agreement to "AAI Development Services" are hereby
replaced with references to "AAIPharma Inc." and references to "AAI DS" are
hereby replaced with references to "AAI."

     H. The last sentence of Section 4.2(a) is hereby deleted in its entirety.

     I. In consideration of the amendment to Section 4.2(a) set forth above,
Xanodyne shall pay to AAI $90,000 on or before January 1, 2007 and $90,000 on or
before January 1, 2008.

     J. This Amendment contains the entire agreement of the Parties with respect
to the subject matter covered in this Amendment.

     K. Except as otherwise expressly modified or amended herein, the terms and
conditions of the Agreement remain in full force and effect.

     L. This Amendment may be executed in one or more counterparts, each of
which shall be deemed an original but all of which taken together shall
constitute one and the same document. In addition, this document may be executed
by facsimile, and the parties agree that facsimile copies of signatures shall
have the same effect as original signatures.

     M. This Amendment shall be governed by and construed in accordance with the
laws of the State of New York applicable to contracts made and performed in such
State.

                      [Signature Page Immediately Follows]

<PAGE>

     IN WITNESS WHEREOF, the Parties hereto have caused this Amendment to be
executed by their respective officers thereunto duly authorized, as of the
Effective Date.

XANODYNE PHARMACEUTICALS, INC.       AAIPHARMA INC.

By: /s/ William A. Nuerge            By: /s/ Vito Mangiardi
    ------------------------------       ---------------------------------------
Name: William A. Nuerge              Name: Vito Mangiardi
Title: CEO                           Title: President, North American Operations
Dated: 5/18/06                       Dated: 5/25/06

                                       -2-<PAGE>

                                                                   Exhibit 10.11

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                  ASSIGNMENT, TRANSFER AND ASSUMPTION AGREEMENT

     This ASSIGNMENT, TRANSFER AND ASSUMPTION AGREEMENT (the "Agreement") is
entered into as of February 18, 2002 (the "Effective Date"), by and between
NEOSAN PHARMACEUTICALS INC. ("NeoSan"), a corporation organized and existing
under the laws of the State of Delaware with offices located at 2320 Scientific
Park Drive, Wilmington, NC 28409, and ELI LILLY AND COMPANY ("Lilly"), a
corporation organized and existing under the laws of the State of Indiana with
offices located at Lilly Corporate Center, Indianapolis, Indiana 46285. NeoSan
and Lilly are sometimes referred to herein individually as a "Party" and
collectively as "Parties".

                                    RECITALS

     WHEREAS, subject to the terms and conditions set forth in this Agreement,
Lilly and NeoSan desire to enter into an agreement pursuant to which: (i) Lilly
will sell or license to NeoSan, and NeoSan will purchase or license from Lilly,
certain promotional materials, new drug applications, copyrights, trade dress,
technology and trademarks owned by Lilly or its Affiliates, as set forth below,
(ii) NeoSan will license to Lilly (or Lilly will reserve) certain rights under
the new drug applications, technology, copyrights, trade dress, trademarks and
other assets purchased by or licensed to NeoSan to be used by Lilly to
manufacture Product for NeoSan under the Manufacturing Agreement, and (iii)
NeoSan will assume certain liabilities associated with the rights transferred
herein, each in accordance with the terms and conditions set forth herein; and

     WHEREAS, Lilly and NeoSan desire to enter into a separate manufacturing
agreement of even date herewith (the "Manufacturing Agreement") whereby Lilly
will manufacture certain presentations of Product on behalf of NeoSan.

     NOW, THEREFORE, in consideration of the foregoing, the covenants and
promises contained in this Agreement, and other good and valuable consideration,
the sufficiency and receipt of which are hereby acknowledged, Lilly and NeoSan
agree as follows:

<PAGE>

                                    ARTICLE 1
                                   DEFINITIONS

     For purposes of this Agreement, the following terms will have the meanings
     set forth below:

1.1  "ACTION OR PROCEEDING" means any action, suit, proceeding, arbitration,
     inquiry, hearing, assessment with respect to fines or penalties, or
     litigation (whether civil, criminal, administrative, investigative or
     informal) commenced, brought, conducted or heard by or before, or otherwise
     involving, any Governmental or Regulatory Authority.

1.2  "ACTIVITIES" means the manufacturing, packaging, marketing, distribution,
     promoting, co-marketing, co-promoting and selling of the Product as
     conducted by Lilly in the United States on or before the Closing Date.

1.3  "AFFILIATES" means, with respect to a Party, any Persons directly or
     indirectly controlling, controlled by, or under common control with, such
     Party. For purposes of this definition, a Person has control of another
     Person if it has the direct or indirect ability or power to direct or cause
     the direction of management policies of such other Person or otherwise
     direct the affairs of such other Person, whether through ownership of at
     least fifty percent (50%) of the voting securities of such other Person, by
     contract or otherwise.

1.4  "APPLICABLE LAWS" means all applicable laws, ordinances, rules,
     regulations, writs, judgments, decrees, injunctions (whether preliminary or
     final), orders and other requirements of any kind whatsoever of any
     Governmental or Regulatory Authority, including all laws, ordinances, rules
     and regulations promulgated by the World Health Organization and the FDA,
     including cGMP (as defined in the Manufacturing Agreement).

1.5  "ASSIGNED TRADE DRESS" means any unique appearance, look, shape, size or
     color of the Product marketed by Lilly or its Affiliates as of the
     Effective Date other than the Licensed Trademark and Trade Dress.

1.6  "ASSIGNED TRADEMARKS" means the trademarks listed in SCHEDULE 1.6 attached
     hereto, and all amendments thereto. For avoidance of doubt, the Assigned
     Trademarks do not include the Assigned Trade Dress or Licensed Trademarks
     and Trade Dress.

1.7  "ASSUMED LIABILITIES" will have the meaning set forth in Article 10.

                                       2

<PAGE>

1.8  "BASE YEAR'S AVERAGE QUARTERLY NET SALES" means fifteen million eight
     hundred thousand US dollars ($15,800,000). For any partial Calendar Quarter
     in which a NeoSan New Product is sold, the Base Year's Average Quarterly
     Net Sales for such Calendar Quarter with respect to such NeoSan New Product
     means the product of (a) fifteen million eight hundred thousand U.S.
     dollars ($15,800,000) multiplied by (b) the quotient of the number of days
     in such partial Calendar Quarter divided by ninety (90) days.

1.9  "B OF A" will have the meaning set forth in Section 6.25.

1.10 "BOND OFFERING" will have the meaning set forth in Section 6.25.

1.11 "BOND FINANCING HIGHLY-CONFIDENT LETTER" will have the meaning set forth in
     Section 6.25.

1.12 "BOOKS AND RECORDS" means all files, documents, instruments, papers, books
     and records (including scientific, regulatory and financial) owned by Lilly
     or an Affiliate of Lilly to the extent, and only to the extent, they are
     significantly related to the Purchased Assets (including the Products or
     the manufacture, marketing, promotion, sale or distribution thereof),
     including any sales records, pricing lists, customer lists (to the extent
     owned by Lilly or its Affiliates), vendor lists, financial data, regulatory
     information or files (including adverse event reports and annual regulatory
     reports), litigation files, patent prosecution files, adverse claims or
     demands, investigation information or files, trademark registration
     certificates, trademark renewal certificates.

1.13 "CALENDAR QUARTER" means the three month period ending on March 31, June
     30, September 30, or December 31. The initial Calendar Quarter will be
     deemed to begin on the Closing Date and end on the first to occur of March
     31, June 30, September 30 or December31.

1.14 "CALENDAR YEAR" means the twelve (12) month period ending on December 31st.
     The initial Calendar Year will be deemed to begin on the Closing Date and
     end on December 31, 2002.

1.15 "CLOSING DATE" will have the meaning set forth in Section 7.3(a).

1.16 "COMBINATION PATENTS" will have the meaning set forth in Section 3.7.

1.17 "COMMON LAW LICENSED TRADE DRESS" means the rights to the appearance, look,
     shape or size (but not color) of the parabaloidal capsule as it relates to
     the Product in the United States.

                                       3

<PAGE>

1.18 "CONFIDENTIAL INFORMATION" means information received (whether disclosed in
     writing, machine readable form, orally or by observation) by one Party (the
     "Receiving Party") from the other Party (the "Disclosing Party") that the
     Receiving Party has a reasonable basis to believe is confidential to the
     Disclosing Party or is treated by the Disclosing Party as confidential,
     unless such information:

          (a) was known to the Receiving Party or its Affiliates prior to
     receipt from the Disclosing Party, as documented in written records or
     publications, that lawfully are in the possession of the Receiving Party or
     its Affiliates;

          (b) was lawfully available to the trade or to the public prior to
     receipt from the Disclosing Party;

          (c) becomes lawfully available to the trade or to the public after
     receipt from the Disclosing Party through no act on the part of the
     Receiving Party or its Affiliates;

          (d) is obtained by the Receiving Party or its Affiliates from any
     Third Person without an obligation of confidentiality; or

          (e) is independently developed by an employee, contractor or agent of
     the Receiving Party or its Affiliates, subsequent to and without access or
     reference to the information received from the Disclosing Party, as
     demonstrated by contemporaneous written records.

          Notwithstanding the foregoing, (i) where a Disclosing Party discloses
     Confidential Information relating to an asset of such Disclosing Party to
     the Receiving Party, and the Receiving Party is or later becomes the owner
     of the asset, the Confidential Information then will be deemed to be
     Confidential Information of the Receiving Party, and the Disclosing Party
     may disclose and use such Confidential Information only in accordance with
     Article 8, below, provided, however, that where such Confidential
     Information was originally owned by Lilly, Lilly may use such Confidential
     Information for, and disclose such Confidential Information in connection
     with, the Permitted Uses without the prior written consent of NeoSan, and
     (ii) with respect to Confidential Information related to the Licensed
     Technology and Licensed Trademark and Trade Dress, NeoSan may use and
     disclose such Confidential Information without the prior written consent of
     Lilly.

1.19 "CONTRACT" means any and all legally binding commitments, contracts,
     purchase orders, leases, or other agreements, whether written or oral.

                                       4

<PAGE>

1.20 "COPYRIGHTS" means all of Lilly's copyright rights listed in SCHEDULE 1.20
     attached hereto, and any and all package inserts (excluding any Lilly-owned
     trademarks, logos or designs or trademarks, logos or designs licensed by
     Lilly other than those trademarks, logos or designs expressly assigned or
     licensed to NeoSan pursuant to the terms hereof), which are or were used or
     exercised by Lilly or its Affiliates in connection with the Activities or
     the Product.

1.21 "DAMAGES" means any and all costs, losses, claims, demands for payment,
     threatened government enforcement actions, liabilities, fines, penalties,
     expenses, court costs, and reasonable fees and disbursements of counsel,
     consultants and expert witnesses incurred by a Party hereto or its
     Affiliates (including interest which may be imposed in connection
     therewith).

1.22 "DEA" means the United States Drug Enforcement Agency, and any successor
     agency or entity thereto that may be established hereafter.

1.23 "DEDUCTIBLE AMOUNT" will have the meaning set forth in Section 11.4.

1.24 "EFFECTIVE DATE" will have the meaning set forth in the first paragraph of
     this Agreement.

1.25 "ENCUMBRANCE" means any mortgage, pledge, assessment, security interest,
     deed of trust, lease, lien, adverse claim, levy, charge or other
     encumbrance, third-party right or retained right of any kind, or any
     conditional sale or title retention agreement or other agreement to give
     any of the foregoing in the future.

1.26 "EXCLUDED LIABILITIES" means all Obligations of Lilly and its Affiliates
     other than Assumed Liabilities, including:

          (a) any Obligations arising out of any claims by the FDA, DEA or any
     other government entity or regulatory body that Lilly has failed to fulfill
     Lilly's regulatory obligations in connection with the NDAs prior to the
     Closing Date (except to the extent that such Damages arise out of any
     action or inaction on the part of NeoSan);

          (b) any Obligations arising out of the manufacture, marketing or sale
     of the Product prior to the Closing Date; and

          (c) any Obligations that Lilly expressly covenants and agrees to
     perform pursuant to the provisions of this Agreement or the Manufacturing
     Agreement.

1.27 "EXPIRED TRADEMARKS" will have the meaning set forth in Section 4.1.

                                       5

<PAGE>

1.28 "FDA" means the United States Food and Drug Administration, and any
     successor agency or entity thereto that may be established hereafter.

1.29 "GOVERNMENTAL OR REGULATORY AUTHORITY" means any United States federal,
     state or local governmental or regulatory authority, agency, commission,
     court or instrumentality, including the FDA.

1.30 "HSR ACT" means the Hart-Scott-Rodino Antitrust Improvements Act of 1976,
     Section 7A of the Clayton Act, 15 U.S.C. Section 18a, as amended.

1.31 "IMPLEMENTATION TEAM" will have the meaning set forth in Section 6.1.

1.32 "INDEMNIFIED PARTY" and "INDEMNIFYING PARTY" will have the meanings set
     forth in Section 11.3.

1.33 "INTELLECTUAL PROPERTY" will have the meaning set forth in Section 4.1.

1.34 "KNOW-HOW" means all of the following to the extent pertaining to Product
     as of the Closing Date and any pending or terminated analogs, derivatives,
     improvements or variations thereon as of the Closing Date and the
     manufacture, promotion, marketing, sale, use or importation of the
     foregoing (except to the extent specifically and exclusively related to the
     Combination Patents) as of the Closing Date: specifications; tangible or
     intangible manufacturing, physical chemistry and formulation know-how;
     analytical testing methods and validations; technical knowledge; expertise;
     skill; practices and procedures; formulae; tangible or intangible trade
     secrets; inventions (whether or not patentable); ideas; conceptions;
     reductions-to-practice; confidential and/or proprietary information;
     analytical methodology; processes (including any portion, step and
     component of such processes); methods; preclinical, clinical, stability and
     other data and results; chemical samples or substances; market studies; and
     all other experience and know-how, whether or not patentable, provided that
     nothing in this Agreement will require Lilly to locate or review the files
     or records specifically pertaining to the Combination Patents or the
     combination products covered thereby for potential Know-How and provided
     further that, subject to the limitations set forth in Section 3.2, the
     foregoing exclusion with respect to the Combination Patents will not
     preclude NeoSan or its Affiliates or permitted sublicensees or assignees
     from utilizing the Know-How licensed or transferred hereunder with respect
     to their own combination pharmaceutical products that do not infringe the
     Combination Patents.

                                       6

<PAGE>

1.35 "LICENSED TECHNOLOGY" means all Know-How which have been issued, filed,
     developed, created, made, used or acquired on or before the Closing Date by
     Lilly or its Affiliates, to the extent such Know-How are used by Lilly in
     connection with the development, manufacture, use or sale of the Products
     in the United States as of the Closing Date; provided that "Licensed
     Technology" does not include the Combination Patents.

1.36 "LICENSED TRADEMARK AND TRADE DRESS" means (i) the United States
     Pulvules(R) Trademark, (ii) the Common Law Licensed Trade Dress, and (iii)
     the United States Parabaloidal Capsule Trade Dress.

1.37 "LOAN FACILITY" will have the meaning set forth in Section 6.25.

1.38 "LOAN FACILITY HIGHLY-CONFIDENT LETTER" will have the meaning set forth in
     Section 6.25.

1.39 "MANUFACTURING AGREEMENT" will have the meaning set forth in the second
     WHEREAS clause of this Agreement.

1.40 "MARKETING MATERIALS" means (i) all market research, marketing plans, media
     plans, advertising, marketing-related clinical study results, form letters
     and medical queries, sale straining materials, customer information solely
     with respect to sales of Products in the United States (including doctors,
     general purchasing organizations (GPOs) and pharmacists), promotional and
     marketing books and records owned by Lilly and its Affiliates solely
     pertaining to the marketing and promotion of the Products in the United
     States; and (ii) the Promotional Materials, provided that "Marketing
     Materials" will exclude the labeling of the Products, which will be deemed
     part of the Regulatory Approvals.

1.41 "MATERIAL ADVERSE EFFECT" means an effect or condition that individually or
     in the aggregate is materially adverse to (i) the Purchased Assets taken as
     a whole; (ii) any material Product or its Regulatory Approval in the United
     States, each taken individually; or (iii) the business of manufacturing,
     marketing or selling Products, taken as a whole, as conducted by Lilly and
     its Affiliates in the ordinary course of business in the United States
     prior to the Closing Date.

1.42 "MYLAN" means Mylan Pharmaceuticals, Inc.

1.43 "MYLAN AGREEMENT" means the propoxyphene Supply Agreement between Lilly and
     Mylan entered into as of the 18th of April 1994, as thereafter amended.

1.44 "NDAS" mean the United States New Drug Applications and Investigational New
     Drug applications ("IND") listed in SCHEDULE 1.44 attached hereto and all
     other submissions, sup-

                                       7

<PAGE>

     plements or amendments pertaining thereto, and the official and working
     regulatory and clinical files and data pertaining to any of the foregoing
     in the possession or control of Lilly or its Affiliates as of the Closing
     Date. For avoidance of doubt, the NDAs do not include any marketing
     authorizations in any jurisdiction outside of the United States or any
     other submissions, supplements or amendments pertaining thereto filed
     outside of the United States.

1.45 "NEOSAN IMPROVEMENTS" means any inventions, ideas, conceptions, or
     reductions-to-practice, patentable or not, information, works, and/or data
     pertaining to Products or analogs, derivatives, improvements or variations
     thereof that are generated, identified, discovered, created and/or made by
     NeoSan, its Affiliates, or its or its Affiliates' employees or a Third
     Person contracted by or otherwise controlled by NeoSan based on the use or
     practice of the Licensed Technology.

1.46 "NEOSAN NEW PRODUCT" means (i) any pharmaceutical product that is an
     analog, derivative, improvement or variation of a Product arising out of
     NeoSan Improvements, (ii) any pharmaceutical product which includes
     propoxyphene or any analog, derivative, improvement, or variation of
     propoxyphene as an active ingredient arising out of an invention related to
     the Product conceived and reduced to practice by a NeoSan or a NeoSan
     Affiliate employee(s) or a Third Person contracted by or otherwise
     controlled by NeoSan, (iii) any other pharmaceutical product developed by
     NeoSan and/or a Third Person contracted by or otherwise controlled by
     NeoSan which includes propoxyphene or any analog, derivative, improvement,
     or variation of propoxyphene as an intended active ingredient, or (iv) any
     pharmaceutical product marketed under a name which includes "Darvon,"
     "Darvocet," "Distalgesic," "Digesic"or "Doloxene." Notwithstanding the
     foregoing, a pharmaceutical product which includes propoxyphene or any
     analog, derivative, improvement or variation thereof will not constitute an
     NeoSan New Product to the extent such product is acquired by NeoSan or its
     Affiliates as a result of any (a)(i) merger or (ii) acquisition by NeoSan
     or its Affiliates of substantially all of the assets of a Third Person
     (each, an "NeoSan Relationship"), in which the other party or parties
     involved in such NeoSan Relationship at that time already conducts or
     engages in the manufacturing, marketing, selling, promoting, distributing,
     co-marketing, co-promoting, importing, exporting or active developing of a
     pharmaceutical product which includes propoxyphene or any analog,
     derivative, improvement or variation thereof, or (b) acquisition by NeoSan
     or its Affiliates of any pharmaceutical product (whether or not containing
     propoxyphene as an active ingredient), either before or after the
     acquisitions contemplated by this Agreement, and any analogs, derivatives,
     improvements or variations of or for such acquired pharmaceutical product,
     that are not marketed under a name which includes "Darvon," "Darvocet,"
     "Distalgesic," "Digesic" or "Doloxene".

                                       8

<PAGE>

1.47 "NET SALES" means, with respect to the Product or any NeoSan New Product,
     as the context requires, the gross amount invoiced by Lilly or a Permitted
     Seller of the Product or such NeoSan New Product, as the context requires,
     for sales of the Product or such NeoSan New Product, as the context
     requires, to Third Persons (other than Permitted Sellers), less

          (a) trade, quantity and/or cash discounts actually allowed;

          (b) discounts, refunds, rebates, chargebacks, retroactive price
     adjustments and any other allowances, credits or payments which effectively
     reduce the net selling price;

          (c) actual Product or NeoSan New Product returns and allowances, as
     the context requires; and

          (d) any costs of insurance, freight or sales Tax or governmental
     levies, and import duties, provided that they are included in such gross
     invoice amount and are itemized or readily identifiable on such invoice or
     other readily accessible documentation.

     Such amounts will be determined from books and records maintained in
     accordance with U.S. Generally Accepted Accounting Principles ("GAAP"). No
     deductions will be made for commissions.

1.48 "NET SALES VOLUME ADJUSTMENT" will have the meaning set forth in Section
     2.2.

1.49 "OBLIGATIONS" will have the meaning set forth in Article 10.

1.50 "PATENTS" means U.S. patents, patent applications, and statutory invention
     registrations (which, for the purpose of this Agreement, will be deemed to
     include provisional applications and invention disclosures), including
     reissues, divisions, continuations, continuations-in-part, extensions and
     reexaminations thereof, all inventions disclosed therein, all rights
     provided by international treaties and conventions, and all rights to
     obtain and file for patents and registrations thereto.

1.51 "PERMITTED ENCUMBRANCE" means (i) any Encumbrance for Taxes, assessments
     and other governmental charges not yet due and payable or that may
     thereafter be paid without penalty, or that are being contested in good
     faith by appropriate proceedings for which adequate reserves have been
     established, (ii) any imperfection of title or other Encumbrance that,
     individually or in the aggregate with other such imperfections and
     Encumbrances, would not have a material adverse effect on any material
     Purchased Asset, and (iii) any rights expressly reserved or retained by
     Lilly pursuant to the terms of this Agreement.

                                       9

<PAGE>

1.52 "PERMITTED SELLER" means NeoSan and its Affiliates and any assignee,
     licensee or sublicensee having the right to sell Product or a NeoSan New
     Product.

1.53 "PERMITTED USES" means, with respect to Lilly or its Affiliates, (a)
     manufacturing the Product, or having the Product manufactured, for NeoSan
     under the Manufacturing Agreement and otherwise fulfilling its obligations
     thereunder, (b) making or having the Product made in the United States for
     purposes of Lilly or its Affiliates distributing, using, selling, offering
     to sell, importing (except importing into the United States), exporting
     (except exporting to the United States), marketing, promoting, co-marketing
     and co-promoting the Product outside the United States, or (c) making,
     having made, distributing, using, selling, offering to sell, importing
     (except importing into the United States), exporting (except exporting to
     the United States), marketing, promoting, co-marketing and co-promoting the
     Product outside of the United States.

1.54 "PERSON" means a natural person, a corporation, a partnership, a trust, a
     joint venture, a limited liability company, any Governmental or Regulatory
     Authority or any other organization or entity.

1.55 "PRODUCT" means propoxyphene or propoxyphene-based pharmaceutical products
     (including such products wherein propoxyphene is at least one of the active
     ingredients) in all forms marketed or marketable in the United States under
     the NDAs, as existing as of the Closing Date, under whatever name sold.
     Notwithstanding the foregoing, "Product" will not mean or include any new
     formulations (including any NeoSan New Product).

1.56 "PRODUCT INTELLECTUAL PROPERTY" means (a) the Copyrights, (b) Assigned
     Trade Dress, and (c) the Assigned Trademark. NeoSan acknowledges and agrees
     that "Product Intellectual Property" does not include the Combination
     Patents or any rights thereto.

1.57 "PROMOTIONAL MATERIALS" means all existing advertising and promotional
     materials, including flyers, brochures, pamphlets, video cassettes,
     computer disks, CD-ROMs, non- licensed software, tradeshow materials and
     booths, literature, journal articles or reprints, or any similar materials
     or items, which are owned by Lilly and are readily available and pertain
     solely to the promotion of the Product in the United States or the
     Activities.

1.58 "PURCHASED ASSETS" means: (i) all rights, title and interest in and to the
     Products; (ii) all rights, title and interest in and to the Regulatory
     Approvals; (iii) the Product Intellectual, Property; (iv), the Marketing
     Materials; or (v) the Books and Records. The Purchased Assets do not
     include any fixed assets or inventory.

                                       10

<PAGE>

1.59 "QUALITY AGREEMENT" will have the meaning set forth in the Manufacturing
     Agreement.

1.60 "REGULATORY APPROVALS" means the NDAs.

1.61 "REMEDIES" will have the meaning set forth in Section 6.17.

1.62 "REQUIRED LILLY THIRD PARTY CONSENTS" has the meaning set forth in Section
     4.14.

1.63 "REPRESENTATIVES" of a Party means that Party's agents, contractors,
     employees, officers, directors, consultants, and advisors; its Affiliates;
     and the agents, contractors, employees, officers, directors, consultants
     and advisors of its Affiliates, agents, contractors, consultants and
     advisors.

1.64 "SUBSEQUENT EXCHANGE OFFER" will have the meaning set forth in Section
     8.2(g).

1.65 "TAX" means all of the following tax by any Governmental or Regulatory
     Authority in connection with the operations of either Party or its
     Affiliates or the transactions contemplated hereby: (i) any net income,
     alternative or add-on minimum tax, gross income, gross receipts, sales,
     use, ad valorem, transfer, franchise, profits, license, excise, severance,
     stamp, occupation, premium, property, environmental or windfall profit tax,
     custom, duty or other tax, governmental fee or other like assessment; (ii)
     any Obligation for the payment of any amounts of the type described in (i)
     above as a result of being a member of any affiliated, consolidated,
     combined, unitary or other group for any taxable period; and (iii) any
     Obligation for the payment of any amounts of the type described in (i) or
     (ii) above as a result of any express or implied obligation to indemnify
     any other person.

1.66 "THIRD PERSON" means a Person that is not a Party to this Agreement or an
     Affiliate of a Party to this Agreement.

1.67 "TRANSACTION FINANCING" will have the meaning set forth in Section 6.25.

1.68 "UNITED STATES" or "U.S." means the fifty (50) states and the District of
     Columbia constituting the United States of America and any territory or
     commonwealth owned or controlled by the United States of America, including
     Puerto Rico.

1.69 "UNITED STATES PARABOLOIDAL CAPSULE TRADEMARK" means the United States
     registered trademark design for a paraboloidal capsule, registration number
     732,292, registration date 06/05/1962.

                                       11

<PAGE>

1.70 "UNITED STATES PULVULES(R) TRADEMARK" means the United States registered
     trademark Pulvules(R), registration number 144210, registration date
     06/28/1921.

                                    ARTICLE 2
                                  CONSIDERATION

          In consideration of (i) Lilly's sale of Purchased Assets to NeoSan as
     set forth in this Agreement and (ii) the licenses granted by Lilly to
     NeoSan under the Licensed Technology and Licensed Trademark and Trade
     Dress, as set forth in this Agreement, NeoSan will pay the following
     amounts, as set forth in Sections 2.1 and 2.4:

2.1  NEOSAN'S PAYMENT UPON THE CLOSING DATE. On the Closing Date, NeoSan will
     pay to Lilly the sum of Two Hundred Eleven Million Four Hundred Thousand
     United States Dollars (US$211,400,000) by Federal Reserve electronic wire
     transfer in immediately available funds to an account designated by Lilly.

2.2  NET SALES VOLUME ADJUSTMENT. In the event that, during any consecutive
     twelve (12) calendar month period occurring between (and including) January
     1,2002 and the last day of the calendar month that contains the first year
     anniversary of the Closing Date, the aggregate of the (i) Net Sales of
     Product by Lilly and (ii) the Net Sales of Product by NeoSan or other
     Permitted Sellers equals or exceeds fifty million United States dollars
     ($50,000,000), Lilly will not owe NeoSan any purchase price adjustment
     ("Net Sales Volume Adjustment") pursuant to this Section 2.2; otherwise,
     Lilly will pay to NeoSan a Net Sales Volume Adjustment calculated as set
     forth in SCHEDULE 2.2 attached hereto. For purposes of this Agreement, a
     Net Sale of Product will be deemed to have been made by Lilly, NeoSan or a
     Permitted Seller, as applicable, as of the recorded sale date according to
     GAAP, without regard to whether its customer has actually paid Lilly,
     NeoSan or a Permitted Seller, as applicable. NeoSan will deliver to Lilly
     within fifteen (15) days of the end of each calendar month, a report
     detailing the Net Sales made by NeoSan or another Permitted Seller during
     the previous Calendar Month. Lilly will pay any Net Sales Volume Adjustment
     owed by Lilly pursuant to this Section 2.1 within thirty days after the
     last day of the calendar month that contains the one (1) year anniversary
     of the Closing Date.

                                       12

<PAGE>

2.3  PURCHASE PRICE ADJUSTMENT. For any Net Sales of Product by Lilly during any
     calendar month during the period beginning February 1, 2002 and ending the
     day before the Closing Date in excess of (i) four million one hundred
     sixty-seven thousand United States dollars ($4,167,000) for each full
     calendar month during such period, and (ii) the product of four million one
     hundred sixty-seven thousand United States dollars ($4,167,000) multiplied
     by the quotient of the number of days prior to the Closing Date in the
     calendar month that the Closing Date occurs divided by thirty (30) (the
     "Excess Net Sales"), Lilly will pay to NeoSan within thirty (30) days after
     the Closing Date a purchase price adjustment equal to ninety percent (90%)
     of such Excess Net Sales.

2.4  ROYALTY PAYMENT.

          (a) NeoSan will accrue and owe a royalty to Lilly equal to [**]
     percent ([**]%) of Net Sales of a NeoSan New Product in a Calendar Quarter
     in the United States by a Permitted Seller (collectively referred to as the
     "Royalty Payment"), to the extent, and only to the extent, that such Net
     Sales of all NeoSan New Products plus all Net Sales of Products by
     Permitted Sellers in such Calendar Quarter in the United States exceed, in
     the aggregate, the Base Year's Average Quarterly Net Sales. For any partial
     Calendar Quarter in which a NeoSan New Product is sold in the United
     States, for purposes of determining if and to what extent a Royalty Payment
     is due and owing with respect to such NeoSan New Product, the Net Sales of
     all NeoSan New Products in the United States plus all Net Sales of Products
     by Permitted Sellers in the United States in such Calendar Quarter will be
     deemed to be equal to the product of (a) the total of such Net Sales
     multiplied by (b) the quotient of the number of days in such partial
     Calendar Quarter divided by ninety (90) days. For purposes of clarity and
     not in limitation thereof, no royalties will be owed by NeoSan or its
     Affiliates with respect to any Net Sales of Products or any pharmaceutical
     product not coming within the definition of "NeoSan New Product". This
     Section 2.3(a) will be in force with respect to each NeoSan New Product in
     the United States until ten (10) years from the commercial launch of such
     NeoSan New Product in the United States.

          (b) NeoSan will pay to Lilly the Royalty Payment attributable to Net
     Sales of NeoSan New Products made during a Calendar Quarter within sixty
     (60) days of the end of such Calendar Quarter, without regard to whether
     the Permitted Seller's customer has actually paid NeoSan. For purposes of
     this Agreement, a Net Sale of a NeoSan New Product will be deemed to have
     been made as of the recorded sale date according to GAAP, without regard to
     whether its customer has actually paid NeoSan. Within sixty (60) days of
     the end of such Calendar Quarter, NeoSan will provide Lilly with a written
     report detailing the Net

                                       13

<PAGE>

     Sales of NeoSan New Products made during the previous Calendar Quarter. All
     payments to Lilly pursuant to this Section 2.2 will be made by NeoSan by
     wire transfer on its due date to an account designated by Lilly no less
     than two business days prior to the date of payment, unless otherwise
     instructed by Lilly.

2.5  AUDITS. NeoSan will keep full and accurate books and records relating to
     the performance required of it of its Royalty Payment obligations under
     this Agreement and its Net Sales of Product. For any period in which NeoSan
     is obligated to pay a Royalty Payment with respect to Net Sales of NeoSan
     New Products, plus two (2) years thereafter, and the period beginning on
     the Closing Date and ending the last day of the calendar month that
     contains the one (1) year anniversary of the Closing Date with respect to
     Net Sales of Product, plus two (2) years thereafter, Lilly will have the
     right, during regular business hours and upon reasonable advance notice, to
     have such books and records of NeoSan audited no more frequently than once
     per Calendar Year so as to verify the accuracy of the information
     previously reported to Lilly. Lilly will, for purposes of such audit,
     utilize only the services of an independent CPA firm selected by Lilly and
     approved by NeoSan, such approval not to be unreasonably withheld.

          Such audit may cover the two (2) Calendar Years preceding the date of
     the request for such audit. Notwithstanding the foregoing, no audit of
     NeoSan pursuant to this Section 2.3 will cover any period of time preceding
     the Closing Date. As a condition for their access to conduct such audit,
     such accountants will agree with NeoSan to keep confidential any in
     formation obtained during such audit and will report to Lilly only their
     conclusions, with a copy or full summary of their oral or written reports
     being provided to NeoSan. The cost of such audit will be borne by Lilly;
     however, in the event such audit reveals that the Royalty Payments or Net
     Sales of Product previously reported to Lilly are less than the properly
     calculated amount of Royalty Payments hereunder or Net Sales of Product, as
     applicable, by five percent (5%) or more, the cost of the audit will be
     borne by NeoSan. NeoSan will include in all sublicenses granted in
     accordance herewith, and any other agreements enabling a Third Person to be
     a Permitted Seller, an audit provision substantially similar to the
     foregoing requiring such Permitted Seller to keep full and accurate books
     and records relating to sales of Products and NeoSan New Products thereby
     and granting Lilly the right to have an independent public accounting firm
     audit the accuracy of the information reported by the sublicensee in
     connection therewith.

2.6  LATE PAYMENTS. Any amounts not paid by either Party when due under this
     Agreement or the Manufacturing Agreement will be subject to interest from
     and including the date payment

                                       14

<PAGE>

     is due through and including the date upon which the other Party has
     collected the funds in accordance herewith at a rate equal to the lesser of
     (i) the sum of three percent (3%) plus the prime rate of interest quoted in
     the Money Rates section of the Wall Street Journal, calculated daily on the
     basis of a three hundred sixty-five (365) day year, or (ii) the maximum
     interest rate allowed by law.

                                    ARTICLE 3
                    ASSIGNMENT AND LICENSE OF RIGHTS; CLOSING

3.1  ASSIGNMENT OF PURCHASED ASSETS TO NEOSAN. Subject to the terms and
     conditions set forth herein and in the bill of sale, a form of which is
     attached hereto as Exhibit A ("Lilly Bill of Sale"), on the Closing Date,
     Lilly agrees to assign, sell, convey, transfer and deliver to Neo San and
     to cause its Affiliates to assign, sell, convey, transfer and deliver to
     NeoSan, and NeoSan agrees to buy and accept, Lilly's and its Affiliates'
     entire right, title and interest in and to the Purchased Assets, free and
     clear from all Encumbrances other than Permitted Encumbrances. NeoSan
     hereby acknowledges receipt of copies of certain Books and Records during
     the due diligence process. Lilly will deliver to NeoSan any additional
     Books and Re cords requested by NeoSan on or after the Closing Date within
     a commercially reasonable time after such request. Notwithstanding the
     foregoing, Lilly will be entitled to retain a copy of all or any portion of
     the Books and Records for archive purposes. In the event, following the
     Closing Date, that Lilly or NeoSan discover that any of the Purchased
     Assets were held at the time of Closing by any Affiliate of Lilly and not
     transferred to NeoSan at the Closing, Lilly will cause the transfer thereof
     to NeoSan or NeoSan's designee as soon as is commercially practicable after
     such discovery. Notwithstanding the foregoing, Lilly and its Affiliates'
     assignment, sale, conveyance, transfer and delivery of the Assigned Trade
     Dress is restricted to the use of such trade dress with the Product and any
     NeoSan New Product, and neither this Section 3.1 nor any other part of this
     Agreement will be construed to restrict Lilly, its Affiliates or its
     licensees, assignees or successors from utilizing the Assigned Trade Dress
     in connection with any product or use other than the Product and any NeoSan
     New Product.

3.2  GRANT OF LICENSE TO NEOSAN UNDER LICENSED TECHNOLOGY. Subject to the terms
     and conditions set forth herein, as of the Closing Date, Lilly hereby
     grants to NeoSan, on behalf of Lilly and its Affiliates, and NeoSan
     accepts, under the Licensed Technology, an irrevocable (subject to
     suspension to the extent expressly set forth herein), fully-paid,
     royalty-free, exclusive license, with a right to sublicense or assign such
     license rights in

                                       15

<PAGE>

     accordance with the terms of this Agreement, solely to make, have made,
     distribute, use, sell, offer to sell, have sold, market, co-market, import,
     export, promote and co-promote the Products, any analogs, derivatives,
     improvements or variations thereon, the NeoSan Improvements, NeoSan New
     Products, or other pharmaceutical products which utilize propoxyphene as an
     active ingredient thereof, in the United States (and to make or have made
     any of the foregoing outside the United States solely for importation into,
     and distribution, use, sale, market, co-market, promote and co-promote any
     of the foregoing in, the United States); provided, however, that the
     foregoing license with respect to making or having made any of the
     foregoing outside the United States will be non-exclusive; provided
     further, however, that the foregoing license will not be deemed to be a
     representation, warranty or covenant by Lilly that NeoSan will be able to
     practice the Licensed Technology to make and have made anywhere in the
     world any pharmaceutical product other than the Product or to make or have
     made the Product or any other pharmaceutical product outside of the United
     States. Notwithstanding anything in this Section 3.2 to the contrary, the
     license under the Licensed Technology granted to NeoSan pursuant to this
     Section 3.2 will not preclude Lilly from utilizing the Licensed Technology
     for any Permitted Uses during the term thereof. Further notwithstanding
     anything in this Agreement to the contrary, nothing in this Agreement will
     be deemed to preclude Lilly from granting a license under the Licensed
     Technology to a Third Person solely for purposes of making or having made
     the Product in the United States for distribution, exportation (outside of
     the United States), use, sale, marketing, co-marketing, promoting and
     co-promoting the Product outside of the United States, and Lilly will have
     no liability for granting such license. The licenses granted to NeoSan
     pursuant to this Section 3.2 will be subject to the rights reserved by
     Lilly in the preceding two sentences.

3.3  GRANT OF LICENSE TO LICENSED TRADEMARK AND TRADE DRESS TO NEOSAN.

          (a) Subject to the terms and conditions set forth herein, as of the
     Closing Date, Lilly hereby grants to NeoSan, and NeoSan accepts, under the
     Common Law Licensed Trade Dress, a fully paid, royalty-free, exclusive
     license solely to make, have made, distribute, use, sell, offer to sell,
     have sold, market, co-market, promote and co-promote the Product or NeoSan
     New Product in the United States.

          (b) Subject to the terms and conditions set forth herein, as of the
     Closing Date, Lilly hereby grants to NeoSan, and NeoSan accepts, under the
     United States Pulvules(R) Trademark and United States Paraboloidal Capsule
     Trademark, a fully-paid, royalty-free, exclusive license solely to make,
     have made, distribute, use, sell, offer to sell, have sold,

                                       16

<PAGE>

     market, co-market, promote and co-promote the Product or NeoSan New
     Products in the United States.

          (c) All uses by NeoSan of the Licensed Trademark and Trade Dress will
     be in an appropriate manner, without jeopardizing the significance,
     distinctiveness or validity of the Licensed Trademark and Trade Dress; will
     use the designation "R" with the Licensed Trademark and Trade Dress which
     are registered trademarks and trade dress; will indicate that Pulvules(R)
     and the appearance of the paraboloidal capsule are registered trademarks of
     Lilly; and will only be in such form and manner as approved in writing by
     Lilly. All trademark and trade dress rights from NeoSan's use of the
     Licensed Trademark and Trade Dress will inure to the benefit of Lilly.
     NeoSan will not contest or challenge the validity of, or Lilly's ownership
     of, the Licensed Trademark and Trade Dress.

          (d) All Product featuring any of the Licensed Trademark and Trade
     Dress must be manufactured, labeled, sold, distributed and advertised in
     accordance with the Specifications (as defined in the Manufacturing
     Agreement) and all Applicable Laws, including cGMP and FDCA (as those terms
     are defined in the Manufacturing Agreement). Once each Calendar Year, in
     order that Lilly can assure itself of the maintenance of the
     above-described quality standards, NeoSan will: (i) provide to Lilly free
     of charge two (2) then-current production samples of each Product and
     NeoSan New Product featuring any of the Licensed Trademark and Trade Dress
     (with then-current packaging) not manufactured by Lilly, and (ii) permit
     Lilly to inspect the manufacturing process for each Product and NeoSan New
     Product not manufactured by Lilly featuring any of the Licensed Trademark
     and Trade Dress upon five (5) days prior notice.

          (e) Notwithstanding anything in this Section 3.3 to the contrary, the
     licenses under the Licensed Trademark and Trade Dress granted to NeoSan
     pursuant to this Section 3.3 will not preclude Lilly or its Affiliates from
     carrying out activities within the scope of the Permitted Uses. Further
     notwithstanding anything in this Agreement to the contrary, nothing in this
     Agreement will be deemed to preclude Lilly from granting a license under
     the Licensed Trademark and Trade Dress to a Third Person solely for
     purposes of making or having made the Product in the United States for
     distribution, exportation (outside of the United States), use, sale,
     marketing, co-marketing, promoting and co-promoting the Product outside of
     the United States, and Lilly will have no liability hereunder for granting
     such license. The licenses granted to NeoSan pursuant to this Section 3.3
     will be subject to the rights reserved by Lilly in the preceding two
     sentences.

                                       17

<PAGE>

          (f) Notwithstanding anything in this Section 3.3 to the contrary, any
     license granted to NeoSan under a Licensed Trademark and Trade Dress will
     terminate in the United States upon the date that NeoSan ceases to make,
     have made, sell, have sold, use, market, promote, co-market and co-promote
     all Products and NeoSan New Products that use such Licensed Trademark and
     Trade Dress in the United States.

3.4  SUBLICENSES. The licenses granted herein by Lilly to NeoSan pursuant to
     Sections 3.2 and 3.3 may be freely sublicensed by NeoSan after payment of
     the $211,400,000 pursuant to Section 2.1, subject to the sublicensee's
     compliance with the relevant obligations hereof with respect to such
     licensed rights, without any consent by Lilly, provided that (a) NeoSan
     provides written notice of such sublicense or assignment to Lilly prior to
     granting such sublicense, (b) NeoSan and aaiPharma Inc. ("aaiPharma") will
     guarantee the performance of any sublicensee permitted pursuant to this
     Section 3.4 in a form comparable to aaiPharma's guaranty appended hereto
     with respect to NeoSan's obligations hereunder, and (c) NeoSan will remain
     liable for Royalty Payments as a result of Net Sales made by a Third Person
     pursuant to a sublicense or license permitted pursuant to this Section 3.4.
     The licenses granted herein by Lilly to NeoSan pursuant to Sections 3.2 and
     3.3 may be sublicensed by NeoSan without continuing liability or guaranty
     to Lilly therefore only with the prior written consent of Lilly, which will
     not unreasonably be withheld.

3.5  GRANT OF LICENSE TO LILLY.

          (a) Subject to the terms and conditions set forth herein, as of the
     Closing Date, NeoSan hereby grants to Lilly and its Affiliates, for no
     additional consideration, and Lilly and its Affiliates accept, a
     royalty-free, non-exclusive license, with a right to sublicense, except as
     limited below, in the United States under the Product Intellectual
     Property, the NDAs and the Marketing Materials solely to manufacture, or to
     have manufactured, the Products for NeoSan under the Manufacturing
     Agreement and otherwise fulfill its obligations thereunder; provided,
     however, that the non-exclusive license granted by NeoSan above will
     terminate effective upon the termination of the Manufacturing Agreement.

          (b) Subject to the terms and conditions set forth herein, as of the
     Closing Date, NeoSan hereby grants to Lilly and its Affiliates, for no
     additional consideration, and Lilly and its Affiliates accept, an
     exclusive, royalty-free license, with the right to sublicense, under the
     Marketing Materials, Copyrights and Assigned Trade Dress to sell,
     distribute, use, offer to sell, import, market and promote the Product
     outside the United States or to make or have made the Product inside the
     United States for selling, distributing, using, offering to sell,
     importing, marketing and promoting the Product outside of the United
     States. The license

                                       18

<PAGE>

     granted pursuant to this Section 3.5(b) will terminate with respect to the
     Copyrights, the Marketing Materials or the Assigned Trade Dress on NeoSan's
     receipt of written notification from Lilly that it is abandoning its
     license with respect to the Copyrights, the Marketing Materials and the
     Assigned Trade Dress.

3.6  RETAINED RIGHTS. Notwithstanding anything in this Agreement to the
     contrary, the rights granted to NeoSan pursuant to this Agreement will not
     be deemed to preclude Lilly or its Affiliates from (i) delivering any
     remaining Product to Mylan that Lilly is required to deliver pursuant to
     the Mylan Agreement, and (ii) manufacturing in the United States and
     supplying propoxyphene to Lilly's or its Affiliates' customers outside the
     United States within the scope of Permitted Uses or otherwise conducting
     the Permitted Uses. The assets assigned or licensed to NeoSan pursuant to
     this Agreement are subject to the rights and obligations of Lilly, its
     Affiliates and Third Persons under the foregoing sentence.

3.7  EXCLUDED ASSETS. Anything herein to the contrary notwithstanding, except as
     set forth in the Manufacturing Agreement, NeoSan will have no right, title
     or interest in or to: (i) the trademarks "ELI LILLY AND COMPANY" and
     "LILLY" and any variation thereof, and any other rights in or to such
     names; and (ii) the patents and patent applications listed in SCHEDULE 3.7
     attached hereto (the "Combination Patents"); and (iii) the Mylan Agreement.

3.8  LILLY EMPLOYEE HEALTH SERVICES. Lilly reserves the right, and the rights
     granted or licensed to NeoSan are subject to Lilly's right, to utilize all
     supplies of finished Product held by Lilly's employee health services on
     the Closing Date for purpose of dispensing Product to its employees and
     relatives of employees until such supply is exhausted.

                                    ARTICLE 4
                     REPRESENTATIONS AND WARRANTIES OF LILLY

4.1  INTELLECTUAL PROPERTY. Lilly represents and warrants that the Product
     Intellectual Property (other than the Assigned Trade Dress), Marketing
     Materials, the Licensed Trademark and Trade Dress (other than the Common
     Law Licensed Trade Dress), and the Licensed Technology (collectively, the
     "Intellectual Property") and the Assigned Trade Dress and Common Law
     Licensed Trade Dress contain all the Patents, Know-How, technology, trade
     secrets, trademarks, and trade dress necessary to conduct the Activities or
     to make, have made, distribute, use, sell, offer to sell, have sold,
     market, co-market, import (into the United States), promote and co-promote
     Products in the United States. However, should Lilly or NeoSan

                                       19

<PAGE>

     after the Closing Date discover or learn that Lilly has inadvertently
     omitted any Intellectual Property or any Patents (other than the
     Combination Patents) that contain claims that directly relate to the
     manufacture, use or sale of Product and are used by Lilly to conduct the
     Activities, the Parties will discuss in good faith how to amend this
     Agreement to include (whether by assignment or license) such inadvertently
     omitted intellectual property or Patents, such omission will not be deemed
     to be a breach of this Agreement by Lilly, and Lilly will have no liability
     whatsoever with respect to such omission. Lilly makes no representation or
     warranty that NeoSan will be able to conduct the Activities after the
     Closing Date without acquiring the consents, approvals and permits and
     taking other procedural or substantive steps that are required by
     Applicable Law. For avoidance of doubt, "Intellectual Property does not
     mean or include the Assigned Trade Dress or Common Law Licensed Trade
     Dress. Notwithstanding the foregoing, NeoSan acknowledges and agrees that
     Lilly is not and will not be assigning or licensing to NeoSan the expired
     trademarks listed in SCHEDULE 4.1 attached hereto or any other expired
     trademarks directly and exclusively related to Lilly's propoxyphene
     business (collectively referred to herein as the "Expired Trademarks"), and
     Lilly will have no liability for failing to do so. Lilly acknowledges and
     agrees that NeoSan will have no liability to Lilly in the event that
     NeoSan, following the Closing Date, acts to register or otherwise obtain
     new trademarks substantially similar to, or the same as, the Expired
     Trademarks or uses such new trademarks on its products. The Expired
     Trademarks do not include any of the trademarks listed on Schedule 1.6
     hereto.

4.2  OWNERSHIP OF INTELLECTUAL PROPERTY. Lilly represents and warrants that: (i)
     either Lilly or an Affiliate of Lilly is the owner of the Intellectual
     Property, and (ii) Lilly or its Affiliates can, and have the right to,
     assign or license, as applicable, the Intellectual Property to NeoSan
     without the consent of any Third Person. However, should Lilly or NeoSan
     after the Closing Date discover or learn that the consent of additional
     Third Persons is necessary with respect to the Intellectual Property, if
     the omitted consent does not result in material harm to a material Product
     being sold, or to be sold, by NeoSan in the United States, then such
     inadvertent omission will not be deemed to be a breach of this Agreement by
     Lilly and Lilly will have no liability whatsoever with respect to such
     omission; provided, however, that Lilly diligently pursues such consent
     from such Third Persons.

4.3  CLAIMS RELATED TO USE OF INTELLECTUAL PROPERTY. Lilly represents and
     warrants that there are no pending, or to Lilly's knowledge as of the
     Effective Date, threatened claims against Lilly or its Affiliates asserting
     that any of the Intellectual Property infringes or violates the rights of
     Third Persons or that NeoSan, by practicing under the Intellectual Property
     in conducting

                                       20

<PAGE>

     the Activities in the United States as of the Closing Date, would violate
     any of the intellectual property rights of any Third Person.

4.4  NOTICE TO THIRD PERSONS. Lilly represents and warrants that Lilly has not
     given any notice within the two (2) years prior to the Effective Date to
     any Third Persons, asserting infringement by such Third Persons upon any of
     the Intellectual Property.

4.5  VALIDITY OF TRADEMARKS, TRADE DRESS, COPYRIGHTS AND TECHNOLOGY. Lilly
     represents and warrants that, to its knowledge as of the Effective Date,
     the Product Intellectual Property (other than the Assigned Trade Dress) and
     the Licensed Trademark and Trade Dress (other than the Common Law Licensed
     Trade Dress), are valid and enforceable, and, to Lilly's knowledge as of
     the Effective Date, the Licensed Trademark and Trade Dress (other than the
     Common Law Licensed Trade Dress) are free of all Encumbrances except
     Permitted Encumbrances. Notwithstanding the foregoing, NeoSan acknowledges
     that the status of the Assigned Trademarks will change in the ordinary
     course of business prior to the Closing Date. Lilly will not be in breach
     of this representation or warranty with respect to, and NeoSan will have no
     right to refuse to close the transactions contemplated by this Agreement
     because of, changes in the status of the Assigned Trademarks so long as
     Lilly maintains the Assigned Trademarks in the ordinary course of business
     prior to the Closing Date. Lilly is assigning, selling, conveying,
     transferring and delivering the Assigned Trade Dress to NeoSan "AS IS", and
     is licensing the Common Law Licensed Trade Dress to NeoSan "AS IS."

4.6  RIGHTS GRANTED TO THIRD PERSONS. Except with respect to the remaining
     deliveries required pursuant to Mylan Agreement, rights granted to its
     Affiliates that, following the Closing Date, will not extend past the
     Permitted Uses, rights granted to its wholesalers and government
     purchasers, Lilly represents and warrants that Lilly and its Affiliates
     have not executed or granted to any Third Person, directly or indirectly,
     or entered into any agreement for, or retained, any license or other right
     to develop, manufacture, market, distribute, sell or offer for sale the
     Product or generic substitutes therefor in the United States or to import
     the Product or any other rights in or with respect to the Products, generic
     substitutes therefor, or other propoxyphene-based pharmaceutical products
     into the United States.

4.7  MAINTENANCE. Lilly represents and warrants that, as of the Closing Date,
     all necessary papers and fees concerning the Assigned Trademarks (which are
     registered as of the Closing Date and are unexpired), and the Licensed
     Trademark and Trade Dress (other than the Common Law Licensed Trade Dress)
     have been timely paid and filed with the appropriate governmental agencies
     or authority.

                                       21

<PAGE>

4.8  NDAS; REGULATORY MATTERS. Lilly represents and warrants that Lilly has
     furnished NeoSan with access to a complete copy of the NDAs, including all
     amendments and supplements thereto and that Lilly has no new drug
     applications or INDs pertaining to propoxyphene-based pharmaceutical
     products, whether issued, pending, abandoned, withdrawn, or in draft form,
     other than those pertaining to the NDAS. Although the NDAs are not "state
     of the art" (which NeoSan hereby acknowledges), Lilly further represents
     and warrants that (i) Lilly has complied in all material respects with all
     Applicable Laws in connection with the preparation and submission to the
     FDA of each of the NDAs, (ii) each of the NDAs has been approved by FDA,
     and, except with respect to those of the NDAs listed in SCHEDULE 4.8
     attached hereto, nothing has come to the attention of Lilly which has led
     Lilly to believe that any of the NDAs are not in good standing with the
     FDA, and (iii) Lilly has filed with the FDA all required notices,
     supplemental applications and annual or other reports, including adverse
     experience reports, with respect to each NDA which are material to the
     ability of Lilly to conduct the Activities. All of the Regulatory Approvals
     are owned exclusively by Lilly or its Affiliates. All Products being sold
     by Lilly in the United States are covered by a Regulatory Approval therein
     that permits such sale in the United States. There is no Action or
     Proceeding by any Governmental or Regulatory Authority pending or, to the
     knowledge of Lilly as of the Effective Date, threatened seeking the
     revocation or suspension of any Regulatory Approval. Except as set forth in
     SCHEDULE 4.8 attached hereto, during the three years prior to the date of
     this Agreement, Lilly and its Affiliates have not received or been subject
     to: (i) any FDA Form 483's directly relating to any Product or directly
     relating to any facility in which such Product is manufactured; (ii) any
     FDA Notices of Adverse Findings directly relating to any Product or
     directly relating to any facility in which such Product is manufactured; or
     (iii) any warning letters or other written correspondence from the FDA or
     any other Governmental or Regulatory Authority directly relating to the
     Product or directly relating to any facility in which such Product is
     manufactured, in which the FDA or such other Governmental or Regulatory
     Authority asserted that the operations of Seller were not in compliance
     with Applicable Law with respect to any Product or the facilities in which
     any Product is manufactured, tested or stored. Except for the
     representation and warranty contained in this Section 4.8, NeoSan has had
     full and adequate opportunity to review and evaluate the NDAs, NeoSan is
     relying upon its own judgment and experience in connection with the NDAs,
     and Lilly is assigning, selling, conveying, transferring and delivering the
     NDAs to NeoSan "AS IS."

4.9  ORGANIZATION AND STANDING. Lilly represents and warrants that Lilly is a
     corporation duly organized, validly existing, and in good standing under
     the laws of the State of Indiana. Lilly and its relevant Affiliates
     hereunder are duly qualified to conduct its business and is in good

                                       22

<PAGE>

     standing in the United States wherein the nature of such business requires
     such qualification, except for any failure to be so qualified could not
     reasonably be expected to have a Material Adverse Effect or materially
     impair or delay Lilly's ability to perform its obligations hereunder.

4.10 POWER AND AUTHORITY. Lilly represents and warrants that (i) Lilly has all
     requisite corporate power and authority to execute, deliver, and perform
     this Agreement and the other agreements and instruments to be executed and
     delivered by it pursuant hereto and thereto and to consummate the
     transactions contemplated herein and therein; and (ii) the execution,
     delivery and performance of this Agreement by Lilly does not, and the
     consummation of the transactions contemplated hereby will not, violate any
     provisions of Lilly's organizational documents, bylaws, or any Applicable
     Law applicable to Lilly, or any agreement, mortgage, lease, instrument,
     order, judgment, or decree to which Lilly is a party or by which Lilly or
     any of the Purchased Assets is bound.

4.11 CORPORATE ACTION; BINDING EFFECT. Lilly represents and warrants that (i)
     Lilly has duly and properly taken all action required by law, its
     organizational documents, or otherwise, to authorize the execution,
     delivery, and performance of this Agreement and the other instruments to be
     executed and delivered by it pursuant hereto and thereto and the
     consummation of the transactions contemplated hereby and thereby; and (ii)
     this Agreement has been duly executed and delivered by Lilly and
     constitutes, and the other instruments contemplated hereby when duly
     executed and delivered by Lilly will constitute, legal, valid, and binding
     obligations of Lilly enforceable against it in accordance with its
     respective terms, except as enforcement may be affected by bankruptcy,
     insolvency, or other similar laws.

4.12 REGULATORY STATUS OF NDAS. Except as set forth in SCHEDULE 4.12, Lilly
     represents and warrants that, to Lilly's knowledge, there have been no
     recalls, withdrawals, or market replacements of the Product in the United
     States in the past two (2) years and that, to Lilly's knowledge as of the
     Effective Date, there exists no set of facts or circumstances that would
     cause Lilly to believe or suspect that a recall, withdrawal or market
     replacement for the Product in the United States is pending, likely or
     necessary.

4.13 LAWS AND REGULATIONS. Lilly represents and warrants that it and its
     Affiliates have conducted all the Activities in material compliance with
     Applicable Laws.

4.14 CONSENTS AND APPROVALS. Lilly represents and warrants that no consent,
     approval, waiver, order or authorization of, or registration, declaration
     or filing with, any Governmental or Regulatory Authority or any other Third
     Person is required in connection with the execution,

                                       23

<PAGE>

     delivery and performance of this Agreement, or any agreement or instrument
     contemplated by this Agreement, by Lilly or the performance by Lilly of its
     obligations contemplated hereby and thereby other than (a) the filings
     required of both Parties pursuant to the HSR Act, (b) the information
     submissions required of a former owner of the NDAs pursuant to 21 C.F.R.
     Section 314.72, (c) any filings reasonably requested by NeoSan as may be
     necessary to change the records of ownership in the U.S. Trademark or
     Copyright Office, and (d) as set forth in SCHEDULE 4.14 attached hereto.
     SCHEDULE 4.14 sets forth a complete and accurate list of all consents,
     waivers, approvals, or authorizations of, or notices to, any third party
     (other than a Governmental or Regulatory Authority) that are required by or
     with respect to Lilly or its Affiliates in connection with the execution
     and delivery of this Agreement by Lilly as it relates to the United States
     or the performance of its obligations hereunder as it relates to the United
     States, except for such consents, waivers, approvals, or authorizations the
     failure to obtain which, and such notices the failure to give which, would
     not have a Material Adverse Effect or materially impair or delay Lilly's
     ability to perform its obligations hereunder (the "Required Lilly Third
     Party Consents").

4.15 BROKERAGE. Lilly represents and warrants that no broker, finder or similar
     agent has been employed by or on behalf of Lilly, and no Person with which
     Lilly has had any dealings or communications of any kind is entitled to any
     brokerage commission, finder's fee or any similar compensation, in
     connection with this Agreement or the transactions contemplated hereby.

4.16 NOT DEBARRED. Lilly represents and warrants that Lilly is not debarred and
     has not and will not use in any capacity the services of any Person
     debarred under subsections 306(a) or (b) of the Generic Drug Enforcement
     Act of 1992. If at any time this representation and warranty is no longer
     accurate, Lilly will immediately notify NeoSan of such fact.

4.17 LITIGATION. Lilly represents and warrants that there are no pending or, to
     Lilly's knowledge as of the Effective Date, threatened judicial,
     administrative or arbitral Actions or Proceedings pending as of the date
     hereof against Lilly or its Affiliates in the United States which, either
     individually or together with any other, will have a material adverse
     effect on the ability of Lilly to perform its obligations under this
     Agreement or any agreement or instrument contemplated hereby or otherwise
     have a Material Adverse Effect.

4.18 MATERIAL CONTRACTS. SCHEDULE 4.18 sets forth a complete and correct list of
     each Contract (other than wholesaler agreements) to be performed in the
     United States to which Lilly or any of its Affiliates is a party with a
     value in excess of $50,000 and that relates to (i) the manufacture,
     marketing, sale or distribution of any of the Products in the United
     States; (ii)

                                       24

<PAGE>

     the acquisition, sale, licensing in or out, or assignment of Product
     Intellectual Property; or (iii) sales of Products to any Governmental or
     Regulatory Authority (collectively, the "Material Contracts"). Lilly has
     made available to NeoSan complete and correct copies of Material Contracts.
     The Material Contracts are the only Contracts material to the Activities in
     the United States other than wholesaler agreements. Each of the Material
     Contracts is in effect and constitutes a legal, valid and binding
     agreement, enforceable in accordance with its terms, of Lilly; and Lilly
     has performed all of its required material obligations under, and is not in
     material violation or breach of or default under, any such Material
     Contract; and no other party to the Material Contracts is in material
     violation or breach of or default under any such Contract.

4.19 TITLE TO PURCHASED ASSETS. Lilly, on the Closing Date, will have good and
     marketable title to the Purchased Assets, free and clear of any
     Encumbrances other than Permitted Encumbrances, and will have the legal
     right and ability to transfer the Purchased Assets to NeoSan.

4.20 SURVIVAL PERIOD. The representations and warranties contained in this
     Article 4 and any indemnification obligation of Lilly set forth in Article
     11 associated with such representations and warranties will terminate on
     the one (1) year anniversary date of the date of expiration or termination
     of the Manufacturing Agreement, provided that any claims with respect
     thereto that are timely brought prior to such termination will survive and
     continue until their final resolution.

4.21 IMPLIED WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED IN THIS ARTICLE 4 AND
     ARTICLE 6 OF THE MANUFACTURING AGREEMENT, LILLY MAKES NO REPRESENTATION OR
     WARRANTY AS TO THE PRODUCT, COPYRIGHTS, THE LICENSED TECHNOLOGY, THE
     ASSIGNED TRADEMARKS, ASSIGNED TRADE DRESS, THE MARKETING MATERIALS, THE
     EXPIRED TRADEMARKS, BOOKS AND RECORDS, THE LICENSED TRADEMARKS AND TRADE
     DRESS, NDAs OR THE ACTIVITIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY
     OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND LILLY SPECIFICALLY DISCLAIMS
     ANY AND ALL IMPLIED OR STATUTORY WARRANTIES, INCLUDING ANY IMPLIED WARRANTY
     OF MERCHANTABILITY, WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE AND
     WARRANTY OF NON-ENFRINGEMENT. Without limiting the foregoing, NeoSan
     acknowledges that it has not and is not relying upon any implied warranty
     of merchantability, fitness for a particular purpose, noninfringement, or
     upon any representation or warranty whatsoever as to the future prospects
     (financial, regulatory or otherwise), or the likelihood of commercial
     success of the Activities after the date of this Agreement.

                                       25

<PAGE>

                                    ARTICLE 5
                    REPRESENTATIONS AND WARRANTIES OF NEOSAN

5.1  ORGANIZATION AND STANDING. NeoSan represents and warrants that NeoSan is a
     corporation duly organized, validly existing, and in good standing under
     the laws of the State of Delaware.

5.2  POWER AND AUTHORITY. NeoSan represents and warrants that (i) NeoSan has all
     requisite corporate power and authority to execute, deliver, and perform
     this Agreement and the other agreements and instruments to be executed and
     delivered by it pursuant hereto and thereto and to consummate the
     transactions contemplated herein and therein; (ii) the execution, delivery,
     and performance of this Agreement by NeoSan does not, and the consummation
     of the transactions contemplated hereby will not, violate any provisions of
     NeoSan's organizational documents, bylaws, any Applicable Law applicable to
     NeoSan, or any agreement, mortgage, lease, instrument, order, judgment, or
     decree to which NeoSan is a party or by which NeoSan is bound.

5.3  CORPORATE ACTION; BINDING EFFECT. NeoSan represents and warrants that (i)
     NeoSan has duly and properly taken all action required by law, its
     organizational documents, or otherwise, to authorize the execution,
     delivery, and performance of this Agreement and the other instruments to be
     executed and delivered by it pursuant hereto and thereto and the
     consummation of the transactions contemplated hereby and thereby; and (ii)
     this Agreement has been duly executed and delivered by NeoSan and
     constitutes, and the other instruments contemplated hereby when duly
     executed and delivered by NeoSan will constitute legal, valid, and binding
     obligations of NeoSan enforceable against it in accordance with its
     respective terms, except as enforcement may be affected by bankruptcy,
     insolvency, or other similar laws.

5.4  GOVERNMENTAL APPROVAL. NeoSan represents and warrants that no consent,
     approval, waiver, order or authorization of, or registration, declaration
     or filing with, any Governmental or Regulatory Authority or any other Third
     Person is required in connection with the execution, delivery and
     performance of this Agreement, or any agreement or instrument contemplated
     by this Agreement, by NeoSan or the performance by NeoSan of its
     obligations contemplated hereby and thereby other than (a) the filings
     required of both Parties pursuant to the HSR Act, and (b) the information
     submissions required by the FDA with respect to the NDAs.

                                       26

<PAGE>

5.5  BROKERAGE. NeoSan represents and warrants that no broker, finder or similar
     agent has been employed by or on behalf of NeoSan, and no Person with which
     NeoSan has had any dealings or communications of any kind is entitled to
     any brokerage commission, finder's fee or any similar compensation, in
     connection with this Agreement or the transactions contemplated hereby.

5.6  NOT DEBARRED. NeoSan represents and warrants that NeoSan is not debarred
     and has not and will not use in any capacity the services of any Person
     debarred under subsections 306(a) or (b) of the Generic Drug Enforcement
     Act of 1992. If at any time this representation and warranty is no longer
     accurate, NeoSan will immediately notify Lilly of such fact.

5.7  LITIGATION. NeoSan represents and warrants that there are no pending or, to
     NeoSan's knowledge as of the Effective Date, threatened judicial,
     administrative or arbitral Actions or Proceedings pending as of the date
     hereof against NeoSan which, either individually or together with any
     other, will have a material adverse effect on the ability of NeoSan to
     perform its obligations under this Agreement or any agreement or instrument
     contemplated hereby.

5.8  NO OTHER OR IMPLIED WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED IN THIS
     ARTICLE 5 AND ARTICLE 7 OF THE MANUFACTURING AGREEMENT, NEOSAN MAKES NO
     OTHER REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, EITHER IN FACT OR BY
     OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND NEOSAN SPECIFICALLY
     DISCLAIMS ANY AND ALL IMPLIED OR STATUTORY WARRANTIES.

                                    ARTICLE 6
                       ADDITIONAL COVENANTS AND AGREEMENTS
                                 OF THE PARTIES

6.1  IMPLEMENTATION TEAM. The Parties will form a team (the "Implementation
     Team") to oversee the activities contemplated by this Agreement. The
     Implementation Team will be comprised of three (3) members from each Party.
     Each Party will appoint a member representing each of manufacturing,
     marketing/sales and regulatory. Either Party may change its
     representative(s) on the Implementation Team at any time by providing prior
     written notice to the other Party. Unless otherwise agreed to by the
     Parties, after the Closing Date, the Implementation Team will meet (in
     person or by telephone or video conference) at least one (1) time each
     Calendar Quarter upon no less than thirty (30) days prior written notice
     from one Party to the other to discuss any matters arising out of a Party's
     performance (or non-

                                       27

<PAGE>

     performance) of its obligations under this Agreement. The Implementation
     Team will initially be responsible for creating detailed operational plans
     for the transition contemplated by this Agreement; provided, however, that
     the activities contemplated by the foregoing will not take place until
     after the Closing Date to the extent doing so would be in violation of
     Applicable Law. The detailed operational plans will include a time line and
     clear understanding of roles and responsibilities contemplated by this
     Agreement. The Implementation Team will also have responsibility for
     coordinating effective communication of progress and issues that arise
     between the Parties. Special meetings of the Implementation Team may be
     called by either Party upon no less than thirty (30) days' prior written
     notice to the other Party, which notice must be accompanied by a written
     agenda of items to be discussed at such special meeting.

6.2  GOVERNMENTAL FILINGS. Lilly and NeoSan each agree to prepare and file
     whatever filings, requests or applications are required to be filed with
     any Governmental or Regulatory Authority in connection with the transfer of
     rights in Article 3 of this Agreement and to cooperate with one another as
     reasonably necessary to accomplish the foregoing, including (i) the filings
     required of both Parties pursuant to the HSR Act, (ii) the information
     submissions to the FDA provided for pursuant to 21 C.F.R. Section 314.72,
     and (iii) any necessary submissions to the DEA that will facilitate the
     transfer of manufacturing capabilities from Lilly to NeoSan or a contract
     manufacturer of NeoSan during the term of the Manufacturing Agreement.
     NeoSan will deliver to Lilly the information submission described in (ii),
     above, on the Closing Date.

6.3  COMPLIANCE WITH LAW. NeoSan agrees and acknowledges that as owner of the
     NDAs, it will have sole responsibility for, among other things, adverse
     event reporting, product quality complaints, label maintenance, other
     regulatory reporting obligations, payment of any and all product
     establishment fees, and medical and technical inquiries. Lilly and NeoSan
     each will keep all records and reports required to be kept by Applicable
     Laws, and each will make its facilities available at reasonable times
     during regular business hours for inspection by representatives of
     governmental agencies. Lilly and NeoSan each will notify the other within
     twenty-four (24) hours of receipt of any notice or any other indication
     whatsoever of any FDA, DEA or other governmental agency inspection,
     investigation or other inquiry, or other notice or communication of any
     type from a governmental agency, involving the manufacturing, selling,
     marketing, promoting, co-promoting and co-marketing of the Product in the
     United States. NeoSan and Lilly will cooperate with each other during any
     such inspection, investigation or other inquiry including allowing upon
     reasonable request a representative of the other to be present during the
     applicable portions of any such inspection, investigation or

                                       28

<PAGE>

     other inquiry and providing copies of all relevant documents. NeoSan and
     Lilly will discuss any response to observations or notifications received
     in connection with any such inspection, investigation or other inquiry and
     each will give the other an opportunity to comment upon any proposed
     response before it is made. In the event of disagreement concerning the
     form or content of such response, however, Lilly will be responsible for
     deciding the appropriate form and content of any response with respect to
     any of its cited activities and NeoSan will be responsible for deciding the
     appropriate form and content of any response with respect to any of its
     cited activities.

6.4  EXPENSES. Lilly and NeoSan will each bear their own direct and indirect
     expenses incurred in connection with the negotiation and preparation of
     this Agreement and, except as set forth in this Agreement, the performance
     of the obligations contemplated hereby.

6.5  REASONABLE EFFORTS. Lilly and NeoSan each hereby agrees to use all
     reasonable efforts to take, or cause to be taken, all actions and to do, or
     cause to be done, all things reasonably necessary or proper to make
     effective the transactions contemplated by this Agreement, including such
     actions as may be reasonably necessary to obtain approvals and consents of
     Governmental or Regulatory Authorities and other Persons (including all
     applicable drug listing and NDA notifications to the FDA and DEA
     identifying NeoSan as a distributor of the Product); provided, however,
     that no Party will be required to (i) pay money (other than as expressly
     required pursuant to this Agreement or as implicitly required in order for
     a Party to carry out its obligations hereunder), or (ii) assume any other
     material obligation not otherwise required to be assumed by this Agreement.

6.6  PUBLICITY. The Parties agree that no publicity release or announcement
     concerning the transactions contemplated hereby and under the Manufacturing
     Agreement or, with respect to a NeoSan publicity release or announcement,
     that includes the name of Lilly with respect to such transaction, will be
     issued without the advance written consent of the other, which will not be
     unreasonably withheld, except to the extent such publicity release or
     announcement is after the later of the date of (i) the last to be delivered
     to Lilly of the Loan Facility Highly-Confident Letter and the Bond
     Financing Highly-Confident Letter executed by B of A or (ii) the date that
     both Parties have made the filings required by both Parties pursuant to the
     HSR Act, and is substantially similar to, or whose relevant statements are
     consistent with the statements in, the press release set forth in SCHEDULES
     6.6 attached hereto. Notwithstanding the above, upon the later of the date
     of (i) the last to be delivered to Lilly of the Loan Facility
     Highly-Confident Letter and the Bond Financing Highly-Confident Letter
     executed by B of A or (ii) the date that both Parties have made the filings
     required by both Parties pursuant to

                                       29

<PAGE>

     the HSR Act (or such later date as agreed to by the Parties), NeoSan may
     issue the press release set forth at SCHEDULE 6.6. Notwithstanding anything
     in this Section 6.6 and Article 8 to the contrary, each Party may make
     filings or disclosures that are required by Applicable Laws (as determined
     to be so required by outside counsel for the disclosing Party) including
     filings or disclosures required by or to the Securities and Exchange
     Commission (and any other applicable securities exchanges) that discuss the
     subject matter of this Agreement or the Manufacturing Agreement or
     otherwise make reference to the other Party in any way whatsoever;
     provided, however, that such Party provides the other Party with no less
     than three (3) business days to review and comment on such filings, or the
     relevant portions thereof, pertaining to the transactions contemplated
     hereby or by the Manufacturing Agreement, and such Party does not
     unreasonably reject the incorporation of such comments into such filings;
     provided further, however, that such Party will redact any Confidential
     Information of the other Party that, in the opinion of such disclosing
     Party's outside counsel, is not required by Applicable Laws from such
     filings or disclosures; provided further, however, that, such Party will
     use commercially reasonable efforts to obtain confidential treatment by
     such security exchanges with respect thereto.

6.7  COOPERATION. If either Party becomes engaged in or participates in any
     investigation, claim, litigation or other proceeding with any Third Person,
     including the FDA and DEA, relating in any way to the manufacturing,
     selling, marketing, promoting, co-marketing or co-promoting the Product in
     the United States, the other Party will cooperate in all reasonable
     respects with such Party in connection therewith, including using its
     reasonable efforts to make available to the other such employees who may be
     helpful with respect to such investigation, claim, litigation or other
     proceeding, provided that, for purposes of this provision, reasonable
     efforts to make available any employee will be deemed to mean providing a
     Party with reasonable access to any such employee at no cost for a period
     of time not to exceed twenty-four (24) hours (e.g., three (3) eight (8)
     -hour business days), and provided further that neither Party is required
     to disclose any legally privileged documents or information to the other
     Party. Thereafter, any such employee will be made available for such time
     and upon such terms and conditions (including compensation) as the Parties
     may mutually agree.

6.8  CONFLICTING RIGHTS. Neither Party will grant any right to any Third Person
     which would violate the terms of or conflict with the rights granted by
     such Party to the other Party pursuant to this Agreement.

                                       30

<PAGE>

6.9  DEEMED BREACH OF COVENANT. Neither Lilly nor NeoSan will be deemed to be in
     breach of this Agreement to the extent such Party's breach is the result of
     any action or inaction on the part of the other Party.

6.10 CUSTOMER ORDERS. Lilly will take such steps as may be reasonably required
     to insure that all customer orders for Product received after the Closing
     Date from customers in the United States are forwarded to NeoSan in writing
     within forty-eight (48) hours after receipt by Lilly. Lilly agrees that any
     customer in the United States ordering or requesting any information with
     respect to the Product after the Closing Date will be informed that NeoSan
     is now supplying the Product.

6.11 EXISTING CONTRACTS. NeoSan will fulfill all contractual pricing offered by
     Lilly on Product only for a period of time sufficient to ensure that Lilly
     is in compliance with its contractual obligation to a Third Person for sale
     of Products in the United States ("Customer Contracts"). Other than
     complying with these preexisting contractual obligations, NeoSan will be
     free in its sole and absolute discretion and without consultation with
     Lilly, to set its prices on Product offered by NeoSan. Lilly and NeoSan
     agree to prorate as of the Closing Date any amounts under the Customer
     Contracts in favor of Lilly with respect to amounts which become due and
     payable after the Closing Date to the extent the benefit is attributable to
     the period prior to the Closing Date, and any amounts under the Customer
     Contracts in favor of NeoSan with respect to amounts which are paid prior
     to the Closing Date to the extent the benefit is attributable to the period
     subsequent to the Closing Date.

6.12 NO ASSIGNMENT OR LICENSES OUTSIDE THE UNITED STATES. Notwithstanding
     anything in this Agreement to the contrary, NeoSan acknowledges and agrees
     that Lilly is not assigning or licensing to NeoSan the rights to make, have
     made, distribute, use, sell, offer to sell, have sold, import, market,
     co-market, promote or co-promote the Product outside the United States,
     except for the non-exclusive rights to make or have made Product outside of
     the United States solely for importation and sale in the United States. The
     rights granted to NeoSan in the United States will in no way limit Lilly's
     rights outside the United States.

6.13 NEOSAN NEW PRODUCTS. During the three-year period beginning on the date of
     receipt by Lilly of written notice from NeoSan that NeoSan has initiated
     development activities related to NeoSan New Products (which NeoSan must do
     within a reasonable time after initiating such development activities),
     NeoSan will, at its sole cost and expense, work diligently and using
     commercially reasonable efforts, consistent with prudent business judgment
     and a balancing of important priorities of NeoSan, based upon the existing
     business situation, to develop at least two NeoSan New Products where in
     NeoSan's good faith opinion, such devel-

                                       31

<PAGE>

     opment is technically feasible and commercially justifiable ("Commercially
     Attractive Neo San New Products"), devoting the same degree of attention
     and diligence to such efforts that it devotes to such activities for its
     other products at a comparable stage in development and of comparable
     commercial and development potential, with the objective of developing such
     Commercially Attractive NeoSan New Products for the United States as soon
     as commercially practicable, provided that NeoSan may terminate such
     development activities at any time in the event that it determines in good
     faith that such candidates are unlikely to succeed in becoming Commercially
     Attractive NeoSan New Products.

6.14 MEDICAID AND OTHER REBATES. The Parties will administer and pay all
     rebates, chargebacks and other similar programs as follows:

          (a) Lilly Sales Prior to Closing Date. Lilly will process and be
     responsible for the administration and payment of all federal, state and
     local managed care and other rebate programs, including Medicaid/Medicare
     rebates and Obligations, as well as chargebacks for the Product, in each
     case, related to Product that was sold by Lilly prior to the Closing Date;

          (b) Sales After the Closing Date. NeoSan will process and be
     responsible for the administration and payment of all federal, state and
     local managed care and other rebate programs in the United States,
     including Medicaid/Medicare rebates and Obligations, as well as chargebacks
     for the Product and NeoSan New Products, in each case, related to Product
     and NeoSan New Product that is sold by NeoSan on or after the Closing Date.
     If the Parties are unable to determine whether a Product was sold by Lilly
     prior to the Closing Date or by NeoSan on or after the Closing Date, then
     Lilly will be responsible for any and all such rebates and chargebacks
     received during the sixty (60) day period following the Closing Date, and
     NeoSan will be responsible thereafter.

          (c) Product Returns. NeoSan will be responsible for all returns of
     Product sold on or after the Closing Date in the United States, and Lilly
     will be responsible for returns of Product sold before the Closing Date. If
     the Parties are unable to determine whether a Product was sold by Lilly
     prior to the Closing Date or by NeoSan on or after the Closing Date, in
     each case in the United States, then Lilly will be responsible for all
     returns of such Product received during the sixty (60) day period following
     the Closing Date, and NeoSan will be responsible thereafter with respect to
     the United States.

6.15 RESPONSIBILITY FOR THE NDAS. On the Closing Date, Lilly will transfer the
     NDAs to NeoSan. Following the Closing Date, NeoSan will be responsible for
     and will fulfill all regulatory requirements with respect to the Product
     that are imposed upon NeoSan as the owner of

                                       32

<PAGE>

     the NDAs under Applicable Laws. NeoSan will provide Lilly with all
     assistance that is reasonably necessary to effectuate such transfers.
     Notwithstanding the sale and transfer of the NDAs, Lilly will complete the
     assay validations and supplement the NDAs with respect to the change of
     equipment in Lilly's Puerto Rico facility, all as further described in
     SCHEDULE 6.15 attached hereto; provided, however, that if Lilly
     subsequently determines in its reason able discretion that regulatory
     submissions identified in SCHEDULE 6.15 are not needed in order to continue
     manufacturing the Product and the FDA does not require such regulatory
     submissions, Lilly will have no obligation to complete the activities
     described in this sentence or supplement the NDA as described in SCHEDULE
     6.15. Nothing in this Section 6.15 will be construed as requiring Lilly to
     update or upgrade the NDAs to "state of the art" conditions, or requiring
     Lilly to otherwise update the NDA. Upon the Closing Date, NeoSan hereby
     grants to Lilly the right to reference the NDAs for purposes of obtaining
     and/or maintaining marketing authorizations outside of the United States.

6.16 INTELLECTUAL PROPERTY MAINTENANCE. Following the Closing, NeoSan will have
     the sole right to file, prosecute and maintain, at its sole cost and
     expense, (i) the Product Intellectual Property and (ii) any patent
     applications or Patents that cover a NeoSan New Product(s) developed by
     NeoSan or its Affiliates. Lilly will be responsible for and promptly pay
     when due all fees necessary to and will otherwise maintain the Licensed
     Trademark and Trade Dress (other than the Common Law Licensed Trade Dress).

6.17 ENFORCEMENT OF INTELLECTUAL PROPERTY RIGHTS.

          (a) Right to Seek Relief. NeoSan will promptly notify Lilly of any
     infringement or suspected infringement which may come to its notice of any
     Licensed Technology or the Licensed Trademark and Trade Dress, and will
     provide Lilly with any information with respect thereto. Lilly will
     promptly notify NeoSan of any infringement or suspected infringement which
     may come to its notice of any intellectual property rights relating to the
     Product, including the Product Intellectual Property, Licensed Technology,
     or the Licensed Trademark and Trade Dress, and will provide NeoSan with any
     information with respect thereto. In the event of any past, present or
     future infringement by a Third Person of any intellectual property rights
     relating to Copyrights, Assigned Trade Dress (only as it relates to an
     infringement in the United States) or Assigned Trademarks, NeoSan will have
     the sole right (but no obligation) to pursue any and all injunctive relief,
     and any or all compensatory and other remedies and relief (collectively,
     "Remedies") against such Third Person.

          In the event of any infringement by a Third Person of any intellectual
     property rights relating solely to Assigned Trade Dress (as it relates to
     infringement outside the United

                                       33

<PAGE>

     States), Licensed Technology or Licensed Trademark and Trade Dress, Lilly
     will have the first right (but not the obligation) to pursue any and all
     Remedies against such Third Person. Should Lilly determine not to pursue
     Remedies with respect to any such intellectual property within thirty (30)
     days after notice from NeoSan requesting Lilly to do so, then NeoSan will
     have the right (but not the obligation) to pursue Remedies against such
     Third Person inside the United States.

          In the event of any infringement by a Third Person in the United
     States of any intellectual property related to the Product or NeoSan New
     Products other than that described in the preceding sentences, NeoSan will
     have the first right (but not the obligation) to pursue any and all
     Remedies against such Third Person. Should NeoSan determine not to pursue
     Remedies with respect to any such intellectual property within thirty (30)
     days after notice from Lilly requesting NeoSan to do so, then Lilly will
     have the right (but not the obligation) to pursue Remedies against such
     Third Person.

          (b) Assistance and Cooperation. In the event that a Party will pursue
     Remedies hereunder, the other Party will use all reasonable efforts to
     assist and cooperate with the Party pursuing such Remedies. Each Party will
     bear its own costs and expenses relating to such pursuit. Any damages or
     other amounts collected will be distributed, first, to the Party that
     pursued Remedies to cover its costs and expenses and, second, to the other
     Party to cover its costs and expenses, if any, relating to the pursuit of
     such Remedies; any remaining amount will be distributed to the Party that
     pursued the Remedies.

6.18 INFRINGEMENT OF THIRD PERSON RIGHTS. In the event that a Third Person
     institutes a patent, trade secret, trademark or other infringement suit, or
     a misappropriation or unfair competition suit in the United States
     (including any suit claiming confusion, deception or dilution of a
     trademark by the Assigned Trademarks, Assigned Trade Dress or Licensed
     Trademark and Trade Dress or interference with any patent claim (pending or
     issued)) against NeoSan or another Permitted Seller during the term of this
     Agreement, alleging that the manufacture, marketing, sale or use of the
     Product infringes one or more Patent, trademark or other intellectual
     property rights held by such Third Person or constitutes misappropriation
     or unfair competition, then NeoSan will have the first right (but not the
     obligation), at its sole expense, to assume direction and control of the
     defense of such claims except to the extent such suit relates to the
     Assigned Trade Dress (as it relates to an infringement outside of the
     United States), the Licensed Technology, or the Licensed Trademark and
     Trade Dress, as to which Lilly will have the first right (but not the
     obligation), at its sole expense, to assume direction and control of the
     defense of such claims. Should NeoSan or Lilly, as applicable, determine

                                       34

<PAGE>

     not to pursue the defense of a particular claim within thirty (30) days
     after notice from the other Party requesting NeoSan or Lilly, as
     applicable, to do so, then the other Party will have the right (but not the
     obligation), at its sole expense, to assume direction and control of such
     claims. NeoSan will not have the right to settle or otherwise dispose of
     any such claim with respect to the Assigned Trade Dress (as it relates to
     an infringement outside of the United States), the Licensed Technology or
     the Licensed Trademark and Trade Dress without the consent of Lilly, which
     consent will not be unreasonably withheld.

6.19 SALES TRAINING. Lilly will have no obligation to provide sales training to
     NeoSan.

6.20 NO LIENS. NeoSan will keep the Licensed Technology and Licensed Trademark
     and Trade Dress free from all Encumbrances other than Permitted
     Encumbrances.

6.21 MAINTENANCE OF ACTIVITIES PRIOR TO CLOSING. Except as otherwise set forth
     in Section 6.25, from the date of this Agreement to the Closing Date, Lilly
     will conduct the Activities in the ordinary course of business and not
     enter into any new Contracts including the Product or other Purchased
     Assets (a) giving any third Persons any rights, title or interests in the
     Purchased Assets (other than sales of Products in the ordinary course of
     business), or (b) creating any Encumbrances on the foregoing other than
     Permitted Encumbrances. Lilly agrees that: after the date hereof, without
     NeoSan's prior written consent, which will not be unreasonably withheld, it
     will not take any action with respect to any Material Contract that would
     (x) extend the term of such Material Contract with respect to any Product,
     (y) create or agree to any additional obligations with respect to any
     Product other than price adjustments in the normal course of business, or
     (z) otherwise materially adversely affect NeoSan (other than to terminate
     any such Material Contract in the ordinary course of business).

6.22 UNAVAILABLE CONSENTS.

          (a) Notwithstanding anything to the contrary contained in this
     Agreement, if the sale, assignment, transfer, conveyance or delivery or
     attempted sale, assignment, transfer, conveyance or delivery to NeoSan of
     any asset that would be a Purchased Asset is (i) prohibited by any
     Applicable Law or (ii) would require any authorizations, approvals,
     consents or waivers from a Third Person or Governmental or Regulatory
     Authority and such authorizations, approvals, consents or waivers will not
     have been obtained prior to the Closing Date, then in either case the
     Closing may proceed without the sale, assignment, transfer, conveyance or
     delivery of such affected asset and this Agreement will not constitute a
     sale, assignment, transfer, conveyance or delivery of such asset; provided
     that nothing in this Section 6.22 will be deemed to waive the rights of
     NeoSan not to consummate the transactions con-

                                       35

<PAGE>

     templated by this Agreement if the conditions to its obligations set forth
     in Article 7 have not been satisfied or waived.

          (b) In the event that the Closing proceeds without the sale,
     assignment, transfer, conveyance or delivery of any such affected asset set
     forth in Section 6.22(a), then (i) following the Closing, the Parties will
     use their commercially reasonable best efforts, and cooperate with each
     other, to obtain promptly such authorizations, approvals, consents or
     waivers, and (ii) pending such authorization, approval, consent or waiver,
     the Parties will cooperate with each other in any mutually agreeable,
     reasonable and lawful arrangements designed to provide to NeoSan the
     benefits of use of such asset and to Lilly the benefits, including any
     indemnities, that, in each case, it would have obtained had the asset been
     conveyed to NeoSan on the Closing Date; provided, however, that such
     arrangement does not cause either Party to be in breach of any obligation
     owed to a Third Person.

          (c) If authorization, approval, consent or waiver for the sale,
     assignment, transfer, conveyance or delivery of any such asset not sold,
     assigned, transferred, conveyed or delivered on the Closing Date is
     subsequently obtained, Lilly will assign, transfer, convey and deliver such
     asset to NeoSan at no additional cost to NeoSan; provided, however, that
     NeoSan has paid the full purchase price described in Section 2.1, above.

6.23 GUARANTY. NeoSan will cause aaiPharma to execute a Guaranty in the form
     attached hereto as Exhibit B (the "Guaranty").

6.24 FINANCIAL STATEMENTS. Lilly will deliver to NeoSan, at NeoSan's expense,
     audited financial statements with respect to the Products in the United
     States for calendar years 1999, 2000 and 2001 which are compliant with the
     rules and regulations of the United States Securities and Exchange
     Commission and will specifically include Net Sales and gross margin of the
     Products in the United States (the "Financial Statements"). NeoSan will pay
     the cost of the Financial Statements regardless of whether the transactions
     contemplated by this Agreement close.

6.25 FINANCING. NeoSan (or aaiPharma on NeoSan's behalf) will use its
     commercially reasonable best efforts to initiate an offering to raise, on
     commercially reasonable terms (for a comparably-sized company and a
     comparably-sized financing transaction, including interest rate and
     duration), the funds necessary to pay the purchase price described in
     Section 2.1 and, pursuant to such offering, to deliver Offering Memoranda
     to potential investors no later than February 21, 2002 (with respect to the
     Offering Memoranda pertaining to the loan syndication portion of the
     Transaction Financing (the "Loan Facility")) and March 1, 2002 (with
     respect

                                       36

<PAGE>

     to the Offering Memoranda pertaining to the bond offering portion of the
     Transaction Financing (the "Bond Offering")). NeoSan (or aaiPharma on
     NeoSan's behalf) will utilize its commercially reasonable best efforts to
     close the financings described in both Offering Memoranda (the "Transaction
     Financing") no later than March 15, 2002. The Transaction Financing will
     take the form of a syndicated loan or bond offering, or any combination
     thereof. Notwithstanding anything in this Agreement to the contrary, Lilly
     will be free to discuss transactions related to the Product with Third
     Persons (but not sign any binding agreements) until NeoSan (or aaiPharma on
     NeoSan's behalf) closes the Transaction Financing for the purpose of having
     a back-up purchaser for the asset should the Transaction Financing fail. A
     prerequisite for NeoSan's distribution of the Offering Memoranda pertaining
     to the Loan Facility to banks and other financial institutions will be (i)
     Lilly's prior written approval of such Offering Memoranda, such approval
     not to be unreasonably withheld, and (ii) Bank of America's ("B of A")
     providing to NeoSan and aaiPharma (and NeoSan will have provided a copy
     thereof to Lilly) a duly executed "highly confident" letter with respect to
     the successful funding of such Loan Facility at the closing of the
     Transaction Financing in a form substantially similar to Exhibit C attached
     hereto (the "Loan Facility Highly-Confident Letter"). A prerequisite for
     NeoSan's distribution of the Offering Memoranda pertaining to the Bond
     Offering to potential investors will be (i) Lilly's prior written approval
     of such Offering Memoranda, such approval not to be unreasonably withheld,
     (ii) B of A's providing to NeoSan and aaiPharma (and NeoSan will have
     provided a copy thereof to Lilly) a duly executed "highly confident" letter
     with respect to the successful funding of the Bond Offering at the closing
     of the Transaction Financing in a form substantially similar to Exhibit D
     attached hereto (the "Bond Financing Highly-Confident Letter"), and (iii)
     that NeoSan (or aaiPharma on NeoSan's behalf) will have been and will
     continue to actively progress with the closing of the Loan Facility in good
     faith. In the event that B of A fails to provide NeoSan (and NeoSan fails
     to provide Lilly with a copy) with the Loan Facility Highly-Confident
     Letter by February 21, 2002, fails to provide the Parties with the Bond
     Financing Highly-Confident Letter by March 1, 2002, or is prohibited from
     issuing the Offering Memorandum pertaining to the Bond Offering as of March
     1, 2002 because of its (or aaiPharma's on NeoSan's behalf) failure to
     actively progress with the closing of the Loan Facility in good faith,
     Lilly will have the right (but not the obligation) to terminate this
     Agreement by written notice to NeoSan at any time prior to B of A's
     delivery to Lilly of such Loan Facility Highly-Confident Letter or such
     Bond Financing Highly-Confident Letter or NeoSan's or aaiPharma's active
     progression with the closing of the Loan Facility in good faith, as the
     case may be. Unless aaiPharma is advised by its outside SEC counsel that,
     in such counsel's opinion, earlier public disclosure or filing with the
     Securities and Exchange Commission or

                                       37

<PAGE>

     relevant securities exchange with respect to the transactions covered by
     this Agreement is required by applicable law or regulation, NeoSan will
     not, and will cause aaiPharma not to, make any such public disclosure or
     filing until the Parties have received the Bond Financing Highly-Confident
     Letter. Following the receipt of such Bond Financing Highly-Confident
     Letter or such legal advice of an earlier public disclosure or filing
     obligation, whichever comes first, NeoSan and aaiPharma will be free to
     make such legally required public disclosures or filings, provided that
     such public disclosures or filings will be limited to that which
     aaiPharma's outside SEC counsel advises aaiPharma is legally required, in
     such counsel's opinion, or which is otherwise permitted under Section 6.6
     or Article 8 (other than 8.2(g)) hereof at the relevant time, unless Lilly
     consents to additional disclosure. Notwithstanding the foregoing, NeoSan's
     right to make such public disclosure or filing pursuant to this Section
     6.25 is subject to the conditions set forth in the three provisos at the
     end of Section 6.6 pertaining to disclosures that are required by
     Applicable Laws. NeoSan will cause B of A to have in place Confidentiality
     Agreements no less restrictive than those confidentiality obligations
     customarily used by B of A with Third Persons in other loan syndication
     transactions, with Third Persons to which B of A or its representatives
     discuss the Loan Facility portion of the Transaction Financing.

                                    ARTICLE 7
                CONDITIONS PRECEDENT TO THE CLOSING; CLOSING DATE

7.1  CONDITIONS PRECEDENT TO NEOSAN'S OBLIGATIONS. Subject to waiver as set
     forth in Section 12.3, below, all obligations of NeoSan to close the
     transactions contemplated under this Agreement are subject to the
     fulfillment or satisfaction of each of the following conditions precedent:

          (a) Representations and Warranties True as of the Closing Date. The
     representations and warranties of Lilly contained in this Agreement, the
     Manufacturing Agreement and in any schedule, certificate or document
     delivered by Lilly to NeoSan pursuant to the provisions hereof will have
     been true on the date hereof and will be true on the Closing Date with the
     same effect as though such representations and warranties were made as of
     such date.

          (b) Compliance with this Agreement. Lilly will have performed and
     complied with all agreements and conditions required by this Agreement to
     be performed or complied with by it prior to or by the Closing Date.

                                       38

<PAGE>

          (c) Closing Certificate. NeoSan will have received a certificate from
     Lilly, executed by an officer of Lilly, certifying in such detail as NeoSan
     may reasonably request that the conditions specified in Sections 7.1 (a)
     and 7.1 (b), above, have been fulfilled and certifying that Lilly has
     obtained all consents and approvals required by Section 7.1(e), below.

          (d) No Threatened or Pending Litigation. Except for Actions or
     Proceedings, injunctions or final judgments solely pertaining to contracts
     or other obligations between NeoSan and any Third Person on the Effective
     Date, no Action or Proceeding, or injunction or final judgment relating
     thereto, will be threatened or be pending against Lilly or NeoSan or its
     Affiliates before any Governmental or Regulatory Authority in which it is
     sought to restrain or prohibit or to obtain damages or other relief in
     connection with this Agreement or the consummation of the transactions
     contemplated hereby, and no investigation that might result in any such
     suit, action or proceeding will be pending or threatened.

          (e) Consents and Approvals. Lilly will have either received notice
     from the Federal Trade Commission or the U.S. Department of Justice of
     early termination of the waiting period provided by the HSR Act or such
     waiting period will have expired with no further action required or sought
     by the Competition Authority on the part of Lilly or NeoSan.

          (f) Quality Agreement. Lilly will have entered into the Quality
     Agreement.

          (g) Receipt of Funds. NeoSan (or aaiPharma or any of its Affiliates)
     will have received an amount equal to the payment set forth in Section 2.1
     hereof as described in Section 6.25 hereof.

          (h) Financial Statements. NeoSan will have received the Financial
     Statements.

7.2  CONDITIONS PRECEDENT TO LILLY'S OBLIGATIONS. Subject to waiver as set forth
     in Section 12.3, below, all obligations of Lilly to close the transactions
     contemplated under this Agreement are subject to the fulfillment or
     satisfaction of each of the following conditions precedent:

          (a) Representations and Warranties True as of the Closing Date. The
     representations and warranties of NeoSan contained in this Agreement, the
     Manufacturing Agreement, and in any schedule, certificate or document
     delivered by NeoSan to Lilly pursuant to the provisions hereof will have
     been true on the date hereof and will be true on the Closing Date with the
     same effect as though such representations and warranties were made as of
     such date.

                                       39

<PAGE>

          (b) Compliance with this Agreement. NeoSan will have performed and
     complied with all agreements and conditions required by this Agreement to
     be performed or complied with by it prior to or by the Closing Date.

          (c) Closing Certificate. Lilly will have received a certificate from
     NeoSan, executed by an officer of NeoSan, certifying in such detail as
     Lilly may reasonably request that the conditions specified in Sections
     7.2(a) and 7.2(b), above, have been fulfilled and certifying that NeoSan
     has obtained all consents and approvals required by Section 7.2(e), below.

          (d) No Threatened or Pending Litigation. On the Closing Date, no
     Action or Proceeding, or injunction or final judgment relating thereto,
     will be threatened or be pending against Lilly or NeoSan or any of its
     Affiliates before any Governmental or Regulatory Authority in which it is
     sought to restrain or prohibit or to obtain damages or other relief in
     connection with this Agreement or the consummation of the transactions
     contemplated hereby, and no investigation that might result in any such
     suit, action or proceeding will be pending or threatened.

          (e) Consents and Approvals. NeoSan will have either received notice
     from the Federal Trade Commission or the U.S. Department of Justice of
     early termination of the waiting period provided by the HSR Act or such
     waiting period will have expired with no further action required or sought
     by the Federal Trade Commission or the U.S. Department of Justice on the
     part of NeoSan.

          (f) Quality Agreement and Guaranty. NeoSan will have entered into the
     Quality Agreement and aaiPharma will have entered into the Guaranty.

7.3  CLOSING DATE.

          (a) Subject to Section 7.3(b), below, the closing of the transactions
     contemplated by this Agreement will take place at 10:00 a.m., Indianapolis
     time, on the third (3rd) Lilly business day following the later of (i) the
     date on which the last required FTC notice of the early termination of the
     waiting period provided by the HSR Act or such applicable waiting periods
     have expired with no further action required of either Party, (ii) the day
     on which the last of the certificates required by Sections 7.1(c) and
     7.2(c) has been delivered by one Party to the other, unless receipt of such
     certificate has been waived in writing by the necessary Party, and (iii)
     the day that the last condition precedents set forth in Sections 7.1 and
     7.2 above has been satisfied or waived by the necessary party, or on such
     other date as may be mutually agreed upon in writing by the Parties (the
     "Closing Date") at the offices of Eli Lilly

                                       40

<PAGE>

     and Company, Lilly Corporate Center, Indianapolis, Indiana. Each Party
     hereby agrees to use its commercially reasonable best efforts to deliver
     the certificates described in Sections 7.1(c) and 7.2(c) to the other in a
     timely manner.

          (b) If the closing of the transactions contemplated hereby will not
     have taken place on or before sixty (60) days after the Effective Date, or
     such later date as will be mutually agreed to in writing by Lilly and
     NeoSan, because the conditions described in Sections 7.1 and/or 7.2, above,
     have not been satisfied or waived, then Lilly and NeoSan agree to discuss
     in good faith which substantive terms set forth in this Agreement, the
     Manufacturing Agreement, or any document attached hereto and thereto need
     to be modified as a result of the delay in such closing; provided, however,
     that neither Party will have an obligation to agree to such modification.
     Each Party hereby agrees to use commercially reasonable best efforts to
     consummate the transactions contemplated herein, as modified, on or before
     the sixtieth (60th) day after the Effective Date; provided, however, that
     if the Parties are unable to close the transactions contemplated hereby
     within one-hundred twenty (120) days after the Effective Date, or such
     later date as is mutually agreed to in writing by Lilly and NeoSan, then
     any Party that is not in material default of its obligations under this
     Agreement (including its obligation to deliver the certificates described
     in Sections 7.1(c) in the case of Lilly and 7.2(c) in the case of NeoSan)
     may terminate this Agreement upon written notice to the other and each may
     pursue such other remedies as are available to it at law, in equity or
     under this Agreement. If neither Party is then in default of its
     obligations under this Agreement upon delivery of such termination notice,
     then this Agreement will terminate and neither Party will have any
     Obligation to the other with respect to such termination. In all other
     circumstances, the Parties may each pursue such remedies as are available
     to it at law, in equity or under this Agreement. In addition to, but in no
     way in limitation of the foregoing, Lilly may terminate this Agreement in
     its entirety if NeoSan (or aaiPharma) has not initiated the Loan Facility
     portion of the Transaction Financing by February 21, 2002 (unless such
     termination right has not been exercised by written notice to NeoSan prior
     to the commencement of the offering of the Loan Facility), the Bond
     Offering Portion of the Transaction Financing by March 1, 2002 (unless such
     termination right has not been exercised by written notice to NeoSan prior
     to the commencement of the Bond Offering), and closed the Transaction
     Financing by March 15, 2002 as more fully described in Section 6.25. In the
     event Lilly terminates this Agreement for NeoSan's or aaiPharma's failure
     to close the Transaction Financing by March 15, 2002, NeoSan will have no
     Obligation to Lilly with respect to such termination provided that NeoSan
     and/or aaiPharma used commercially reasonable best efforts to close the
     Transaction Financing by March 15, 2002 and NeoSan is not otherwise in
     breach of this Agreement.

                                       41

<PAGE>

7.4  DELIVERIES AT CLOSING.

          (a) CLOSING DELIVERIES BY LILLY. At the Closing, Lilly will deliver or
     cause to be delivered to NeoSan:

               (i) physical possession of all tangible personal property
     included in the Purchased Assets, including (A) the Regulatory Approvals,
     and (B) the Marketing Materials;

               (ii) the duly executed Lilly Bill of Sale;

               (iii) copies of all Required Lilly Third Party Consents obtained
     as of Closing Date;

               (iv) a duly executed counterpart of the Quality Agreement; and

               (v) the certificate contemplated by Section 7.1 (c), above, duly
     executed by an authorized representative of Lilly.

          (b) CLOSING DELIVERIES BY NEOSAN. At the Closing, NeoSan will deliver
     or cause to be delivered to Lilly:

               (i) the payment required of it pursuant to Section 2.1;

               (ii) a duly executed counterpart of the Quality Agreement;

               (iii) the certificate contemplated by Section 7.2(c), above, duly
     executed by an authorized representative of NeoSan; and

               (iv) the Guaranty duly executed by an authorized representative
     of aaiPharma.

7.5  SALES TAXES. Lilly will be responsible for all sales, use, stamp duty,
     transfer, value added and other related or similar Taxes (excluding VAT
     Taxes associated with Product delivered to NeoSan in accordance with the
     Manufacturing Agreement), if any, arising out of the sale by Lilly and its
     Affiliates of the Purchased Assets to NeoSan pursuant to this Agreement or
     payable in connection with the transactions contemplated hereby.

                                       42

<PAGE>

                                    ARTICLE 8
                                 CONFIDENTIALITY

8.1  CONFIDENTIAL INFORMATION. The Parties agree that, for a ten (10)-year
     period following the Effective Date, the Receiving Party will keep
     completely confidential, will not publish or otherwise disclose and will
     not use directly or indirectly for any purpose other than as contemplated
     by this Agreement or the Manufacturing Agreement any such Confidential
     Information of the Disclosing Party, whether such Confidential Information
     was received by the Receiving Party prior to, on or after the Effective
     Date. Notwithstanding anything to the contrary herein, neither Party will
     be under any non-disclosure or non-use obligation whatsoever with respect
     to its own Confidential Information.

8.2  DISCLOSURE. Each Party may disclose the other Party's Confidential
     Information to the extent that such disclosure is:

          (a) made in response to a valid order or subpoena of a court of
     competent jurisdiction or other governmental body of a country or any
     political subdivision thereof of competent jurisdiction; provided, however,
     that the Receiving Party will first have given notice to the Disclosing
     Party and given the Disclosing Party a reasonable opportunity to quash such
     order or subpoena and to obtain a protective order requiring that the
     Confidential Information and documents that are the subject of such order
     or subpoena be held in confidence by such court or governmental body or, if
     disclosed, be used only for purposes for which the order or subpoena was
     issued; provided further, however, that if a disclosure order or subpoena
     is not quashed or a protective order is not obtained, the Confidential
     Information disclosed in response to such court or governmental order or
     subpoena will be limited to that information which is legally required to
     be disclosed in such response to such court or governmental order or
     subpoena;

          (b) otherwise as required by law, in the opinion of legal counsel to
     the Receiving Party, as expressed in an opinion letter in form and
     substance reasonably satisfactory to the Disclosing Party, which will be
     provided to the Disclosing Party at least twenty-four (24) hours prior to
     the Receiving Party's disclosure of the Confidential Information pursuant
     to this Section 8.2;

          (c) made by NeoSan as the Receiving Party to the Governmental or
     Regulatory Authority as required to obtain or maintain marketing approval
     for the Product or a NeoSan New Product, provided that reasonable measure
     will be taken to assure confidential treatment of such information;

                                       43

<PAGE>

          (d) made by Lilly as Receiving Party to a Third Person as may be
     necessary or useful in connection with the activities of Lilly and its
     Affiliates following the Closing Date within the scope of the Permitted
     Uses during the remaining term thereof or made by NeoSan as the Receiving
     Party in connection with the activities of NeoSan, its Affiliates and
     contractors in the manufacture or development and commercialization of the
     Product and NeoSan New Product, provided that the Receiving Party will in
     each case obtain from the proposed Third Person recipient a written
     confidentiality agreement containing confidentiality obligations no less
     onerous than those set forth in this Section;

          (e) made by the Receiving Party to a United States tax authority;

          (f) made by the Receiving Party to its Representatives; provided,
     however, that (i) the Representative has a need to know such Confidential
     Information for purposes of this Agreement or the Manufacturing Agreement;
     (ii) the Receiving Party informs its Representatives receiving Confidential
     Information of its confidential nature; and (iii) the Receiving Party will
     be responsible for any breach of this Section 8 by any of its
     Representatives to the same extent as if the breach were by the Receiving
     Party; or

          (g) by NeoSan and aaiPharma with respect to the Financial Statements
     (and Confidential Information pertaining to the Products that is required,
     in the opinion of their outside SEC counsel, to be included in legally
     required filings or disclosures with the Securities and Exchange Commission
     or that, in the opinion of their outside counsel or of B of A, is
     commercially necessary in carrying out the Transaction Financing and
     subsequent public exchange offer for the Bond Offering (the "Subsequent
     Exchange Offer")) that are incorporated into, included in, or attached to,
     (I) aaiPharma's filings with the Securities and Exchange Commission
     pertaining to the entering into of this Agreement by the Parties, at such
     times as aaiPharma makes such filings as provided in Sections 6.6 or 6.25,
     subject to the conditions set forth in the three provisos at the end of
     Section 6.6 pertaining to disclosures that are required by Applicable Laws;
     provided, however, that such disclosure of information for which aaiPharma
     receives confidential treatment from the Securities and Exchange Commission
     will only be made to the Securities and Exchange Commission, and provided
     further that NeoSan and aaiPharma may use and disclose, without further
     restriction, Confidential Information included in any such filings or
     disclosures with the Securities and Exchange Commission which is not
     accorded confidential treatment by the Securities and Exchange Commission
     and, as a result, enters the public domain; and (II) the Offering Memoranda
     and other documents pertaining to the Transaction Financing and Subsequent
     Exchange Offer, (A) at any time (with respect to recipients who have
     entered into Confidentiality Agreements no

                                       44

<PAGE>

     less restrictive than those confidentiality obligations customarily used by
     B of A with Third Persons in other similar transactions), and (B) at and
     after the time set forth in Section 6.25 (i.e., following the receipt of
     such Bond Financing Highly-Confident Letter or such legal advice of an
     earlier public disclosure or filing obligation (subject to the conditions
     set forth in Section 6.25), whichever comes first) (with respect to the
     Offering Memoranda and other documents related to the Bond Offering and
     Subsequent Exchange Offer) to potential investors; provided, however, that
     such disclosures will only be made as permitted by and within the scope of
     Section 6.25.

8.3  NOTIFICATION. The Receiving Party will notify the Disclosing Party
     immediately, and cooperate with the Disclosing Party as the Disclosing
     Party may reasonably request, upon the Receiving Party's discovery of any
     loss or compromise of the Disclosing Party's Confidential Information.

8.4  REMEDIES. Each Party agrees that the unauthorized use or disclosure of any
     Confidential Information by the Receiving Party in violation of this
     Agreement or any other agreement forming a part of this transaction will
     cause severe and irreparable damage to the Disclosing Party. In the event
     of any violation of this Article 8, the Receiving Party agrees that the
     Disclosing Party will be authorized and entitled to obtain from any court
     of competent jurisdiction injunctive relief, whether preliminary or
     permanent, without the necessity of proving irreparable harm or monetary
     damages, as well as any other relief permitted by applicable law. The
     Receiving Party agrees to waive any requirement that the Disclosing Party
     post bond as a condition for obtaining any such relief. Except as otherwise
     limited pursuant to Section 11.7, below, the rights provided in the
     immediately preceding sentences will be cumulative and in addition to any
     other rights or remedies that may be available to Disclosing Party. Nothing
     in this Section is intended, or should be construed, to limit a Party's
     right to preliminary and permanent injunctive relief or any other remedy
     for a breach of any other provision of this Agreement.

                                    ARTICLE 9
                                   TERMINATION

9.1  TERMINATION PRIOR TO THE CLOSING. Anything herein to the contrary
     notwithstanding, this Agreement may be terminated as follows prior to the
     Closing Date:

          (a) Termination for Insolvency. Each Party may Immediately terminate
     this Agreement by providing written notice to the other Party if the other
     Party (or, in the case of

                                       45

<PAGE>

     NeoSan, an Affiliate of NeoSan) is declared insolvent or bankrupt by a
     court of competent jurisdiction, or a voluntary petition of bankruptcy is
     filed in any court of competent jurisdiction by the other Party (or, in the
     case of Neosan, an Affiliate of NeoSan), or an involuntary petition for
     relief under the United States Bankruptcy Code is filed in a court of
     competent jurisdiction against the other Party (or, in the case of NeoSan,
     an Affiliate of NeoSan) which is not dismissed within thirty (30) days of
     its filing, or the other Party (or, in the case of NeoSan, an Affiliate of
     NeoSan) makes or executes any assignment for the benefit of creditors.

          (b) Termination for Default. Either Party may terminate this entire
     Agreement because of a material breach or material default of this
     Agreement by the other Party as follows: The terminating Party will give
     the other Party prior written notice thereof, specifying in reasonable
     detail the alleged material breach or material default, and if such alleged
     material breach or material default continues unremedied for a period of
     thirty (30) days with respect to monetary breaches or defaults or sixty
     (60) days with respect to non-monetary material breaches or material
     defaults after the date of receipt of the notification or, if the
     non-monetary material breach or material default reasonably cannot be
     corrected or remedied within sixty (60) days, then if (i) the defaulting
     Party has not commenced remedying said material breach or material default
     with said sixty (60) days and be diligently pursuing completion of same,
     and (ii) said material breach or material default has not been corrected or
     remedied within one-hundred twenty (120) days, then such terminating Party
     may immediately terminate this Agreement by again providing written
     notification to the defaulting Party. Except as otherwise limited pursuant
     to Section 11.7 of this Agreement and Section 11.2 of the Manufacturing
     Agreement, this Section 9.1(b) will not be exclusive and will not be in
     lieu of any other remedies available to a Party hereto for any breach or
     default hereunder on the part of the other Party.

9.2  TERMINATION FOLLOWING CLOSING. Following the Closing Date and the payment
     by NeoSan of the $211,400,000 to be paid pursuant to Section 2.1, this
     Agreement may not be terminated by either Party, except that Lilly may
     suspend the licenses granted pursuant to Sections 3.2 and 3.3 utilizing the
     procedures set forth in Section 9.1(b) as a result of any breach by NeoSan
     in the payment of Royalty Payments owed with respect to a NeoSan New
     Product in the United States only to the extent such licenses relate to the
     affected NeoSan New Product therein (but will have no such effect with
     respect to any Products or other NeoSan New Products in the United States
     and will not constitute a material breach of this Agreement or give Lilly
     any rights to terminate any rights of NeoSan hereunder whatsoever other
     than the foregoing express suspension with respect to the relevant NeoSan
     New Product) until and

                                       46

<PAGE>

     unless NeoSan pays Lilly any Royalty Payments so owed (including with
     respect to relevant Net Sales of such NeoSan New Product during any period
     of suspension), plus accrued interest as provided in Section 2.5, at which
     time such licenses will be automatically reinstated. Except as otherwise
     set forth in this Section 9.2, the Parties agree that the sole and
     exclusive remedies following the Closing Date will be to seek injunctive
     relief to require compliance by the breaching Party and relief to seek
     damages (subject to Section 11.7) with respect to such breach.

9.3  TERMINATION OF SUBLICENSES. Any sublicenses granted by NeoSan under this
     Agreement with respect to the Licensed Technology or License Trademark and
     Trade Dress will provide for immediate termination (or suspension, as the
     case may be) upon termination (or suspension) of this Agreement or the
     licenses granted in Sections 3.2 and 3.3, as the case may be, to the same,
     and only to the same, extent as such termination (or suspension).

9.4  CONTINUING OBLIGATIONS. Termination of this Agreement for any reason will
     not relieve the Parties of any antecedent breach of the provisions of this
     Agreement or any obligation accruing prior thereto and, subject to Section
     11.7, below, will be without prejudice to the rights and remedies of either
     Party with respect to any antecedent breach of the provisions of this
     Agreement. Without limiting the generality of the foregoing and in addition
     to the foregoing, no termination of this Agreement, whether by lapse of
     time or otherwise, will serve to terminate the rights and obligations under
     Section 9.4 and Articles 8, 11 and 12 hereof, and such obligations will
     survive any such termination.

9.5  NON-EXCLUSIVE REMEDIES. Except as otherwise limited pursuant to Section
     11.7, below, the remedies set forth in this Article 9 or elsewhere in this
     Agreement will be in addition to, and will not be to the exclusion of, any
     other remedies available to the Parties at law, in equity or under this
     Agreement,

                                   ARTICLE 10
                       ASSUMPTION OF LIABILITIES BY NEOSAN

          Except as otherwise provided in this Agreement, NeoSan hereby assumes
     and agrees, in each case, following the Closing Date, to bear and be
     responsible for and to perform and satisfy all responsibilities, duties
     (including compliance with all Applicable Laws), obligations, claims,
     Damages, liabilities, debts, burdens and problems of any nature whatsoever
     (whether known or unknown, asserted or unasserted, absolute or contingent,
     accrued or

                                       47

<PAGE>

     unaccrued, liquidated or unliquidated, matured or unmatured, determinable
     or undeterminable and due or to become due) (collectively, the
     "Obligations") to the extent arising following the Closing Date from
     NeoSan's ownership, licensing, operation and/or use of the Product
     Intellectual Property, the Marketing Materials, the Licensed Trademark and
     Trade Dress, the NDAs, Books and Records and the Licensed Technology, as
     well as those associated directly or indirectly with the manufacturing (but
     only to the extent the Product has been manufactured by NeoSan or its
     contractor (other than Lilly)), distributing, marketing, promoting, selling
     or using the Product from and after the Closing Date, including all
     recalls, all warranty claims and all product liability claims (without
     regard to the nature of the causes of action alleged or theories of
     recovery asserted) arising in connection with Product sold on or after the
     Closing Date, except for those Obligations with respect to which Lilly is
     providing indemnification pursuant to the provisions of Section 11.1 of
     this Agreement, which Obligations will remain the responsibility of Lilly
     as set forth herein. All of the foregoing are hereinafter collectively
     referred to as the "Assumed Liabilities." Notwithstanding the foregoing,
     NeoSan will not be deemed to, and does not, assume the Excluded
     Liabilities.

                                   ARTICLE 11
                           INDEMNIFICATION; INSURANCE

11.1 INDEMNIFICATION BY LILLY. Lilly will indemnify and hold NeoSan (and its
     Affiliates, and its and its Affiliates' directors, officers, and employees)
     harmless from and against any and all Damages incurred or suffered by
     NeoSan (and its Affiliates, and its and its Affiliates' directors, officers
     and employees) to the extent caused by or arising out of or in connection
     with:

          (a) any breach of any representation or warranty made by Lilly in this
     Agreement or the Manufacturing Agreement;

          (b) any failure to perform duly and punctually any covenant, agreement
     or undertaking on the part of Lilly contained in this Agreement or the
     Manufacturing Agreement;

          (c) any Excluded Liabilities;

          (d) Lilly's failure to comply in all material respects with Applicable
     Laws in connection with the performance of its obligations hereunder or the
     Manufacturing Agreement;

                                       48

<PAGE>

          (e) the negligence, gross negligence or willful misconduct of Lilly,
     its Affiliates, or its or its Affiliates' employees, agents or contractors
     (other than NeoSan); and

          (f) Lilly's and its Affiliates' conduct of Activities prior to the
     Closing Date, including the material compliance of such Activities pursuant
     to Applicable Law or applicable obligations pursuant to Contracts.

11.2 INDEMNIFICATION BY NEOSAN. NeoSan will indemnify and hold Lilly (and its
     Affiliates and its and its Affiliates' directors, officers and employees)
     harmless from and against any and all Damages incurred or suffered by Lilly
     (and its Affiliates and its and its Affiliates' directors, officers and
     employees) to the extent caused by or arising out of or in connection with:

          (a) any breach of any representation or warranty made by NeoSan in
     this Agreement or the Manufacturing Agreement;

          (b) any failure to perform duly and punctually any covenant, agreement
     or undertaking on the part of NeoSan contained in this Agreement or the
     Manufacturing Agreement;

          (c) any Assumed Liabilities;

          (d) any NeoSan New Product or assets related to the NeoSan New
     Products infringing or violating the patent rights or other intellectual
     property rights of Third Persons;

          (e) the manufacturing, handling, possession, marketing, distribution,
     promotion, sale, importation or use of the Product by NeoSan or a Permitted
     Seller after the Closing Date including any Third Person claim alleging
     breach of any express or implied warranties of merchantability or fitness
     for a particular purpose or asserting strict liability, except to the
     extent such Damage is caused by Lilly Error (as defined in the
     Manufacturing Agreement), by a breach of this Agreement or the
     Manufacturing Agreement by Lilly or is an Excluded Liability;

          (f) NeoSan's failure to comply in all material respects with
     Applicable Laws in connection with the performance of its obligations
     hereunder or under the Manufacturing Agreement or NeoSan's failure to
     comply with Applicable Laws relating to its using, importing, distributing,
     marketing, promoting and selling of the Product or NeoSan New Products on
     or following the Closing Date;

          (g) the handling, possession, marketing, distribution, promotion,
     sale, importation or use of any NeoSan New Product by NeoSan or any other
     Permitted Seller, including

                                       49

<PAGE>

     any Third Person claim alleging breach of any express or implied warranties
     of merchantability or fitness for a particular purpose or asserting strict
     liability; and

          (h) the negligence, gross negligence or willful misconduct of NeoSan,
     its Affiliates or its or its Affiliates' employees, agents or contractors
     (other than Lilly).

11.3 NOTICE AND OPPORTUNITY TO DEFEND. Promptly after receipt by a Party hereto
     of notice of any claim which could give rise to a right to indemnification
     pursuant to Section 11.1 or 11.2, such Party (the "Indemnified Party") will
     give the other Party (the "Indemnifying Party") written notice describing
     the claim in reasonable detail. The failure of an Indemnified Party to give
     notice in the manner provided herein will not relieve the Indemnifying
     Party of its obligations under this Article 11, except to the extent that
     such failure to give notice materially prejudices the Indemnifying Party's
     ability to defend such claim. The Indemnifying Party will have the right,
     at its option, to compromise or defend, at its own expense and by its own
     counsel, any such matter involving the asserted liability of the Party
     seeking such indemnification. The assumption of the defense of a claim by
     the Indemnifying Party will be construed as a binding acknowledgement that
     the Indemnifying Party is liable to indemnify any indemnitee for Damages in
     respect to such claim. If the Indemnifying Party undertakes to compromise
     or defend any such asserted liability, it will promptly (and in any event
     not more than ten (10) business days after receipt of the Indemnified
     Party's original notice) notify the Indemnified Party in writing of its
     intention to do so, and the Indemnified Party agrees to cooperate fully
     with the Indemnifying Party and its counsel in the compromise or defense
     against any such asserted liability, provided that the Indemnified Party is
     not obligated to disclose legally privileged documents or information in
     such cooperation. All reasonable costs and expenses incurred in connection
     with such cooperation will be borne by the Indemnifying Party. If the
     Indemnifying Party elects not to compromise or defend the asserted
     liability, fails to timely notify the Indemnified Party of its election to
     compromise or defend as herein provided, fails to admit its obligation to
     indemnify under this Agreement or the Manufacturing Agreement with respect
     to the claim, or, if in the reasonable opinion of the Indemnified Party,
     the claim could result in the Indemnified Party becoming subject to
     injunctive relief or relief (other than the payment of money damages) that
     could materially adversely affect the ongoing business of the Indemnified
     Party, the Indemnified Party will have the right, at its option, to pay,
     compromise or defend such asserted liability by its own counsel and its
     reasonable costs, expenses, and any payment made therewith will be included
     as part of the indemnification obligation of the Indemnifying Party
     hereunder, where such indemnification obligation exists hereunder.
     Notwithstanding the foregoing, neither the Indemnifying Party nor the
     Indemnified Party may settle or compromise any claim without

                                       50

<PAGE>

     consent of the other where such settlement or compromise would impose
     injunctive obligations on the non-settling or non-compromising Party or any
     Damages on the non-settling or non-compromising Party that are not subject
     to indemnification hereunder; provided, however, that consent to settlement
     or compromise will not be unreasonably withheld. In any event, the
     Indemnified Party and the Indemnifying Party may participate, at their own
     expense (or at the Indemnifying Party's expense, in the circumstances
     described above (i.e., if the Indemnifying Party elects not to compromise
     or defend the asserted liability where such indemnification obligation
     exists hereunder)), in the defense of such asserted liability. If the
     Indemnifying Party chooses to defend any claim, the Indemnified Party will
     make available to the Indemnifying Party any non-privileged books, records
     or other documents within its control that are necessary or appropriate for
     such defense; provided, however, any such books, records or other documents
     within the control of the Indemnified Party which are made available to the
     Indemnifying Party hereunder will be held in strict confidence by the
     Indemnifying Party (except to the extent disclosure is reasonably necessary
     for the defense of such claim) and will be disclosed by the Indemnified
     Party to the Indemnifying Party only to the extent that such books, records
     or other documents relate to the claim.

          Notwithstanding anything to the contrary in this Section 11.3, (a) the
     Party conducting the defense of a claim will (1) keep the other Party
     informed on a reasonable and timely basis as to the status of the defense
     of such claim (but only to the extent such other Party is not participating
     jointly in the defense of such claim), and (2) conduct the defense of such
     claim in a prudent manner, and (b) to the extent the Indemnifying Party has
     elected to defend a claim, the Indemnifying Party will not cease to defend
     such claim without the prior written consent of the Indemnified Party
     (which consent will not be unreasonably withheld).

11.4 INDEMNIFICATION PAYMENT OBLIGATION. Notwithstanding anything in this
     Agreement to the contrary, Lilly and NeoSan will have no obligations under
     subsections 11.1 (a) and 11.2(a), respectively, of this Agreement and as
     incorporated by reference in the Manufacturing Agreement to indemnify the
     other Party (or its Affiliates or its or its Affiliates' directors,
     officers and employees) until the cumulative aggregate amount of Damages
     incurred or suffered by such other Party (or its Affiliates or its or its
     Affiliates' directors, officers and employees) which Lilly or NeoSan, as
     the case may be, is otherwise subject to under this Agreement and the
     Manufacturing Agreement exceeds one hundred thousand US Dollars
     (US$100,000) (the "Deductible Amount"), at which time Lilly or NeoSan will
     have the obligation under subsections 11.1 (a) and 11.2(a), respectively,
     of this Agreement and as incorporated by reference in the Manufacturing
     Agreement to indemnify the other Party (or its Af-

                                       51

<PAGE>

     filiates or its or its Affiliates' directors, officers and employees) only
     for Damages in excess of the Deductible Amount.

11.5 INDEMNIFICATION PAYMENT ADJUSTMENTS. The amount of any Damages for which
     indemnification is provided under this Article 11 will be reduced by the
     net insurance proceeds received and any other amount recovered, if any, by
     the Indemnified Party with respect to any Damages; provided, however, that
     the foregoing will not under any circumstances reduce the Damages for which
     either Party is obligated to indemnify the other to the extent the
     insurance proceeds received result from a self-insurance program or are
     required to be repaid to the insurer upon recovery of Damages; provided,
     however, that to the extent that an insurance claim would be made under a
     self-insurance program, an Indemnified Party will not be subject to an
     obligation to pursue an insurance claim relating to any Damages for which
     indemnification is sought hereunder, and provided further that the
     Indemnifying Party will reimburse the Indemnified Party for the present
     value of any increased premiums directly attributable to such claims for
     the five year period following such increase, discounted at a 15% discount
     rate. To the extent the preceding sentence is applicable, if any
     Indemnified Party will have received any payment pursuant to this Article
     11 with respect to any Damages and will subsequently have received
     insurance proceeds or other amounts with respect to such Damages, then such
     Indemnified Party will pay to the Indemnifying Party an amount equal to the
     difference (if any) between (a) the sum of the amount of those insurance
     proceeds or other amounts received and the amount of the payment by such
     Indemnifying Party pursuant to this Article 11 with respect to such Damages
     and (b) the amount necessary to fully and completely indemnify and hold
     harmless such Indemnified Party from and against such Damages; provided,
     however, that in no event will such Indemnified Party have any obligation
     pursuant to this sentence to pay to such Indemnifying Party an amount
     greater than the amount of the payment by such Indemnifying Party pursuant
     to this Article 11 with respect to such Damages.

11.6 INDEMNIFICATION PAYMENT. Upon the final determination of liability and the
     amount of the indemnification payment under this Article 11, the
     Indemnifying Party will pay to the Indemnified Party, within ten (10)
     business days after such determination, the amount of any claim for
     indemnification made hereunder.

11.7 LIMITATION OF LIABILITY. EXCEPT FOR (i) THE COSTS OF RECALL ENUMERATED IN
     SECTION 10.3 OF THE MANUFACTURING AGREEMENT TO THE EXTENT SUCH COSTS
     CONSTITUTE INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE
     DAMAGES, AND (ii) WTTH RESPECT TO DAMAGES INCURRED BY

                                       52

<PAGE>

     THIRD PERSONS FOR WHICH A PARTY HERETO OTHERWISE HAS AN INDEMNIFICATION
     OBLIGATION PURSUANT TO SECTION 11.1 OR SECTION 11.2 OF THIS AGREEMENT OR
     SECTION 11.1 OF THE MANUFACTURING AGREEMENT, IN NO EVENT WILL EITHER PARTY
     BE LIABLE FOR INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL (INCLUDING LOST
     PROFITS) OR PUNITIVE DAMAGES, HOWEVER CAUSED OR UPON ANY THEORY OF
     LIABILITY (INCLUDING A PARTY'S OR ITS AFFILIATES' OWN NEGLIGENCE, GROSS
     NEGLIGENCE OR WILLFUL MISCONDUCT OR THE NEGLIGENCE, GROSS NEGLIGENCE OR
     WILLFUL MISCONDUCT OF A PARTY'S OR A PARTY'S AFFILIATES' EMPLOYEES, AGENTS
     OR CONTRACTORS), ARISING OUT OF THIS AGREEMENT OR THE PERFORMANCE OF, OR
     THE FAILURE TO PERFORM, ANY OBLIGATION(S) SET FORTH HEREIN. NOTWITHSTANDING
     THE FOREGOING, A PARTY'S AGGREGATE LIABILITY TO THE OTHER PARTY UNDER THIS
     AGREEMENT AND THE MANUFACTURING AGREEMENT WITH RESPECT TO ALL INDIRECT,
     SPECIAL, INCIDENTAL, CONSEQUENTIAL (INCLUDING LOST PROFITS) OR PUNITIVE
     DAMAGES INCURRED BY THIRD PARTIES FOR WHICH SUCH PARTY HERETO OTHERWISE HAS
     AN INDEMNIFICATION OBLIGATION PURSUANT TO SECTION 11.1 OR SECTION 11.2 OF
     THIS AGREEMENT OR SECTION 11.1 OF THE MANUFACTURING AGREEMENT WILL BE
     LIMITED TO FIVE MILLION US DOLLARS ($5,000,000).

11.8 INSURANCE. NeoSan will maintain at its own expense, with a reputable
     insurance carrier reasonably acceptable to Lilly, insurance coverage for
     NeoSan, written on a claims made basis, which will name Lilly as an
     additional insured, including errors and omissions insurance and
     comprehensive general liability insurance for claims for damages arising
     from bodily injury (including death) and property damages arising out of
     acts or omissions of NeoSan, which will be specifically endorsed to name
     Lilly as an additional insured. Minimum limits of such insurance (not
     warranted to be necessarily sufficient for the purposes of NeoSan's
     obligation under this Agreement or the Manufacturing Agreement) will be ten
     million US Dollars (US$10,000,000) annual aggregate coverage. Maintenance
     of such insurance coverage will not relieve NeoSan of any responsibility
     under this Agreement or the Manufacturing Agreement for damage in excess of
     insurance limits or otherwise. NeoSan will provide Lilly with a certificate
     from the insurer(s), evidencing such insurance coverage.

11.9 SURVIVAL. Each Indemnified Party's rights under Article 11 will not be
     deemed to have been waived or otherwise affected by such Indemnified
     Party's waiver of the breach of any representation, warranty, agreement or
     covenant contained in or made pursuant this Agreement or the Manufacturing
     Agreement, unless such waiver expressly and in writing

                                       53

<PAGE>

     the Manufacturing Agreement, unless such waiver expressly and in writing
     also waives any or all of the Indemnified Party's right under Article 11.

                                   ARTICLE 12
                                  MISCELLANEOUS

12.1 SUCCESSORS AND ASSIGNS. This Agreement will be binding upon and will inure
     to the benefit of the Parties hereto and their respective successors and
     assigns; provided that NeoSan may only assign this Agreement as follows:

          (a)  NeoSan may freely make such assignments in NeoSan's sole
               discretion following the payment of the $211,400,000 pursuant to
               Section 2.1, for assignments wherein NeoSan remains liable for
               the assignee's performance hereunder; and

          (b)  NeoSan may make such assignments following such payment only with
               Lilly's consent, which may not be unreasonably withheld, for
               assignments wherein NeoSan does not remain liable for the
               assignee's performance hereunder.

12.2 NOTICES. Unless otherwise stated in this Agreement as to the method of
     delivery, all notices or other communications required or permitted to be
     given hereunder will be in writing and will be deemed to have been duly
     given if delivered by hand, courier, facsimile or if mailed first class,
     postage prepaid, by registered or certified mail, return receipt requested
     (such notices will be deemed to have been given on the date delivered in
     the case of hand delivery or delivery by courier, on the date set forth in
     the confirmation sheet in the case of facsimile delivery, and on the fifth
     business day following the date of post mark in the case of delivery by
     mail) as follows:

     If to Lilly, as follows:

          Eli Lilly and Company
          Lilly Corporate Center
          Indianapolis, Indiana 46285
          Facsimile: (317) 433-3000
          Attn: Executive Vice President, Pharmaceutical Products

     With a copy to:

          Eli Lilly and Company
          Lilly Corporate Center

                                       54

<PAGE>

          Indianapolis, Indiana 46285
          Facsimile: (317) 433-3000
          Attn: General Counsel

     If to NeoSan, as follows:

          NeoSan Pharmaceuticals Inc.
          2320 Scientific Park Drive
          Wilmington, NC 28405
          Facsimile: (910) 815-2387
          Attn: Mr. David Hurley, President

     With copies to:

          aaiPharma Inc.
          2320 Scientific Park Drive
          Wilmington, NC 28405
          Facsimile: (910) 815-2387
          Attn: Gregory S. Bentley, General Counsel
          Attn: Dr. Philip Tabbiner, President

     or in any case to such other address or addresses as hereafter will be
     furnished in a written notice as provided in this Section 12.2 by any Party
     hereto to the other Party.

12.3 WAIVER. Any term or provision of this Agreement may be waived at any time
     by the Party entitled to the benefit thereof only by a written instrument
     executed by such Party. No delay on the part of Lilly or NeoSan in
     exercising any right, power or privilege hereunder will operate as a waiver
     thereof, nor will any waiver on the part of either Lilly or NeoSan of any
     right, power or privilege hereunder operate as a waiver of any other right,
     power or privilege hereunder, nor will any single or partial exercise of
     any right, power or privilege hereunder preclude any other or further
     exercise thereof or the exercise of any other right, power or privilege
     hereunder.

12.4 ENTIRE AGREEMENT. This Agreement, the Manufacturing Agreement, each of
     their appendices, exhibits, schedules and certificates and all documents
     and certificates delivered in connection herewith and therewith constitute
     the entire agreement between the Parties with respect to the subject matter
     hereof and supersede all prior agreements or understandings of the Parties
     relating thereto.

12.5 AMENDMENT. This Agreement may be modified or amended only by written
     agreement of the Parties hereto signed by authorized representatives of the
     Parties.

                                       55

<PAGE>

12.6 COUNTERPARTS. This Agreement may be executed in any number of counterparts,
     each of which will be deemed an original but all of which together will
     constitute a single instrument.

12.7 GOVERNING LAW. This Agreement will be governed and construed in accordance
     with the laws of the State of New York excluding any choice of law rules
     that may direct the application of the law of another state.

12.8 CAPTIONS. All section titles or captions contained in this Agreement and in
     any exhibit, schedule or certificate referred to herein or annexed to this
     Agreement are for convenience only, will not be deemed a part of this
     Agreement and will not affect the meaning or interpretation of this
     Agreement.

12.9 NO THIRD-PERSON RIGHTS. No provision of this Agreement will be deemed or
     construed in any way to result in the creation of any rights or obligation
     in any Person not a Party to this Agreement (except for the rights of a
     Party's Affiliates and its and its Affiliates' directors, officers and
     employees to receive indemnification from the other Party hereunder and
     except for rights of permitted assignees hereunder pursuant to Section
     12.1).

12.10 CONSTRUCTION. This Agreement will be deemed to have been drafted by both
     Lilly and NeoSan and will not be construed against either Party as the
     draftsperson hereof. Unless the context of this Agreement otherwise
     requires: (a) words of any gender include each other gender; (b) words
     using the singular or plural number also include the plural or singular
     number, respectively, (c) the terms "hereof," "herein," "hereby" and
     derivative or similar words refer to this entire Agreement; (d) the terms
     "Article" or "Section" refer to the specified Article or Section of this
     Agreement; and (e) the term "including" or "includes" means "including
     without limitation" or "includes without limitation." Whenever this
     Agreement refers to a number of days, such number will refer to calendar
     days unless business days are specified.

12.11 APPENDICES, EXHIBITS, SCHEDULES AND CERTIFICATES. Each appendix, exhibit,
     schedule and certificate attached hereto is incorporated herein by
     reference and made a part of this Agreement.

12.12 NO JOINT VENTURE. Nothing contained herein will be deemed to create any
     joint venture or partnership between the Parties hereto, and, except as is
     expressly set forth herein, neither Party will have any right by virtue of
     this Agreement to bind the other Party in any manner whatsoever.

                                       56

<PAGE>

12.13 SEVERABILITY. If any provision of this Agreement is held to be illegal,
     invalid, or unenforceable under present or future laws effective while this
     Agreement remains in effect, the legality, validity and enforceability of
     the remaining provisions will not be affected thereby.

12.14 FORCE MAJEURE. If either Party is prevented from complying, either totally
     or in part, with any of the terms or provisions set forth herein by reason
     of force majeure, including, by way of example and not of limitation, fire,
     flood, explosion, storm, strike, lockout or other labor dispute, riot, war,
     rebellion, accidents, acts of God, acts of governmental agencies or
     instrumentalities, failure of suppliers or any other similar or dissimilar
     cause, in each case to the extent beyond its control despite its
     commercially reasonable best efforts to avoid, minimize, and resolve such
     cause as promptly as possible, said Party will (a) provide written notice
     of same to the other Party and (b) subject to its following obligations
     with respect to said Party's efforts to remove the disability, its
     obligations that are prevented from compliance by such force majeure are
     suspended, without liability, during such period of force majeure. Said
     notice will be provided within five (5) business days of the occurrence of
     such event and will identify the requirements of this Agreement or such of
     its obligations as may be affected. The Party prevented from performing
     hereunder will use commercially reasonable best efforts to remove such
     disability as promptly as possible and will continue performance whenever
     such causes are removed. The Party so affected will give to the other Party
     a good faith estimate of the continuing effect of the force majeure
     condition and the duration of the affected Party's nonperformance. If the
     Closing Date has not occurred and the period of any previous actual
     nonperformance of Lilly because of Lilly force majeure conditions plus the
     anticipated future period of Lilly nonperformance because of such
     conditions will exceed an aggregate of one hundred twenty (120) days within
     any one year period, NeoSan may terminate this Agreement immediately by
     written notice to Lilly. If the Closing Date has not occurred and the
     period of any previous actual nonperformance of NeoSan because of NeoSan
     force majeure conditions plus the anticipated future period of NeoSan
     nonperformance because of such conditions will exceed an aggregate of one
     hundred twenty (120) days within any one year period, Lilly may terminate
     this Agreement immediately by written notice to NeoSan. When such
     circumstances as those contemplated herein arise, the Parties will discuss
     in good faith, what, if any, modification of the terms set forth herein may
     be required in order to arrive at an equitable solution.

                                       57

<PAGE>

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the date first above written.

                                        ELI LILLY AND COMPANY

                                        By: /s/ John C. Lechleiter
                                            ------------------------------------
                                        Printed Name: John C. Lechleiter
                                        Title: Executive Vice President

                                        NEOSAN PHARMACEUTICALS INC.

                                        By: /s/ Dr. Philip Tabbiner
                                            ------------------------------------
                                            Dr. Philip Tabbiner
                                            President

                                       58
<PAGE>

                                    EXHIBIT A
                               LILLY BILL OF SALE

                                  BILL OF SALE

     KNOW ALL BY THESE PRESENTS, that for good and valuable consideration
described in the Assignment Agreement (hereafter defined), the receipt and
sufficiency of which are hereby acknowledged, Eli Lilly and Company, an Indiana
corporation having offices at Lilly Corporate Center, Indianapolis, Indiana
46285 ("Lilly"), does hereby assign, sell, convey, transfer and deliver to
NeoSan Pharmaceuticals Inc., a corporation organized and existing under the laws
of the State of Delaware with offices located at 2320 Scientific Park Drive,
Wilmington, North Carolina 28405 ("NeoSan"), free and clear of Encumbrances
other than Permitted Encumbrances, all of Lilly's right, title and interest in
and to the Purchased Assets.

     This Bill of Sale is being delivered to NeoSan pursuant to that certain
Assignment, Transfer and Assumption Agreement between Lilly and NeoSan dated the
__________ day of ______________, 2002 (the "Assignment Agreement"), and nothing
herein shall be construed as modifying or superseding the terms of the
Assignment Agreement, the Manufacturing Agreement between Lilly and NeoSan dated
the __________ day of ______________, 2002, or any document or agreement
contemplated by the Assignment Agreement or Manufacturing Agreement. Capitalized
terms not otherwise defined herein will have the meaning given to them in the
Assignment Agreement.

     IN WITNESS WHEREOF, the undersigned duly authorized representative of Lilly
has executed this Bill of Sale effective as of this __________ day of
____________, 2002.

                                        ELI LILLY AND COMPANY

                                        By:
                                            ------------------------------------
                                        Printed Name:
                                                      --------------------------
                                        Title:
                                               ---------------------------------

                                       59

<PAGE>

                                    EXHIBIT B
                                    GUARANTY

                                    Guaranty

     In consideration of Lilly's entering into that certain Assignment, Transfer
and Assumption Agreement dated the ________ day of ________________, 2002 (the
"Assignment Agreement") with NeoSan Pharmaceuticals Inc. ("Neosan"), which is a
wholly-owned subsidiary of aaiPharma Inc., and that certain Manufacturing
Agreement dated the ________ day of ______________, 2002 (the "Manufacturing
Agreement") with NeoSan, aaiPharma Inc. hereby guaranties the performance by
Neosan of Neosan's obligations under the Assignment Agreement and the
Manufacturing Agreement, when and as due, subject to all defenses that Neosan
may lawfully have with respect to any claims by Lilly.

                                        aaiPHARMA INC.

                                        By:
                                            ------------------------------------
                                        Printed Name:
                                                      --------------------------
                                        Title:
                                               ---------------------------------
                                        Dated:
                                               ---------------------------------

                                       60

<PAGE>

                                    EXHIBIT C
                      LOAN FACILITY HIGHLY-CONFIDENT LETTER

                   [BANC OF AMERICA SECURITIES LLC LETTERHEAD]

           HIGHLY CONFIDENT LETTER - SENIOR SECURED CREDIT FACILITIES

February [__], 2002

aaiPharma, Inc.
2320 Scientific Park Drive
Wilmington, NC 28405

Attention: Dr. Philip S. Tabbiner, D.B.A.

Dear Mr. Tabbiner:

You have advised Bane of America Securities LLC ("BAS") that aaiPharma, Inc.
("AAIPHARMA") intends to acquire the United States' rights to the Darvon(R) and
Darvocet(R) branded product lines ("DARVON(R)") from Eli Lilly and Company (the
"ACQUISITION"). You have further advised us that you propose to finance a
portion of the Acquisition (including the refinancing of existing indebtedness)
and related fees and expenses from at least $[**] million in senior secured
credit facilities (the "FINANCING") comprised of (i) term loan facilities
aggregating $[_________] and (ii) a $[_________] million revolving credit
facility.

We are pleased to inform you that, based upon (and subject to) our understanding
of the Acquisition and current market conditions and subject to the conditions
set forth below, we are highly confident of our ability, as underwriter or
placement agent, to sell or place the Financing in connection with the
Acquisition. The structure, interest rate and yield, covenants and terms of, and
the documentation for, the Financing will be as agreed upon by BAS and you based
on market conditions at the time of the sale or placement and on the structure
and documentation of the Acquisition and all the financing therefor.

Our confidence in our ability to consummate the sale or placement of the
Financing is subject to: (i) the principal economic terms and structure of the
Acquisition and the related financing components being on the terms as described
to BAS on the date hereof with such other terms and conditions reasonably
acceptable to BAS and the execution of documentation relating thereto reasonably
satisfactory in form and substance to BAS; (ii)

                                       61

<PAGE>

there not having occurred any material adverse change or development in the
condition (financial or otherwise), results of operations, business or prospects
of aaiPharma and Darvon(R) (including, without limitation, any legal or
regulatory change or development), since December 31, 2001 or in the business
plan of aaiPharma as provided to BAS, in each case, in BAS' reasonable judgment;
and (iii) no new material adverse information concerning aaiPharma or Darvon(R)
having come to the attention of BAS subsequent to the signing of this letter.

You acknowledge that BAS and its affiliates may share with each other any
information related to you, (including information relating to
creditworthiness), or the Acquisition or the financing therefor provided that
BAS and such affiliates agree to hold any non-public information confidential in
accordance with their respective customary policies related to non-public
information and in accordance of BAS' obligations of non-disclosure and non-use
to Eli Lilly and Company.

This letter is not intended to be and should not be construed as a commitment
with respect to the underwriting, sale or placement of the Financing and creates
no obligations or liability on our part or your part, or on the part of any of
our respective affiliates, in connection therewith.

This letter is only for your benefit and no other person or entity shall be a
third party beneficiary of this letter. Except as otherwise required by law or
unless BAS has otherwise consented in writing, you are not authorized to show or
circulate this letter to any other person or entity other than your advisors and
to Eli Lilly and Company and its advisors.

Very truly yours,

BANC OF AMERICA SECURITIES LLC

By:
    ---------------------------------
    Managing Director

                                       62

<PAGE>

                                    EXHIBIT D
                     BOND FINANCING HIGHLY-CONFIDENT LETTER

                   [BANC OF AMERICA SECURITIES LLC LETTERHEAD]

               HIGHLY CONFIDENT LETTER - SENIOR SUBORDINATED NOTES

March 9, 2002

aaiPharma, Inc.
2320 Scientific Park Drive
Wilmington, NC 28405

Attention: Dr. Philip S. Tabbiner, D.B.A.

Dear Dr. Tabbiner:

You have advised Banc of America Securities LLC ("BAS") that aaiPharma, Inc.
("AAIPHARMA") intends to acquire the United States' rights to the Darvon(R) and
Darvocet(R) branded product lines ("DARVON(R)") from Eli Lilly and Company (the
"ACQUISITION"). You have further advised us that you propose to finance a
portion of the Acquisition (including the refinancing of existing indebtedness)
and related fees and expenses from at least $[[**]million in gross cash proceeds
from the issuance of senior subordinated notes (the "SECURITIES") in a public
offering or Rule 144A private placement with registration rights.

We are pleased to inform you that, based upon (and subject to) our understanding
of the Acquisition and current market conditions and subject to the conditions
set forth below, we are highly confident of our ability, as underwriter or
placement agent, to sell or place the Securities in connection with the
Acquisition. The structure, interest rate and yield, covenants and terms of, and
the documentation for, the Securities will be as agreed upon by BAS and you
based on market conditions at the time of the sale or placement and on the
structure and documentation of the Acquisition and all the financing therefor.
We have attached an indicative term sheet for the Securities for your review.

Our confidence in our ability to consummate the sale or placement of the
Securities is subject to: (i) the principal economic terms and structure of the
Acquisition and the related financing components being on the terms as described
to BAS on the date hereof with such other terms and conditions reasonably
acceptable to BAS and the execution of

                                       63

<PAGE>

documentation relating thereto reasonably satisfactory in form and substance to
BAS; (ii) there not having occurred any material adverse change or development
in the condition (financial or otherwise), results of operations, business or
prospects of aaiPharma or Darvon(R) (including, without limitation, any legal or
regulatory change or development), since December 31, 2001 or in the business
plan of aaiPharma as provided to BAS, in each case, in BAS' reasonable judgment;
(iii) there not having been any disruption or change or development in the
market for new issues of high yield securities or the financial or capital
markets in general, in the reasonable judgment of BAS, that could reasonably be
expected to have a material adverse effect on the placement or sale of the
Securities; (iv) the execution of a customary underwriting, purchase or
placement agreement and the satisfaction of the conditions stated therein in all
material respects, and of a customary indenture, registration rights agreement,
if applicable, and other customary documentation, in each case with respect to
the Securities, in form and substance reasonably satisfactory to BAS; (v) no new
material adverse information concerning aaiPharma or Darvon(R) having come to
the attention of BAS subsequent to the execution of this letter; and (vi) the
Securities having been rated at least B- and B3 by Standard & Poors Ratings
Group and Moody's Investor Service, Inc., respectively, with no notice of
possible change to either such rating.

You acknowledge that BAS and its affiliates may share with each other any
information related to you, (including information relating to
creditworthiness), or the Acquisition or the financing therefor provided that
BAS and such affiliates agree to hold any non-public information confidential in
accordance with their respective customary policies related to non-public
information and in accordance of BAS' obligations of non-disclosure and non-use
to Eli Lilly and Company.

This letter is not intended to be and should not be construed as a commitment
with respect to the underwriting, sale or placement of the Securities and
creates no obligations or liability on our part or your part, or on the part of
any of our respective affiliates, in connection therewith.

This letter is only for your benefit and no other person or entity shall be a
third party beneficiary of this letter. Except as otherwise required by law or
unless BAS has otherwise consented in writing, you are not authorized to show or
circulate this letter to any other person or entity other than your advisors and
to Eli Lilly and Company and its advisors.

Very truly yours,

BANC OF AMERICA SECURITIES LLC

By:
    ---------------------------------
    Managing Director

                                       64

<PAGE>

                                  SCHEDULE 1.6

                                   TRADEMARKS

<TABLE>
<CAPTION>
GenericName                          Trademark    Country Name     Status     App In No   Filing Date   Reg No    Reg Date
-----------                         ----------   -------------   ----------   ---------   -----------   ------   ---------
<S>                                 <C>          <C>             <C>          <C>         <C>           <C>      <C>
PROPOXYPHENE NAPSYLATE AND          DARVOCET-N   United States   Registered                24-Sep-71    949683   02-Jan-73
ACETAMINOPHEN, LILLY                             of America
PROPOXYPHENE HYDROCHLORIDE, LILLY   DARVON       United States   Registered                             664975   29-Jul-58
                                                 of America
PROPOXYPHENE NAPSYLATE, LILLY       DARVON-N     United States   Registered                24-Sep-71    952573   06-Feb-73
                                                 of America
</TABLE>

                                       65

<PAGE>

                                  SCHEDULE 1.20

                                   COPYRIGHTS

<TABLE>
<CAPTION>
                                                            LILLY PUBLICATION ORDER
 INDEX                                                          NUMBER OR OTHER
NUMBER                     DESCRIPTION                    PUBLICATION IDENTIFICATION
------   ----------------------------------------------   --------------------------
<S>      <C>                                              <C>
  1      Ring in 1986 with the New Darvon Products               December 1985
         Special Offer

  2      1982 Fall Offer                                        September 1982

  3      A Continuing Tradition                                 September 1974

  4      Similar Yet Different                                     July 1983

  5      Darvocet N-100                                          August, 1976

  6      When Fever and Pain are Part of the Patient's          November, 1977
         Condition

  7      Pharmacokinetic differences of Analgesics...in           March, 1978
         humans

  8      When Pain is a Major Part of the Patient's             November, 1977
         Condition

  9      What do you Prescribe for the Relief of Acute            April, 1978
         Pain? What do you Prescribe for the Relief of
         Chronic Pain?

  10     When Pain is a Major Part of the Patient's              February, 197
         Condition

  11     What do you Prescribe for the Relief of Acute            April, 1970
         Pain? What do you prescribe for the Relief of
         Chronic Pain?
                                                                February, 1979
  12     Darvocet-N 100
</TABLE>

                                       66

<PAGE>

<TABLE>
<S>      <C>                                              <C>
  13     Dentist Dimension                                      April-June 1979

  14     The Most Recent information on Darvocet-N 100            June, 1979

  15     When do you see an Increase in Office Visits            October, 1978
         Due to the Aches and Pains of the Flu?

  16     Therapeutic Agents Useful in Dentistry                December 14, 1978

  17     To Help her Cope with Pain                             November, 1978

  18     When you Diagnose an Infection....                    January 22, 1979

  19     Darvocet-N 100                                            June,1978
</TABLE>

                                       67

<PAGE>

                                  SCHEDULE 1.44

                                      NDAS

      U.S. NEW DRUG APPLICATIONS (NDAS) AND INVESTIGATIONAL NEW DRUG (IND)
                                  APPLICATIONS

                                  NDA/IND LIST

<TABLE>
<CAPTION>
IND/NDA #    LY #   Product Description                            # of Vols   Date Withdrawn
---------   -----   -------------------                            ---------   --------------
<S>         <C>     <C>                                            <C>         <C>
48                  Darvon Compound - with A.S.A.                  1
320         29352   Darvon - Suspension                            1
1194                Darvon and Amytal and A.S.A.                   1
1218                Darvon and Aventyl                             2
3027                Darvon - N Propoxyphene Napsylate              2
1599        21720   Darvon (Ampoules)                              1
1656        29352   Darvon N - Dextro Propoxyphene Napsylate       6                02/67
5159        29352   Darvocet - Propoxyphene HCL w/ Acetaminophen   1                11/90
5655                Darvocet N - Suspension                        1                11/90
5727        29352   Darvocet N - Tablets                           8
10471               Darvon N - Pediatric Suspension                1
                                      APPROX. NUMBER OF IND VOLS   25

16-844              Darvocet tablet                                30
17-122              Darvocet N tablet                              73
17-507              Darvocet N 100 suspension                      3
10-996              Darvon pulvule no                              50
10-997              Darvon pulvule no. 364,365                     45
16-827              Darvon N pulvules                              40
16-829              Darvon N w/ A.S.A.                             4
16-861              Darvon N suspension                            15
16-862              Darvon N tablet                                20
16-863              Darvon N w/ A.S.A. tablet                      13
16-864              Darvocomp N-100 tablet                         7
12-032              Darvotran pulvules                             10
14-168              Darvon with ASA                                                 11/78
                                      APPROX. NUMBER OF NDA VOLS   300
</TABLE>

                                       68

<PAGE>

                                  SCHEDULE 2.2

                           NET SALES VOLUME ADJUSTMENT
                   (ALL FIGURES ARE IN UNITED STATES DOLLARS)

<TABLE>
<CAPTION>
                                 NET SALES VOLUME
    NET SALES OF PRODUCT*      ADJUSTMENT TO NEOSAN
----------------------------   --------------------
<S>                            <C>
   [**] million or greater            None

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

[**] million to [**] million       [**] million
</TABLE>

                                       69

<PAGE>

<TABLE>
<S>                            <C>
[**] million to [**] million       [**] million

[**] million to [**] million       [**] million

    [**] million or less           [**] million
</TABLE>

*    Net Sales of Product in this column represent, during any consecutive
     twelve (12) calendar month period occurring between (and including) January
     1, 2002 and the last day of the calendar month that contains the first year
     anniversary of the Closing Date, the (i) Net Sales of Product by Lilly and
     (ii) the Net Sales of Product by NeoSan or other Permitted Sellers.

                                       70

<PAGE>

                                  SCHEDULE 3.7
                               COMBINATION PATENTS

                                     PATENTS

<TABLE>
<CAPTION>
Patent Number    Date of Patent   Description
-------------    --------------   -----------
<S>              <C>              <C>
U.S. 4,594,358   06/10/86         Analgesic Method
</TABLE>

                               PATENT APPLICATIONS

<TABLE>
<CAPTION>
Application Number   Filing Date   Country                     Status
------------------   -----------   -------                     ------
<S>                  <C>           <C>                         <C>
60/188, 135          03/09/00      United States               Pending
</TABLE>

<TABLE>
<CAPTION>
Application Number   Filing Date   Country                     Status
------------------   -----------   -------                     ------
<S>                  <C>           <C>                         <C>
PCT/US 01/00009      01/16/01      Outside the United States   Pending
</TABLE>

                                       71

<PAGE>

                                  SCHEDULE 4.1

                               EXPIRED TRADEMARKS

<TABLE>
<CAPTION>
GenericName                               Trademark    Country Name     Status    App In No  Filing Date   Reg No   Reg Date
-----------                             ------------  -------------  -----------  ---------  -----------  -------  ----------
<S>                                     <C>           <C>            <C>          <C>        <C>          <C>      <C>
PROPOXYPHENE HYDROCHLORIDE AND          DARVOCET      United States  Expired                   September   950243  January 9,
ACETAMINOPHEN, LILLY                                  of America     January 9,                 24, 1971                 1973
                                                                     1979

PROPOXYPHENE NAPSYLATE, LILLY           DARVON S      United States  Expired                               810739     July 5,
                                                      of America     July 5,                                             1966
                                                                     1986

PROPOXYPHENE AND ACETYLSALICYLIC ACID,  DARVO-TRAN    United States  Expired                               697029     May 30,
LILLY                                                 of America     May 3, 1980                                         1960

ASPIRIN, PHENACETIN AND CAFFEINE,       DARVOCOMP-N   United States  Expired         82271     March 31,  1048852  September
LILLY PROXYPHENE NAPSYLATE                            of America     September                      1976             28, 1976
                                                                     28, 1982

PARMETHASONE, PROPOXYPHENE AND ASPIRIN  STERO-DARVON  United States  Expired                               809172     May 31,
                                                      of America     May 31,                                             1966
                                                                     1986
</TABLE>

                                       72

<PAGE>

                                  SCHEDULE 4.8

                             WITHDRAWN/PENDING NDAS

                                      NDAS

<TABLE>
<CAPTION>
IND/NDA #    LY #   Product Description                              # of Vols   Date Withdrawn
---------   -----   -------------------                              ---------   --------------
<S>         <C>     <C>                                              <C>         <C>
1656        29352   Darvon N - Dextro Propoxyphene Napsylate             6            02/67
5159        29352   Darvocet - Propoxyphene HCL w/ Acetaminophen 1                    11/90
5655                Darvocet N - Suspension                                           11/90
14-168              Darvon with ASA                                      1            11/78
</TABLE>

                                       73

<PAGE>

                                  SCHEDULE 4.12

                            REGULATORY STATUS OF NDAS

                                      NONE

                                       74

<PAGE>

                                  SCHEDULE 4.14

                                REQUIRED CONSENTS

                                      NONE

                                       75

<PAGE>

                                  SCHEDULE 4.18

                               MATERIAL CONTRACTS

<TABLE>
<CAPTION>
COUNTRY       AGREEMENT TYPE              ENTITY NAME          START DATE    END DATE
-------   ---------------------   --------------------------   ----------   ----------
<S>       <C>                     <C>                          <C>          <C>
U.S.                              N.Y.C.H.H.C                  12/05/2000   11/30/2002
U.S.                              N.Y.C.H.H.C                  12/05/2000   11/30/2002
U.S.      CONGRESSIONAL MANDATE   PHS-CE                       1/01/2002    3/31/2002
U.S.      CONGRESSIONAL MANDATE   FSS-PUBLIC HEALTH SE         10/01/2001   09/30/2002
U.S.      CONGRESSIONAL MANDATE   VETERANS ADMINISTRATION      10/01/2001   09/30/2002
U.S.      CONGRESSIONAL MANDATE   DEPT. OF VETERAN'S AFFAIRS   10/01/2001   09/30/2002
U.S.      CONGRESSIONAL MANDATE   MILITARY BUYING GROUP        10/01/2001   09/30/2002
U.S.      CONGRESSIONAL MANDATE   OTHER GOVERNMENT AGENCIES    10/01/2001   09/30/2002
</TABLE>

                                       76
<PAGE>

                                  SCHEDULE 6.6

                                  PRESS RELEASE

AAIPHARMA(TM)                                                               NEWS
DEVELOPING CHEMISTRY INTO MEDICINE                                       RELEASE
2320 SCIENTIFIC PARK DRIVE                                               CONTACT
WILMINGTON NC 28405                                               AAIPHARMA INC.
                                                                      Bill Ginna
NASDAQ: AAII                                             Chief Financial Officer
                                                                     Jon Gavigan
                                                           Corporate Development
                                                                    910-254-7000
                                                       FEINSTEIN KEAN HEALTHCARE
                                                           Media: Harriet Ullman
                                                                    617-577-8110
                                                         MORGEN-WALKE ASSOCIATES
                                                         Investors: Sarah Torres
                                                    Financial Media: Dan Budwick
                                                                    212-850-5600

                                  Draft 2-15-02

FOR IMMEDIATE RELEASE

     aaiPharma Acquires Darvon(R) and Darvocet N(R) Pain Franchise from Eli
                                Lilly and Company

WILMINGTON, NORTH CAROLINA (MARCH ___, 2002) - aaiPharma Inc. (Nasdaq: AAII), a
specialty pharmaceutical company, announced today that its NeoSan
Pharmaceuticals business unit purchased the United States rights to the
Darvon(R) and Darvocet N(R) family of pain products from Eli Lilly and Company
(NYSE: LLY).

Under the terms of the agreement, NeoSan will purchase the product line for
$211.4 million plus royalties on future product reformulations. The Darvon(R)
and Darvocet N(R)

                                       77

<PAGE>

franchise will become the brand outlet for aaiPharma's pipeline of pain
management products.

The completion of this transaction is awaiting clearance by the Federal Trade
Commission and the Department of Justice of NeoSan Pharmaceutical's recent
filing under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. With this
approval and the closing of the transaction, the Darvon(R) and Darvocet N(R)
family of products would become the latest addition to NeoSan's growing product
portfolio.

"Darvon(R) and Darvocet N(R) represent a tremendous entry vehicle for NeoSan
into the Pain Management Marketplace. Upon closing, we will begin to expand our
sales and marketing operations to drive and grow this brand and our R&D programs
to rapidly develop line extensions to better handle unmet patient needs," said
Dr. Philip Tabbiner, President of NeoSan Pharmaceuticals.

The Darvon(R) and Darvocet N(R) family of pain products are indicated for mild
to moderate pain, a specialty market segment which continues to experience solid
growth in the US.

NeoSan Pharmaceuticals plans to market the Darvon and Darvoet N(R) family with
its growing sales and contracting groups.

"With this acquisition, NeoSan Pharmaceuticals will take another step forward in
its quest to build a robust and exciting pipeline of brands with proven safety
and efficacy records," said Fred Sancilio, Ph.D., Chairman and CEO of aaiPharma.
"As with the other products in our pipeline, we are poised to utilize our proven
scientific expertise to enhance and grow these products, thereby maximizing
their value for our shareholders."

ABOUT NEOSAN PHARMACEUTICALS

NeoSan Pharmaceuticals is a specialty pharmaceutical company that acquires,
enhances, and markets branded drugs using the Company's proprietary product life
cycle management expertise. Focusing on targeted therapeutic areas, the Company
applies innovative technologies to increase the commercial potential of products
with proven efficacy and safety histories. As an aaiPharma business unit, NeoSan
Pharmaceuticals leverages more than 20 years of development experience and
established industry relationships into unique pharmaceutical product
commercialization opportunities. For more information, please visit
www.neosan.com.

ABOUT AAIPHARMA

aaiPharma is an experienced leader in pharmaceutical research and development,
uniquely positioned to leverage its long-term businesses and partnerships with
major pharmaceutical companies into new product opportunities. Using its
proprietary drug

                                       78

<PAGE>

delivery technologies as well as its expertise in chemistry, the Company offers
a capability to focus on the development, enhancement, and commercialization of
mature and branded pharmaceutical products. For more information on aaiPharma,
please visit www.aaipharma.com.

FORWARD-LOOKING STATEMENTS

Information in this press release contains certain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities and Exchange Act of 1934, including the statements pertaining
to future plans to use the acquired franchise to become the brand outlet for
aaiPharma's pipeline of pain management products, future product improvements
and line extensions, plans to expand the Company's sales force and efforts, and
collaborative work among the Company's business units to leverage the
capabilities of the other business units to improve NeoSan's products, including
Darvon(R) and Darvocet N(R) products upon closing of the transaction. These
statements involve risks and uncertainties that could cause actual results to
differ materially, including, without limitation, risks and uncertainties
pertaining to aaiPharma's or its individual business units' ability to
successfully find, acquire, develop, improve, enhance the safety or efficacy of
and sell, on a commercially profitable basis, pharmaceutical products without
adversely affecting its fee-for-service client relationships or business
opportunities. Additional factors that may cause the actual results to differ
materially are discussed in aaiPharma's recent filings with the Securities and
Exchange Commission, including, but not limited to, its registration statement,
as amended, its Annual Report on Form 10-K filed with the SEC on April 2, 2001,
its Quarterly Reports on Form 10-Q filed with the SEC on November 13, 2001,
including the exhibits thereof, its Form 8-Ks and its other periodic filings.

                                       ###

                                       79

<PAGE>

                                  SCHEDULE 6.15
                         PENDING REGULATORY SUPPLEMENTS

[**]

[**]

                                       80
<PAGE>

                                                                   Exhibit 10.11

      AMENDMENT NO. 1 TO THE ASSIGNMENT, TRANSFER AND ASSUMPTION AGREEMENT

     This Amendment No. l to the Assignment, Transfer and Assumption Agreement
(the "Amendment") is executed as of the 28th day of March, 2002 ("Amendment
Effective Date"), by and between Eli Lilly and Company ("Lilly") and NeoSan
Pharmaceuticals Inc. ("NeoSan").

                                    RECITALS

     1. Lilly and NeoSan heretofore entered into that certain Assignment,
Transfer and Assumption Agreement (the "Agreement") dated as of February 18,
2002.

     2. The parties now wish to amend the Agreement as set forth in this
Amendment.

     NOW, THEREFORE, in consideration of the foregoing and for other good and
valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties agree as follows:

     1. As of the Effective Date (as defined in the Agreement), SCHEDULE 1.44 of
the Agreement will be replaced in its entirety by SCHEDULE 1.44 attached to this
Amendment and incorporated herein by reference.

     2. As of the Effective Date, SCHEDULE 4.8 of the Agreement will be replaced
in its entirety by SCHEDULE 4.8 attached to this Amendment and incorporated
herein by reference.

     3. As of the Effective Date, the last sentence of Section 6.2 will be
replaced in its entirety with the following: "Lilly and NeoSan will deliver the
information submissions described in (ii) above to the FDA by overnight delivery
to be received by the FDA on the business day following the Closing Date."

     4. As of the Effective Date, the first sentence of Section 6.15 will be
replaced in its entirety with the following: "On the Closing Date, Lilly will
transfer the NDAs to NeoSan; provided, however, that the information submissions
described in (ii) of Section 6.2 will be sent by Lilly and NeoSan to the FDA via
overnight delivery to be received by the FDA on the business day following the
Closing Date."

     5. In all other respects, the Agreement shall remain in full force and
effect.

     6. This Amendment may be executed in any number of counterparts, each of
which will be deemed an original but all of which together constitute a single
instrument.

                            [Signature Page Follows]

<PAGE>

     IN WITNESS WHEREOF, the parties have caused this Amendment to be entered
into by their duly authorized representatives as of the date first above
written.

ELI LILLY AND COMPANY                   NEOSAN PHARMACEUTICALS INC.

By: /s/ John C. Lechleiter              By:
    ---------------------------------       ------------------------------------
Printed Name: John C. Lechleiter        Printed Name:
Title: Executive Vice President                       --------------------------
                                        Title:
                                               ---------------------------------

                                        2

<PAGE>

     IN WITNESS WHEREOF, the parties have caused this Amendment to be entered
into by their duly authorized representatives as of the date first above
written.

ELI LILLY AND COMPANY                   NEOSAN PHARMACEUTICALS INC.

By:                                     By: /s/ David M. Hurley
    ---------------------------------       ------------------------------------
Printed Name:                           Printed Name: David M. Hurley
              -----------------------   Title: President of Neosan
Title:                                          Pharmaceuticals
       ------------------------------

                                        2

<PAGE>

                       AMENDMENT NO. 2 TO THE ASSIGNMENT,
                        TRANSFER AND ASSUMPTION AGREEMENT

     This Amendment No. 2 to the Assignment, Transfer and Assumption Agreement
(the "Amendment") is executed as of the 31st day of October, 2002 and effective
as of March 28, 2002 (the "Effective Date"), by and between Eli Lilly and
Company ("Lilly") and aaiPharma LLC (f/k/a NeoSan Pharmaceuticals Inc.)
("aaiPharma LLC").

                                    RECITALS

     1. Lilly and aaiPharma LLC heretofore entered into that certain Assignment,
Transfer and Assumption Agreement (the "Agreement") dated as of February 18,
2002 and entered into that certain Amendment No. 1 ("Amendment No. 1") dated as
of March 28, 2002.

     2. The parties now wish to further amend the Agreement as set forth in this
Amendment.

     NOW, THEREFORE, in consideration of the foregoing and for other good and
valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties agree as follows:

     1. Capitalized terms not otherwise defined herein will have the meaning
given to them in the Agreement. All references in the Agreement and Amendment
No. 1 to "NeoSan Pharmaceuticals, Inc." are hereby replaced by references to
"aaiPharma LLC", and all references in the Agreement and Amendment No. 1 to
"NeoSan" are hereby replaced by references to "aaiPharma LLC".

     2. As of the Effective Date, SCHEDULE 1.6 of the Agreement will be replaced
in its entirety by SCHEDULE 1.6 attached to this Amendment and incorporated
herein by reference.

     3. As of the Effective Date, Section 1.12 of the Agreement will be replaced
in its entirety with the following:

          "1.12 BOOKS AND RECORDS" means all files, documents, instruments,
     papers, books and records (including scientific, regulatory and financial)
     owned by Lilly or an Affiliate of Lilly to the extent, and only to the
     extent, they are significantly related to the Purchased Assets (including
     the Products or the manufacture, marketing, promotion, sale or distribution
     thereof), including the DMFs, any sales records, pricing lists, customer
     lists (to the extent owned by Lilly or its Affiliates), vendor lists,
     financial data, regulatory information or files (including adverse event
     reports and annual regulatory reports), litigation files, patent
     prosecution files, adverse claims or demands, investigation information or
     files, trademark registration certificates, trademark renewal certificates.

     4. As of the Effective Date, SCHEDULE 1.44 of the Agreement will be
replaced in its entirety by SCHEDULE 1.44 attached to this Amendment and
incorporated herein by reference. The attached SCHEDULE 1.44 replaces and
supersedes the SCHEDULE 1.44 in the Agreement and Amendment No. 1.

     5. As of the Effective Date, SCHEDULE 4.8 of the Agreement will be replaced
in its entirety by SCHEDULE 4.8 attached to this Amendment and incorporated
herein by reference. The attached SCHEDULE 4.8 replaces and supersedes the
SCHEDULE 4.8 in the Agreement and Amendment No. 1.

     6. As of the Effective Date, a new Section 1.71 is hereby added and will
read as follows:

<PAGE>

          "1.71 "DMFS" mean those drug master files listed in SCHEDULE 1.71
     attached hereto."

     7. As of the Effective Date, the SCHEDULE 1.71 attached hereto and
incorporated herein by reference will be SCHEDULE 1.71 of the Agreement.

     8. As of the Effective Date, Section 3.5 will be replaced in its entirety
with the following:

          "3.5 GRANT OF LICENSE TO LILLY.

          (a) Subject to the terms and conditions set forth herein, as of the
     Closing Date, aaiPharma LLC hereby grants to Lilly and its Affiliates, for
     no additional consideration, and Lilly and its Affiliates accept, a
     royalty-free, non-exclusive license, with a right to sublicense, except as
     limited below, in the United States under the Product Intellectual
     Property, the NDAs, the DMFs and the Marketing Materials solely to
     manufacture, or to have manufactured, the Products for aaiPharma LLC under
     the Manufacturing Agreement and otherwise fulfill its obligations
     thereunder; provided, however, that the non-exclusive license granted by
     aaiPharma LLC above will terminate effective upon the termination of the
     Manufacturing Agreement.

          (b) Subject to the terms and conditions set forth herein, as of the
     Closing Date, aaiPharma LLC hereby grants to Lilly and its Affiliates, for
     no additional consideration, and Lilly and its Affiliates accept, an
     exclusive, royalty-free license, with the right to sublicense, under the
     Marketing Materials, DMFs, Copyrights and Assigned Trade Dress to sell,
     distribute, use, offer to sell, import, market and promote the Product
     outside the United States or to make or have made the Product inside the
     United States for selling, distributing, using, offering to sell,
     importing, marketing and promoting the Product outside of the United
     States. The license granted pursuant to this Section 3.5(b) will terminate
     with respect to the Copyrights, the Marketing Materials, the DMFs or the
     Assigned Trade Dress on aaiPharma LLC's receipt of written notification
     from Lilly that it is abandoning its license with respect to the
     Copyrights, the Marketing Materials, the DMFs and the Assigned Trade Dress.

     9. As of the Effective Date, the first sentence of Section 4.1 will be
replaced in its entirety with the following:

          "Lilly represents and warrants that the Product Intellectual Property
     (other than the Assigned Trade Dress), Marketing Materials, the Licensed
     Trademark and Trade Dress (other than the Common Law Licensed Trade Dress)
     and the Licensed Technology (collectively, the "Intellectual Property") and
     the Assigned Trade Dress, Common Law Licensed Trade Dress and DMFs contain
     all the Patents, Know-How, technology, trade secrets, trademarks, and trade
     dress necessary to conduct the Activities or to make, have made,
     distribute, use, sell, offer to sell, have sold, market, co-market, import
     (into the United States), promote and co-promote Products in the United
     States."

<PAGE>

     10. As of the Effective Date, the fourth sentence of Section 4.1 will be
replaced in its entirety with the following: "For avoidance of doubt,
"Intellectual Property" does not mean or include the Assigned Trade Dress,
Common Law Licensed Trade Dress or the DMFs."

     11. As of the Effective Date, the first sentence of Section 4.8 will be
replaced in its entirety with the following: "Except with respect to those of
the NDAs listed in part c. of SCHEDULE 4.8 attached hereto, Lilly represents and
warrants that Lilly has furnished aaiPharma LLC with access to a complete copy
of the NDAs, including all amendments and supplements thereto, and that Lilly
has no new drug applications or INDs pertaining to propoxyphene-based
pharmaceutical products, whether issued, pending, abandoned, withdrawn, or in
draft form, other than those pertaining to the NDAs."

     12. As of the Effective Date, subpart (ii) of the second sentence of
Section 4.8 will be replaced in its entirety with the following: "(ii) except
with respect to those of the NDAs listed in SCHEDULE 4.8 attached hereto which
are designated as never having been approved by the FDA, each of the NDAs has
been approved by FDA, and, except with respect to those of the NDA's listed in
part a. of SCHEDULE 4.8 attached hereto, nothing has come to the attention of
Lilly which has led Lilly to believe that any of the NDAs are not in good
standing with the FDA."

     13. As of the Effective Date, the reference to "SCHEDULE 4.8" in the sixth
sentence of Section 4.8 will be replaced in its entirety with "part b. of
Schedule 4.8."

     14. As of the Effective Date, the last sentence of Section 4.8 will be
replaced in its entirety with the following: "Except for the representation and
warranty contained in this Section 4.8, aaiPharma LLC has had full and adequate
opportunity to review and evaluate the NDAs (except as otherwise disclosed in
SCHEDULE 4.8 attached hereto), aaiPharma LLC is relying upon its own judgment
and experience in connection with all of the NDAs, and Lilly is assigning,
selling, conveying, transferring and delivering all of the NDAs to aaiPharma LLC
"AS IS"."

     15. As of the Effective Date, subpart (c) of the first sentence of Section
4.14 will be replaced in its entirety with the following: "(c) any filing
reasonably requested by aaiPharma LLC as may be necessary to change the records
of ownership of the DMFs with the ED A or to change the records of ownership in
the U.S. Trademark or Copyright Office,".

     16. As of the Effective Date, the last sentence of Section 6.15 will be
replaced in its entirety with the following: "Upon the Closing Date, aaiPharma
LLC hereby grants to Lilly the right to reference the NDAs and DMFs for purposes
of performing the Permitted Uses and obtaining and/or maintaining marketing
authorizations outside of the United States.

     17. In all other respects, the Agreement, as amended by Amendment No. 1,
shall remain in full force and effect.

     18. This Amendment No. 2 may be executed in any number of counterparts,
each of which will be deemed an original but all of which together constitute a
single instrument.

<PAGE>

     IN WITNESS WHEREOF, the parties have caused this Amendment to be entered
into by their duly authorized representatives as of the date first above
written.

ELI LILLY AND COMPANY                   aaiPHARMA LLC

By: /s/ John C. Lechleiter              By: /s/ /s/ David Hurley
    ---------------------------------       ------------------------------------
Printed Name: John C. Lechleiter        By: David Hurley
Title: Executive V.P.                   Title: President

<PAGE>

                                 SCHEDULE 1.44

                                      NDAS

      U.S. NEW DRUG APPLICATIONS (NDAS) AND INVESTIGATIONAL NEW DRUG (IND)
                                  APPLICATIONS

                                  NDA/IND LIST

<TABLE>
<CAPTION>
                                                                                 Date Withdrawn or
IND/NDA#    LY #                 Product Description                 # of Vols      Inactivated
--------   -----   ----------------------------------------------   ----------   -----------------
<S>        <C>     <C>                                              <C>          <C>
48                 Darvon Compound - with A.S.A.                    1                  04/65
320        29352   Darvon - Suspension                              1                  02/66
1,194              Darvon and Amytal and A.S.A.                     1                  07/67
1,218              Darvon and Aventyl                               2                  10/65
1,357              Stero Darvon with ASA                            3                  02/68
3,029              Darvon - N Propoxyphene Napsylate                2                  01/69
1,599      21720   Darvon (Ampoules)                                1                  02/67
1,656      29352   Darvon N - Dextro Propoxyphene Napsylate         6                  11/90
5,159      29352   Darvocet - Propoxyphene HCL w/ Acetaminophen     1                  11/90
5,655              Darvocet N - Suspension                          1                  06/84
5,727      29352   Darvocet N - Tablets                             9
10,471             Darvon N - Pediatric Suspension                  1                  05/84
                   Propoxyphene derivatives, dextro, sustained
1,393              action                                           2                  08/68
9,750              Propoxyphene napsylate and methadone HCL         1                  09/80
                   APPROX. NUMBER OF IND VOLS                       32
16-844             Darvocet tablet                                  30
17-122             Darvocet N tablet                                76
17-507             Darvocet N 100 suspension                        3
10-996             Darvon pulvule                                   50
10-997             Darvon pulvule no. 364,365                       47
16-827             Darvon N pulvules                                38
16-829             Darvon N w/ A.S.A.                               4
16-861             Darvon N suspension                              13
16-862             Darvon N tablet                                  20
16-863             Darvon N w/ A.S.A. tablet                        13
</TABLE>

<PAGE>

<TABLE>
<S>        <C>     <C>                                              <C>          <C>
16-864             Darvocomp N-100 tablet                           7
12-032             Darvotran pulvules                               10                  03/75
14-768             Stero-Darvon with ASA                            13                  11/78
16-828             Darvon-N Compound 100 with aspirin, phenacetin   4                     NA
                   and caffeine
17-124             Actimets Darvon                                  4                     NA
13-804             Darvon Injection                                 11                  11/65
12-928             Levo-propoxyphene napsylate pulvules             9
10-995             Darvon with A.S.A. pulvules                      2                   09/71
13-662             Propoxyphene napsylate suspension                8                   08/71
12-629             Levo-propoxyphene oxide HCL                      none found          08/71
13-097             Levo-propoxyphene with aspirin                   2                   06/77
                   APPROX. NUMBER OF NDA VOLS                       364
</TABLE>

NA = NEVER APPROVED

<PAGE>

                                 SCHEDULE 1.71

                                      DMFS

<TABLE>
<CAPTION>
DMF#              Compound/location                Status
----   --------------------------------------   -----------
<S>    <C>                                      <C>
4886   propoxyphene hydrochloride- Mayaguez     current
5430   propoxyphene hydrochloride- Tippecanoe   not current
4880   propoxyphene napsylate- Mayaguez         current
5477   propoxyphene napsylate- Tippecanoe       not current
</TABLE>

<PAGE>

                                  SCHEDULE 4.8

                             A. WITHDRAWN INDS/NDAS

<TABLE>
<CAPTION>
IND/NDA #    LY#                  Product Description                # of Vols   Date Withdrawn
---------   -----   ----------------------------------------------   ---------   --------------
<S>         <C>     <C>                                              <C>         <C>
1,357               Stero Darvon with ASA                            3           02/68
1,599       21720   Darvon (Ampoules)                                1           02/67
1,656       29352   Darvon N - Dextro Propoxyphene Napsylate         6           11/90
5,159       29352   Darvocet - Propoxyphene HCL w/ Acetaminophen     1           11/90
12-032              Darvotran pulvules                               10          03/75
14-768              Darvon with ASA                                  13          11/78
10-995              Darvon with A.S.A. pulvules                      2           09/71
13-662              Propoxyphene napsylate suspension                8           08/71
12-629              Levo-propoxyphene oxide HCL                      0           08/71
13-097              Levo-propoxyphene with aspirin                   2           06/77
1,393               Propoxyphene derivatures, dextro, sustained      2           08/68
                    action
9750                Propoxyphene napsylate and methadone             1           09/80
13-804*             Darvon Injection                                 11          11/65
16-828*             Darvon N compound 100 with aspirin, phenacetin   4           NA
                    and caffeine
17-124*             Actimets Darvon                                  4           NA
</TABLE>

                                  B. FORM 483S

     Form 483 issued by the FDA November 10, 1999 with respect to Lilly's
Mayaguez, Puerto Rico facility

                  C. COPIES NOT MADE AVAILABLE TO AAIPHARMA LLC

<TABLE>
<CAPTION>
IND/NDA #    LY#                  Product Description                # of Vols   Date Withdrawn
---------   -----   ----------------------------------------------   ---------   --------------
<S>         <C>     <C>                                              <C>         <C>
12-928              Levo-Propoxyphene napsylate pulvules             9
1,357               Stero Darvon with ASA                            3           02/68
10-995              Darvon with A.S.A. pulvules                      2           09/71
13-662              Propoxyphene napsylate suspension                8           08/71
12-629              Levo-propoxyphene oxide HCL                      0           08/71
13-097              Levo-propoxyphene with aspirin                   2           06/77
</TABLE>

<PAGE>

<TABLE>
<S>         <C>     <C>                                              <C>         <C>
1,393               Propoxyphene derivatures, dextro, sustained      2           08/68
                    action
9,750               Propoxyphene napsylate and methadone HCL         1           09/80
13-804*             Darvon Injection                                 11          11/65
</TABLE>

*    NDAs never approved by FDA

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}]]